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Polysaccharides are biocompatible and biodegradable long carbohydrate molecules organized in 
repeated monosaccharide units interconnected with glycosidic bonds. These polymers constitute a 
large source of biomaterials for drug vehicles, controlled drug delivery, tissue engineering etc. 
The ionic character and the presence of reactive functional group led them to be good candidates for 
the development of controlled release formulations. They are well tolerated by living tissues and 
body cavities due to their biocompatibility and biodegradability. In fact, polysaccharides have been 
widely proposed as drug delivery devices for many administration routes such as oral, parenteral, 
ophthalmic, nasal and transdermal route. 
Furthermore, polysaccharides can be considered appropriate for tissue engineering thanks to their 
mechanical and biochemical functions and ability to deliver and foster cells.  
The aim of the present work was the development of polysaccharides based platform formulations 
suitable for the delivery of drugs into specific anatomical districts.  
Self-emulsifying pellets can be considered a multiple unit dosage form capable of 
transferring a lipophilic drug in the gastric fluids dissolved in fine oil droplets. The combined 
advantages of this composite formulation are improved stability and absorption of lipophilic drugs, 
lower dose dumping in gastric transit time tank to a smother movement in the gastrointestinal track. 
Self-emulsifying mixtures (oil/surfactant/drug), in the form of o/w emulsions, consisting of 
caprylic/capric triglyceride, and three Cremophors (ELP, RH40, and RH60) at 1.5 and 2.3 weight 
ratios, and two drugs (furosemide and propranolol) of different lipophilicity were prepared and used 
as wetting liquids for the preparation of microcrystalline cellulose (MCC) pellets. 
Properties of emulsions such as droplet size, zeta potential (ζ),viscosity and evaluation of 
reconstituted emulsions were determined. Furthermore, the characteristics of pellets such as pellet 
size, shape, friability, tensile strength, disintegration, and drug migration in pellets were evaluated. 
An experimental factorial design and 3-way ANOVA was performed in order to assess the effect of 
drug, surfactant and oil/surfactant ratio on the above-mentioned properties of emulsions and pellets. 
The results of these studies revealed that the 3 factors affected droplet size, viscosity and ζ of 
emulsions and size, shape, and friability of MCC pellets. Drug migration was more evident for the 
less lipophilic drug (furosemide) and lower oil/surfactant ratio. 
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Hepatocellular carcinoma (HCC) is a high chemoresistant tumour and localized anticancer 
therapies play a key role inthe treatment of advanced stages of HCC. Among them, transarterial 
embolization (TAE) implies the injection of embolic materials in the artery feeding the tumour, 
which results in ischemia and subsequent tumour necrosis. 
Indocyanine green (ICG) loaded chitosan/glycerophosphate (C/GP) thermogelling solutions were 
prepared with the aim to develop a new platform for the imaging and loco-regional treatment of 
HCC. ICG was incorporated in these formulations in order to evaluate their potential for the 
detection of tumours by fluorescence. The technological properties of these systems such as gel 
formation, gelling time, injectability, gel strength, gelling temperature, biodegradability and in vitro 
dye release studies were assessed. Ex vivo embolization studies were carried out for a preliminary 
embolic evaluation by using an isolated bovine liver.  
It was detected an increase of gel strengths and gelation rate for formulations with higher cross-link 
density between C and GP. These behaviours are unexpectedly more evident for C/GP solutions 
where a gel-like precipitation at 4°C occurred. Solutions with the lowest cross-link density between 
C and GP were more injectable thanks to a lower resistance to flow. Dye loading did not affect the 
hydrogel properties. The release of ICG from all C/GP systems analysed was not significant due to 
a strong electrostatic interaction between C and ICG. Ex vivo studies showed the fast gelation of 
these formulations in correspondence of the injected site. In conclusion, ICG-loaded C/GP thermo 
sensitive solutions have the potential for loco regional treatment of HCC following intraoperative 
fluorescence detection and resection of tumour nodules. 
Antiretroviral therapy against HIV infection shows limited efficacy due to poor 
bioavailability of the corresponding drugs, such as zidovudine (AZT), at HIV reservoir sites. This 
drawback is quite evident in cerebrospinal fluid (CSF) subarachnoid spaces where macrophages are 
the only site of HIV replication in the brain. The rationale is that the active efflux transporters 
extrude zidovudine from the central nervous system (CNS) and macrophages. The prodrug called 
UDCA-AZT made with the conjugation of AZT to ursodeoxycholic, previously synthesized by our 
research group, is able to elude the AET systems. Chitosan chloride-based microparticles (CP) 
loaded with UDCA-AZT were developed for the nasal administration of this molecule as a potential 
strategy to enhance its uptake into the CNS. This formulation was characterized in terms of size, 
morphology, density, water uptake and the dissolution rate of UDCA-AZT. In addition, the CP 
sample was administered to rats via the nasal route. Drug release studies showed the capability of 
this formulation to release the drug in a relatively short time. Thus, a rapid absorption of the 
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prodrug after the nasal administration of the CP can be potentially achieved. In vivo studies 
demonstrated that nasal administration of UDCA-AZT loaded CP microparticles produced 
detectable amount of this prodrug in the CSF of the rats that could be sufficient to achieve an anti-
HIV activity. 
Iron excess is considered a key factor in the etiology of neurological disorders, cancer, 
stroke, muscle diseases, and aging. This toxicity is the consequence of the release of reactive 
oxygen species (ROS) whose are responsible of oxidative damage to various cell components such 
as lipid membranes, DNA, and proteins. Iron dysregulation can be overcame using iron chelators 
such as deferoxamine (DFO). Nevertheless, DFO displays reduced absorption in the gut and short 
plasma half-life. DFO loaded chitosan/alginate hydrogels were developed with the aim to overcome 
DFO limitations by using prolonged delivery systems. DFO loaded hydrogel alone or composite 
systems of chitosan/alginate hydrogels and DFO loaded poly(d,l-lactide-co-glycolide) microspheres 
were investigated in vitro. The influence of the preparation methods on the performance of 
composite hydrogels on controlled DFO release was assessed. Among the formulations studied, 
only the composite hydrogels were able to sustain the release of DFO. In particular, it was observed 
that the inclusion of microspheres into pre-formed chitosan/alginate hydrogel led to the best 
platform for the release of this iron chelator: DFO released from microspheres is strongly entrapped 
in the hydrogel network and, consequently, it is slowly released from the gel matrix by diffusion.  
Ocular infections from Gram-positive and Gram-negative bacteria are commonly treated 
with topical eye drops loaded with ciprofloxacin. This type of formulation displays some drawbacks 
such as the rapid ocular clearance and frequent administrations are required. To overcome this limit, 
ciprofloxacin loaded chondroitin sulphate or lambda carrageenan microparticulate controlled 
release systems were engineered. The ionic interactions between ciprofloxacin and these 
polysaccharides led to coprecipitates that can act as vehicles for the sustained release of this drug 
after being displaced by the mediums ions. Technological parameters such as drug and polymer 
concentration, use of surfactant (kind and concentration), temperature and stirring of the solutions 
were evaluated in order to achieve coprecipitates with a particle size suitable for ophtalmic 
administration. In addition, mucoadhesion tests were performed on the leader formulations in order 
to understand if these systems are capable to be retained in the precornal region. Chondroitin 
sulphate coprecipitates exhibited the best properties in terms of particle size and mucoadhesivity, in 




Polysaccharides as Drug Delivery Systems for different Administration Routes 
Tesi di Dottorato in Scienze e Tecnologie Chimiche-Scienze Farmaceutiche 
Università degli Studi di Sassari 
 
INTRODUCTION 
Biomaterials are considered biocompatible resources with the ability to interact with biological 
systems to evaluate, treat, augment or replace any function, tissue or organ of the body [1].  
Polysaccharides are well-known carbohydrate polymers that constitute one of the most abundant 
supply of biomaterials for drug vehicles, controlled drug delivery, tissue engineering etc. 
Polysaccharides have several natural resources from microbial, algal, plant and human origin [2]. 
The based-molecular structure is composed of one or more monosaccharide repeated units 
interconnected with o-glycosidic bonds. The backbone can be composed of only one kind of 
repeating monosaccharide, named homopolysaccharides or homoglycans (e.g. starch, cellulose), or 
formed by two or more different monomeric units, named heteropolysaccharides or heteroglycans 
(e.g. agar, alginate, carrageenan). 
The general formula is Cx(H2O)y where 200≤ x ≤2500. Taking into account that the repeating units 
in the polymer backbone are usually monosaccharides with six carbons, the general formula can 
also be symbolized as (C6H10O5)n where 40≤ n ≤3000. 
Polysaccharides possess linear or branched chains with the presence of reactive moieties such as 
hydroxyl, amino, and carboxylic acid groups. The presence of this reactive functional group 
indicates the prospect for chemical modifications [3]. Molecular weight range of this class of 
polymeric materials is from hundreds to thousands of Daltons [3]. 
Polysaccharides are widely applied in the drug delivery field due to their following merits: 
1) they can be isolated in a well defined and reproducible way from natural sources including 
plants, animals, and microorganisms [4]; 
2) they are biocompatible and biodegradable due to their biochemical similarity with human 
extracellular matrix components. In particular, they can be immediately recognized and accepted by 
the human body with low immunogenic properties and they can go through enzymatic and/or 
hydrolytic degradation into non-toxic compounds [5] 
3) they are capable of chemical and enzymatic modifications to give origin to different 
derivatives potentially suitable as drug delivery systems [6]; 
4) the ionic character and the presence of reactive functional group led them to be good 
candidates for the development of controlled release formulations; 
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5) ionic polysaccharides, which exhibit sensitiveness to environmental stimuli (chemical or 
physical), are an efficient alternative to synthetic polymers in the development of stimuli responsive 
drug delivery systems [7]; 
6) ionic polysaccharides have mucoadhesive properties [8]; 
7) they are capable to make conjugates and complexes with many macromolecules, such as 
proteins and peptides for achieving active targeting and controlled release systems [9]; 
8) large number of polysaccharides are capable to form interpenetrated hydrogel networks as 
matrices to encapsulate drugs and living cells, as biocompatible scaffolds for tissue engineering and 
for the controlled release of macromolecules like proteins. These hydrogels usually show physic-
chemical characteristics more different from their macromolecular constituents [8,10,11]. 
The purpose of the present introduction is to describe five different polysaccharides that were used 
for the development of my thesis project. 
Cellulose and derivatives  
Cellulose is the most abundant compound of the cell walls of plants, bacteria, fungi and algae, 
which possesses a fundamental structural function. It is primary composed of glucose units 
interconnected with o-glycosidic bonds, organized in a fibrillary structure. This polymer shows high 
rigidity due to the various inter and intra-molecular hydrogen bonding between the hydroxyl groups 
of glucose units into elementary microfibrils which aggregate forming thick macrofibrils [12].  
Cellulose presents different composition and morphology depending on the source from which it is 
obtained. No type of natural celluloses dissolves in common aqueous and organic solvents. The 
presence of hydroxyl groups in the glucose units of cellulose permits to synthesise many cellulose 
derivatives [13]. Among them, cellulose esters, cellulose ethers, microcrystalline cellulose, and 
cross-linked or graft copolymers are widely used in the pharmaceutical field as controlled drug 
delivery systems. Their applications include formulation of membrane controlled drug release 
systems or monolithic matrix systems [14]. The manufacture of membrane controlled release can be 
obtained by film coating with the aim to develop enteric coated dosage forms and osmotic pump 
delivery systems by using semi-permeable membranes [14].Monolithic matrix systems are amongst 
the most popular technologies for controlled drug delivery because of their simplicity of 
formulation, ease of manufacture, low cost, acceptance and applicability to drugs with a wide range 
of solubility [14]. 
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Cellulose ethers and esters have been widely used for the development of oral sustained and 
controlled release dosage forms as coating agents that respond to variations in physiological 
environment, as matrices to enhance the bioavailability and solubility of drugs, to realise a pre-
determined release profile from the final delivery system, and to increase the stability of the 
formulation [15]. 
Cellulose acetate phthalate and phthalated hydroxypropylmethyl cellulose are derivatives used as 
entering coating materials for the development of controlled intestinal targeting drug release 
formulations. Indeed, these polymers are stable in acidic conditions but soluble in a slightly alkaline 
environment [15]. 
Carboxymethyl cellulose and hydroxypropyl cellulose are considered mucoadhesive polymers 
applied for the delivery of drugs sublingually, orally, intravaginally, rectally, nasally and 
ophthalmically. Formulations made with this polymer prolongs the residence time of the drug at the 
site of absorption, allowing to high concentration gradient of the released compound, its protection 
from enzymatic degradation and enhanced absorption [16]. 
Typical cellulose esters used as hydrophobic matrices for sustained release of drugs (including 
highly water-soluble drugs) are cellulose acetate, cellulose acetate propionate, and cellulose acetate 
butyrate. The matrix of these polymers remain essentially intact in the GI tract while drug is 
released [17]. Cellulose esters are also used to construct the semi-permeable membrane of osmotic 
pump delivery systems. When the device is in contact with body fluids, water is able to permeate 
the cellulosic membrane and dissolves the osmotic agent resulting in a water activity gradient across 
the membrane [17]. 
Recently, Plackettet al. [18] have been developed nanocellulose which including cellulose 
nanocrystals, nanofibrilated cellulose, and bacterial cellulose as novel cellulose-based systems 
capable to entrap water soluble drugs and poorly water soluble drugs. These formulations exhibited 
long lasting drug release profile over weeks or even months. 
Another important cellulose derivative is microcrystalline cellulose (MCC). MCC is a partially 
depolymerised cellulose obtained by treating high quality cellulose with hydrochloric acid at high 
temperature. MCC is one of the most important pharmaceutical excipients for pellet and tablet 
formulations. For example, it is used for the preparation of pellet formulations via extrusion–
spheronisation process [19]. The rationale is its efficient binding properties that allow cohesiveness 
to a wetted mass containing MCC. In addition, its large surface area and high internal porosity 
permit to adsorb and retain a big amount of water, enhancing extrusion, wetted mass plasticity and 
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spheronisation [20]. Phase separation during extrusion or spheronisation is avoided because MCC is 
capable to control the movement of water through the plastic mass [21].  
As a consequence of these advantages, MCC-pellets obtained via extrusion–spheronisation display 
good spherical shape, low friability, high density and smooth surface properties [20].  
A possible explanation of the mechanism of action of MCC during extrusion–spheronisation 
process is reported by Dukic-Otta et al. [20]: “the MCC particles are able to retain water in a 
manner similar to a sponge. During extrusion these sponges are compressed, and water that is 
squeezed from the internal structures acts as a lubricant. After extrusion, the volume of the sponges 
expands and they appear dry and brittle, which facilitates the breaking of the extrudates during the 
initial phase of spheronisation. During the spheronisation phase, the sponges are densified due to 
collisions between particles and the spheronizer plate and wall, and water facilitates spheronisation 
of pellets”. 
MCC is used in the pharmaceutical industry as a diluent/binder in tablets for granulation and direct 
compression processes. MCC tablets display fast aqueous penetration even at low porosities, caused 
by breaking of the hydrogen bonds and subsequent widening of the pores [22]. 
MCC has also been studied as an absorption enhancer of the intranasal powder forms for peptides 
such as insulin [23], leuprolide and salmon calcitonin [24]. 
Cellulose and its derivatives have also been applied for bone tissue engineering because of their 
high mechanical and porous properties and osteoinductivity [5]. This polymer has structural and 
functional similarity with collagen, the major extra cellular matrix component of animal tissue. 
Several 3D porous systems of cellulose derivatives such as hydrogels, sponges, fiber matrices have 
been developed as scaffolds with high mechanical characteristics able to support large compressive 
loads. 
Chitosan  
Chitosan is a cationic polysaccharide composed of β-(1-4)-linked D-glucosamine and N-acetyl-D-
glucosamine units obtained by partial N-deacetylation of chitin, a structural element in the 
exoskeleton of crustaceans and insects [25]. 
The cationic character of chitosan, based on its amino groups, rends it useful for the development of 
drug delivery systems [26]. In particular, these amino groups confer well defined properties on 
chitosan such as controlled drug release, mucoadhesion, in situ gelation, transfection, permeation 
enhancement, and efflux pump inhibitory properties [26]. Chitosans have been used to engineer 
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drug vehicles for various administration routes such as oral, buccal, nasal, transdermal, parenteral, 
vaginal, cervical, intrauterine and rectal [27]. These drug carriers include membranes, sponges, 
hydrogels, rods, nanoparticles and microspheres [27]. 
The controlled drug release properties of chitosan are mainly based on retardation mediated by ionic 
interactions [26]. At this point, chitosan is the best choice for sustained anionic drugs release. 
Anionic drugs such as naproxen [28], enoxaparin [29], indomethacin [30] etc., can interact with 
chitosan resulting in cross-linking between chitosan molecules and prolonged release profile.  
In addition, polyanion polymers and/or multivalent inorganic anions were used to make 
polyelectrolyte complexes with chitosan as excipients in drug delivery systems [31]. Polyanions 
such as alginate, carrageenan, pectin, xantan gum, hyaluronic acid, gelatine, polymethacrylate 
copolymer, tripolyphosphate, exhibit favourable physicochemical properties with preservation of 
biocompatible characteristics of chitosan. Furthermore, drugs incorporated in these complexes are 
released in a sustained manner by diffusion and erosion processes [26,31].  
Chitosan exhibits mucoadhesive characteristics due to the ionic interactions between the cationic 
amino groups of this polymer and the anionic substructures of the mucus gel layer. Better 
mucoadhesion was observed for chitosans with high-molecular weight (approximately 1400 kDa) 
[32]. These properties were used to improve the bioavailability of drugs such as amoxicillin, 
diclofenac sodium, nifedipine, buserelin as well as protein and peptides [32]. The muco-adhesion of 
chitosan is negatively influenced if it is used to formulate polyelectrolyte complexes because the 
ionic interactions between chitosan and mucus are in this way limited [33]. Several strategies have 
been proposed to improve the muco-adhesion properties of chitosan. For instance, Jintapattanakit et 
al. [34] developed trimethyl chitosan nanocomplexes exhibiting more cationic character compared 
to chitosan alone. 
The major issue concerning the applicability of chitosan formulations is the impossibility of 
maintaining chitosan in solution up to physiological pH due to its pKa(~6.3). Above a pH of 6, 
chitosan has no charge and forms a gel-like precipitate [35]. Chenite and co-workers [35] developed 
a thermosensitive neutral aqueous solution based on chitosan/glycerophosphate which exhibit sol-
gel transition around body temperature. They found that the addition of polyol salts, such as 
glycerophosphate, leads to the transformation of purely pH-dependent chitosan solutions into 
thermally sensitive pH-dependent solutions, without any chemical modification or crosslink. In the 
presence of glycerophosphate, chitosan solutions remain liquid below room temperature, even with 
pH values within a physiologically acceptable neutral range from 6.8 to 7.2 [35]. These nearly 
12 
Andrea Salis 
Polysaccharides as Drug Delivery Systems for different Administration Routes 
Tesi di Dottorato in Scienze e Tecnologie Chimiche-Scienze Farmaceutiche 
Università degli Studi di Sassari 
neutral chitosan/glycerophosphate aqueous solutions gel when heated [36] (Chenite et al.2001). The 
neutralization behaviour of glycerophosphate is the main characteristic which determines 
chitosan/glycerophosphate solubility and phase transition phenomena. Glycerophosphate presents a 
mild alkalinity (pKa about 6.34) providing correct buffering without inducing immediate 
precipitation or gelation when the temperature provided is between 4 and 15ºC [36]. These 
properties indicate the ability of this liquid chitosan-based material of gelling within the desired 
tissue or body cavity in response to body temperature. Consequently a degradable gel implant in 
situ is formed [37]. Chitosan/glycerophosphate hydrogels are adapted to the delivery of drugs 
protecting them from hostile environments and controlling the release profile. In vitro release 
experiments revealed that these systems could deliver macromolecules and poor-water soluble 
drugs over a period of several hours to a few days [38]. Recently, it was also proposed to use these 
thermosensitive hydrogels for the local administration of paclitaxel at tumour resection sites to 
prevent local tumour recurrence [39].  
Chitosan is also considered a polymer with transfection enhancing properties [26]. Non-viral 
vectors of chitosan have been engineered for the delivery of DNA and siRNA exploiting the ionic 
interaction between the cationic amino groups of chitosan and these polyanionic molecules that lead 
to the spontaneous formation of nanoparticles [40]. The variation of formulation parameters such as 
the molecular weight (Mw) of chitosan, degree of deacetylation (DD), stoichiometry of the 
chitosan/DNA complex (N/P ratio, charge ratio of amine (chitosan) to phosphate (DNA)), plasmid 
concentration, serum concentration, pH of the transfection medium, cell type affect the affinity 
between chitosan and DNA, size, cell uptake and release of the chitosan/DNA complex as well as 
their transfection efficiency [40]. The clinical application of these chitosan-based complexes was 
not recommended due to a low transfection efficiency of the conventional chitosan [26,40]. On the 
contrary, the use of thiolated chitosan and the trimethylation of amino groups led to plasmidic 
nanoparticles with a higher transfection rate [41].  
The cationic amino groups of chitosan give permeation enhancing properties to this polymer. In 
particolar, thi polymer is able to improve absorption of hydrophilic and hydrophobic drugs through 
monostratified and pluristratified epithelia of intestine, nose, vagina and cornea mucosae that are 
rich in tight junctions [42]. The permeation enhancing result of chitosan is due to a transient 
widening of the junctions between cells [43]. The efficacy of chitosan as penetration enhancer is 
limited to its insolubility at pH > 6. The synthesis of partially quaternized derivative N-trimethyl 
chitosan chloride led to more efficient penetration enhancement properties opening the tight 
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junctions between cells and favouring the paracellular transport of hydrophilic and hydrophobic 
drugs [43]. 
Chitosan belongs to the family of polysaccharide with colon targeting properties thanks to its 
preservation in the stomach and small intestine and degradation in the colon by the bacterial flora. 
Thus, it was proposed as coating agent for tablets [26].  
Taking into account all the above-mentioned properties chitosan-based drug vehicles for various 
administration routes were developed. Oral drug delivery formulations were prepared in the form of 
microspheres for the delivery of amoxicillin and diclofenac sodium to the gastric and intestinal 
region respectively [44,45]. Takeuchi et al. [46] developed insulin-loaded liposomes coated with 
chitosan to increase the enteral absorption of insulin exploiting the muco-adhesion properties of 
chitosan. Lueßen et al. [33] used a chitosan hydrochloride solution to improve the bioavailability of 
buserelin in the duodenum taking advantage of the intestinal transport-enhancing effect of chitosan. 
Chitosan glutamate was used as coating agent for pellets and tablets exhibiting swelling and 
permeability characteristics, which were dependent on pH and on the concentration of the 
crosslinking agent [43]. A vesicle system composed of palmitoyl glycol-chitosan was developed for 
gene delivery and as a system for oral delivery of proteins and peptides [47]. Colon-specific insulin 
delivery was obtained through capsules coated with chitosan that were stable in the stomach and in 
the small intestine but they exhibited degradation by the bacterial flora in the colon [48]. 
Chitosan is considered a good material for the development of ocular drug delivery systems thanks 
to its permeation enhancing properties. Chitosan-based in situ gelling systems were developed by 
Gupta et al. [49] with the aim to improve the retention and biodistribution of drugs applied topically 
onto the eye [26]. Chitosan-based nanoparticles loaded with cyclosporine A [50] and chitosan-based 
microparticles loaded with acyclovir [51] were prepared in order to improve the delivery of these 
drugs to the ocular mucosa.  
The mucoadhesive and permeation enhancer properties of chitosan were considered for the 
development of nasal drug delivery carriers such as nanoparticles for the delivery of insulin [52], 
spray solutions loaded with fentanyl [53] and in situ gelling thermosensitive solutions [26].  
Chitosan highly purified and with low molecular weight, was also used for the development of 
injectable preparations for the controller delivery of drugs. For instance, Kim et al. [54] prepared 
chitosan-based nanoparticles for the delivery of RGD peptide (Arg-Gly-Asp) to improve the 
antitumoral activity of this peptide intravenously. Ouchi et al. [55] developed a macromolecular 
system consisted of chitosan conjugated to 5-fluorouracil that was able to induce growth-inhibitory 
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effects on Met-A fibrosarcoma and MH-134Y hepatoma. Furthermore, the 5FU side effects were 
drastically reduced.  
Alginates 
Alginates or alginic acids, are polysaccharides isolated from brown seaweed and marine algae. 
These compounds are linear unbranched copolymers consisted of homopolymeric blocks of (1,4)-
linked β-D-mannuronic acid and α-L-guluronic acid, which are linked together, by covalent bonds, 
in different blocks [56]. This type of polymer is considered a biomaterial with excellent 
biocompatibility and non-immunogenicity. Alginates have been proposed as stabilizers in 
emulsions, suspending agents, binders and disintegrants in tablets [14]. A critical property is its 
gelling behaviour: the carboxylic groups of two guluronic blocks of adjacent polymer chains can be 
cross-linked with multivalent cations, such as Ca2+, allowing to the formation of a gel network 
[56]. The gelling ability of alginates depends on their selective cation binding. Hydrogels with high 
gel strength can be achieved from alginates with high content of guluronic acid residues [57]. 
The gelling properties of alginates were widely employed in the preparations of drug delivery 
systems such as beads, nanoparticles, microparticles, pellets, films and matrices able to encapsulate 
various substances [14].  
Alginate has been applied in oral dosage forms. In particular, sodium alginate is a well known tablet 
binding agent, while alginic acid is considered a tablet disintegrant for immediate drug release 
tablets [57]. The suitability of alginates as oral dosage forms derives from the ability of this 
polymer to create a hydrocolloidal layer under hydration. This layer exhibits high viscosity making 
a diffusion barrier able to control the release of drugs. For this reason, alginate has been used for the 
preparation of gel capsules microspheres and tablets. Joseph et al. [58] developed capsules 
incorporating indomethacin. The release of the drug was controlled by the alginate-based 
encapsulating membrane following zero-order kinetics. In the case of microspheres and tablets, the 
drug is dispersed in the alginate-based matrix. The release of the drug depends on “diffusion 
through matrix swelling and dissolution/erosion at the matrix periphery” [57]. Drug release is more 
prolonged for high concentrations of alginate and when its guluronic content is predominant due to 
the formation of gels with high strength in which the swelling and erosion processes are less evident 
[59]. In the case of selective interactions between drug and alginate residues, higher content of the 
residue that interact with the drug lead to a more sustained release [60]. The drug release profile is 
also influenced by the type of cross-linker. For instance, Takka e al. [61] demonstrated that Ca2+ 
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alginate beads exhibited more prolonged release compared to those prepared by using cross-link 
agents such as Ba2+ and Sr2+.  
The release of drugs from alginate-based marices can be also modulated by using other cross-
linking agents such as glutarladehyde or by using combination of alginates with other polymers 
[57]. Murata et al. [62] developed alginate beads coated with chitosan by strong ionic interaction 
between these polymers. The gel matrix erosion was markedly delayed due to the formation of the 
strong complex chitosan-alginate. Chitosan-alginate beads loaded with diclofenac were prepared by 
Fernandez-Hervas and co-workers [63]. It was demonstrated that a complex between both polymers 
subsisted in a gel form at low pH due to the protonation of chitosan in acid conditions. The release 
profile was dependent on the pH conditions and on the degree of cross-linking between chitosan 
and alginate. At neutral pH, the gel swells and a prolonged release of the drug is achieved by slow 
disintegration of this gel complex. Alginate-based matrices were also used for the preparation of 
compressed tablets. The release of both hydrophilic and hydrophobic drugs is influenced by the 
creation of a hydrated viscous layer surrounding the tablet. This layer is a sort of barrier avoiding 
the penetration of water into the matrix and the leakage of solutes [57].  
An in situ forming hydrogel of sodium alginate for oral administration of theofilline was suggested 
by Miyazaki et al [64]. The in situ gelation was achieved by the sequential administration of two 
solutions, the first containing the polymer and the second containing Ca2+ions. The bioavailability 
of the drug was higher compare to conventional theofilline-based formulations.  
In-situ-forming ophthalmic drug delivery systems prepared from alginates without the addition on 
ionic cross-linker were developed by Cohen et al. [65] An aqueous solution of sodium alginate 
loaded with pilocarpine nitrate was able to gel in the eye with a longer precorneal residence time 
compared to conventional liquid ophthalmic formulations. As a consequence, an increase of ocular 
bioavailability and duration of the pilocarpine action were achieved. The best results in terms of 
gelling time and sustained release were observed for alginates with high contents of guluronic 
residues. 
Another important characteristic of alginate is the ability to incorporate biomacromolecules thanks 
to the following reasons: 
• no use of organic solvents during the gelation process [57]; 
• controlled released due to the porous structure of alginate-based gels [66]; 
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• biocompatibility and low immunogenicity [57]. 
For these reasons, many proteins have been encapsulated in beads consisted of alginate matrices. 
Promising results were also observed for oral and nasal administrations of antigens, DNA and 
cells[57]. 
Alginate-based gels are also able to incorporate other types of formulations. For istance, Josef et al 
[68] developed alginate hydrogels incorporating an o/w emulsion. The emulsion was suitable for the 
delivery of hydrophobic drugs, while the gel matrix was useful to achieve a sustained drug release 
profile.  
Carrageenan  
Carrageenan (CG) are sulphated polysaccharides isolated from red seaweeds and composed of D-
galactose and 3,6-anhydro-D-galactose units linked together by glycosidic bonds [69.]. These 
residues are generally substituted with ester sulphates which are neutralized by cations, such as 
Na+, K+ and Ca2+. The major varieties of CGs are κ, λ- and τ-CG, which differs from the number 
and position of sulphate groups. The κ , λ-, and τ-CG dimers have one, two and three sulphate ester 
groups, respectively [70]. Furthermore, 3, 6-anhydro bridges are present only in κ- and τ-CG. These 
differences affects the properties of CGs, such as solubility temperature and gel strength [69]. 
Indeed, κ-CG can be dissolved in hot water, while λ-CG is soluble in hot and cold water [71]. The 
presence of 3, 6-anhydro bridges confers gelling properties on CGs.  
As a consequence, κ- and τ-CG are able to form brittle gels and softer ones, respectively. On the 
contrary λ-CG cannot form gels due to the lack of 3, 6-anhydro bridges [72]. The gel formation of 
these CGs occurs in a two step process. At high temperatures, the CGs chains exist as random coils 
and upon cooling, a coil-to-helix transition takes place. Then, these helices start to aggregate in 
double helices in which sulphate groups are positioned outside of the helices. The gel network is 
composed of three dimensional double helices stabilised by hydrogen bonds between the two chains 
[73]. 
CGs are widely employed in the field of pharmaceutical technology with the aim to (1) improve 
drug formulation, (2) to develop prolonged drug release systems and (3) to create pH-/temperature-
sensitive delivery systems, which respond to physiological environmental stimuli [72]. 
CG-based tablets were developed for the oral administration of drugs thanks to the appropriate 
properties of these polymers such as high molecular weight, high viscosity and gelling. Tablets can 
be prepared with a unique matrix composed of CG. When the water come in contact with this type 
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of matrix, its outer layer swells and become a gel layer or a viscous one, depending on the type of 
CG. The gel/viscous layer is able to control the release of the loaded drug with a marked resistance 
to erosion [74]. Furthermore, the type of CG influences the release rate. Ghanam et al. [75] 
demonstrated that κ-CG-based tablets had faster erosion compared to the same formulations 
prepared with the other two CG. In addition, the degree of water-uptake is affected by the number 
of sulphate groups on CGs:  λ>  τ>  κ [76]. Prolonged drug release tablets were also obtained 
combining different types of CGs. Tripelennamine-HCL-loaded tablets made with equal amounts of 
λ-CG and τ-CG exhibited a near-zero-order release profile [77]. 
Tablets composed of a polymer mixture of CG and other types of polymers such as hydroxypropyl 
cellulose [78], hydroxypropyl methyl cellulose [79] were engineered in order to adjust drug release 
profiles.  
CGs are able to form polyelectrolyte complexes with positively charged polymers such as chitosan. 
For instance, Li et al. [80] developed chitosan-CGs-based tablets that were capable to form an in 
situ polyelectrolyte film in the simulated intestinal fluid and this film could further control drug 
release.  
Taking into consideration the above-mentioned capacity of CGs to interact with positive charged 
compounds, many researchers applied this property for the development of CGs-based formulations 
loaded with a positive charged drug. Among them, Bonferoni et al. [81] observed that λ-CG was 
able to prolong the release of salbutamol sulphate independently of the pH of the dissolution 
medium.  
Polyelectrolyte complexes formed by CGs and chitosan were also used for the development of 
capsules, beads and nanoparticles in order to improve the controlled or prolonged release of drugs. 
The rationale of the preparation of beads with CGs is the thermo reversibility of the gel network and 
the adequate viscoelastic properties of these polymers [69]. For instance, Tomida et al. [82] 
prepared κ-CG-chitosan beads evaluating the release of theophylline as a model drug. It was 
observed that this drug displayed a zero-order release profile. Polyelectrolyte complex beads based 
on chitosan and CG have been also employed as a controlled release platform for colon-specific 
delivery of sodium diclofenac [83]. It was demonstrated that the release of this drug was slow in pH 
1.2 and pH 6.8 fluids but much higher in pH 7.4.  
Pinheiro et al.[84] engineered nanoparticles based on polyelectrolyte complex based on chitosan 
and CG as a potential platform either for the controlled release of drugs and for tissue engineering. 
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These nanoparticles displayed non cytotoxicity in L929 fibroblasts, and a controlled release for up 
to 3 weeks with ovalbumin, as a model protein,was observed. 
CGs were also employed for the preparation of pellets by extrusion/spheronization process. It was 
observed that κ-CG could be used as an extrusion aid due to its elastic and brittle properties [69]. κ-
CG-based pellets exhibited lower tensile strength, faster disintegration and drug release compared 
to pellets prepared with microcrystalline cellulose. Furthermore, the release profile of κ-CG-based 
pellets is less influenced by the drug’s solubility [85]. Thus, κ-CG-based pellets could be 
considered a useful approach to surmount the bioavailability deficiency of poorly soluble drugs. 
Neverthless, considering the fast disintegration of these pellets, an adequate coating is necessary to 
obtain a sustained release [69].  
Another important application of CGs is in the field of microspheres as delivery systems of drugs in 
a controlled and targeted manner. An important contribution in this field was performed by 
Bonferoni and coworkers [85], which developed λ-CG-gelatin-based microspheres loaded with 
timolol maleate for the ocular route, taking into consideration the adequate properties of CGs such 
as gelling, film forming and mucoadhesive ones. The results showed high timolol maleate 
concentration and bioavailability in the aqueous humour and a more efficient alternative to 
commercial formulations. 
As previously reported, CGs such as κ-CG and τ-CG are able to gel. This property is widely used 
for the development of sustained delivery systems for various administration route. Miyazaki et al. 
[86] proposed a τ-CG gel for the oral delivery of drugs to dysphagic patients. CG-based hydrogel 
loaded with microbicides were developed by Li et al.[87] for vaginal administration.  
Many researchers focus their attention on the utilization of gelling CGs added to other polymers in 
order to improve the controlled-release profiles of gels composed solely from conventional 
polymers. For instance, κ-CG-agarose-based hydrogels were able to decrease the release of drugs 
due to an increase of gel strength compared to agarose gels [88]. 
Starch-CG-based gels were prepared by Lefnaoui et al. [89] to improve the prolonged buccal 
delivery of miconazole. In addition, gels composed of methyl cellulose and CGs were able to 
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Chondroitin sulphate (CS) is a negatively charged linear polysaccharide composed of alternate 
sequences of β-glucuronic acid and N-acetylgalactosamine unites, linked by β bonds,  
presenting sulfates, carboxylic acid and hydroxyl moieties. It is an important component of the 
extracellular matrix of articular cartilage linked to the core of proteins. This linkage makes 
proteoglycans, which are resistant to compression stress [91]. CS is synthesised by chondrocytes 
and its primary function is to preserve normal cartilage activities [5]. In particular, CS gives  
cushioning properties to the cartilage by retaining water and acts like a lubricant at the 
articulating surfaces [5]. Furthermore CS is indispensable for cartilage repair because it can 
synthesise the most important component of cartilage such as hyaluronan, collagen type II, and 
glucosamine and it is able to inhibit the enzymes involved in the degradation of extracellular matrix 
[5]. CS in an attractive biomaterial extracted from animal sources, which exhibit biodegradability, 
non-immunogenicity and non toxicity. Cs have been used for tissue engineering as well as for drug 
delivery or controlled drug release.  
As it is reported by Doppaladupi et al. [91], “CS can bind with core protein to produce highly 
absorbent aggregan, which is a major structure inside cartilage and acts as a shock absorber; or, it 
can produce sydecan, a cell receptor that can interact with adhesion proteins, cells and the 
extracellular matrix”. 
From the delivery system’s point of view, the negative charges of these polysaccharides are capable 
to make electrostatic interactions with positively charged polymers or drugs, allowing to the 
development of matrices-based hydrogels, nanoparticles and microparticles.  
CS could be considered a potential carrier for colon-targeted delivery of bioactive agents. Since 
natural CS is water soluble, its persistence as a solid dosage form in the stomach and small intestine 
would not be successful. To overcome this limit, CS cross-linked with other polymers could be a 
better alternative decreasing CS hydrophilicity [92].  
Wang et al. [93] developed hydrogels by crosslinking CS with poly(ethylene glycol) diglycidyl 
ether (CS-EX) or forming an interpenetrating polymer network (CS-EX-IPN). It was observed that 
CS-EX-IPN hydrogel exhibited better three-dimensional structures with smaller pore sizes than the 
CS-EX hydrogel. The release profiles of diclofenac sodium and bovine serum albumin displayed a 
diffusion from these platforms mechanism. Furthermore, the release for macromolecular drugs is 
more sustained than small molecular drugs. Jensen and co-workers [94] prepared CS-based 
hydrogels for the electro-controlled delivery of peptides and proteins. The negative charges of CS 
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allow loading efficiently proteins and peptides positively charged. Moreover, drug loading and the 
electrically-stimulated drug release were influenced by the size of the compound.  
An interesting approach for targeting orally administered drugs to the colon was proposed by 
Amrutkar et al. [95]. Matrix tablets were obtained by forming a polyelectrolyte complex between 
chitosan and CS. Selective delivery of indomethacin to the colon was achieved and the release 
profile was influenced by time of cross-linking and concentration of the polymers used. 
Chitosan-CS polyelectrolyte complex was also exploited for the development of microcapsules 
loaded with the anti-cancer drug 5-fluorouracil [96]. The drug release was affected by the degree of 
crosslinking. the release of 5-fluorouracil was lower for higher cross-link density due to a decrease 
of the swelling ability of the matrix. 
Furthermore, Yeh et al. [97] prepared nanoparticles by using this chitosan-CS polyelectrolyte 
complex. This systems showed high degree of cross-linking and it was able to incorporate proteins 
and peptides. Cellular uptake studies performed on Caco-2 and HEK-293 cells showed edndocytose 
of these nanoparticles into the cells. As a consequence, the developed nanocarrier had the potential 
to deliver hydrophilic compounds such as vaccines. 
 
On the basis of the multiple advantages and versatility of the above mentioned 
polysaccharides as materials for the preparation of pharmaceutical carriers, the aim of the present 
work was the development of polysaccharides-based platform formulations as novel and suitable 
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INTRODUCTION 
Self-emulsifying pharmaceutical pellets combine the advantages of emulsions and multi-particulate 
solid dosage forms, namely improved absorption of lipophilic drugs with lower variability in gastric 
transit time (independently of nutrition state) and better stability in the gastric fluids and easier 
application of coatings for GI track targeting [1–7]. It has been reported that self-emulsifying pellets 
do release the drug in the dog GI tract, as if they were the emulsion liquid itself [8]. Furthermore, it 
has been found that bioavailability of poorly water soluble drugs is improved when they are 
administered as self-emulsifying pellets, although there are no such products yet on the market 
[9,10]. 
Self-emulsifying pellets can be prepared by incorporating self-emulsifying mixtures 
(oil/surfactant/drug) in the form of o/w emulsions in microcrystalline cellulose (MCC) during the 
process of wet massing, before extrusion–spheronization. It has been reported that with surfactants 
of higher hydrophilicity the massing liquid requirements for pelletization increase and faster 
disintegration of the self-emulsifying MCC pellets is achieved, while the reconstitution of emulsion 
is facilitated with higher oil/surfactant ratios [11,12]. 
Until now, the effect of the drug nature on the properties of self-emulsifying drug delivery systems 
has received relatively little attention and even fewer literature reports appear for self-emulsifying 
pellets [13,14]. From the available reports it appears that the presence of drug in the oily phase of 
o/w emulsions affects their droplet size and stability, with maximum destabilization occurring near 
drug saturation [15,16]. Furthermore, the presence of the drug may affect the viscosity of the 
emulsions through its effect on the droplet diameter and its presence on the oil/water interface [17] 
which in turn may affect agglomeration during wet massing of MCC with the emulsion, the 
rheological properties of the resulting wet mass, and the properties of the final pellets [18]. In 
addition, the presence of any free drug in the aqueous phase of the emulsion and its migration 
during drying, towards the surface of the pellets, may alter the distribution of the drug in the pellet 
[19–21]. So far, there is little bibliographic information on this point and no data at all for the 
distribution (migration) of drugs in self-emulsifying pellets, although previously published results 
on the kinetics of drug release and emulsion reconstitution, have indicated the operation of a bi-
phasic release process, a fast initial and a slow terminal release attributed to migration of 
oil/surfactant/drug mixture during drying of pellets [22]. 
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Therefore, the aim of the present work was to expand the already studied effects of formulation 
variables (drug lipophilicity, surfactant type, and oil/surfactant ratio) on the properties of the 
emulsions used for the preparation of MCC pellets (droplet size, ζ, and viscosity) and elucidate 
possible relationships between them and the properties of the produced self-emulsifying pellets 
(micromeritic, mechanical, and drug migration). Furosemide and propranolol that belong to BCS 
class IV and II, respectively, and of similar aqueous solubility (0.063 and 0.051 mg/ml at 25°C) but 
different lipophilicity (log P 2.0 and 3.5) were the drugs, medium chain triglycerides the oil and 
Cremophors ELP, RH40, and RH60, the surfactants, employed at oil/surfactant ratios of 1.5 and 2.3 
previously found to give good reconstitution of emulsions from the self-emulsifying pellets [12,22]. 
MATERIALS AND METHODS 
Materials 
Microcrystalline cellulose (Avicel® PH-101, lot 6950C, FMC Ireland) was used as the pellet 
forming material. Furosemide (FS) and propranolol base (PR) were selected as the active 
pharmaceutical ingredients. Furosemide (Batch 9033HRII) from Ipca (Mumbai, India) was donated 
by Help Hellas (Athens, Greece) and propranolol base was prepared by reacting 20% w/w 
propranolol hydrochloride with 3% w/w sodium bicarbonate water solutions, followed by filtration 
and drying [23]. Medium chain triglycerides of caprylic/capric esters; C8: 59.6%, C10: 39.9%, C14 
0.4% (Radia 7104, Oleon N.V., Oelegen, Belgium), and glyceryl polyethylene glycol ricinoleate 
(Cremophor ELP) or glyceryl polyethylene glycol oxystearate (Cremophors RH 40 and RH 60), 
donated by BASF (Ludwigshafen, Germany), were used as the oil and the surfactant components of 
the self-emulsifying liquid mixture. Distilled water was used as the external phase of the emulsions 
employed as massing liquids during pellet preparation. 
Emulsion Preparation and Characterization 
Appropriate amounts of oil and surfactant were mixed at ratios 1.5 and 2.3 and then drug (2% w/w) 
was added to them. The mixtures were heated at 50°C, until clear solutions were formed. Then, o/w 
emulsions used as massing liquids for the preparation of pellets were made by 1/4 dilution 
containing 25% (w/w) of oil/surfactant/drug mixture and 75% deionized water and their viscosity 
was measured. For the determination of droplet size and ζ of the emulsions, a higher dilution of 
oil/surfactant mixture in water (1/10) was applied to avoid multiple scattering effects. 
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Droplet Size 
The droplet size was measured in triplicate using the Dynamic Light Scattering sizer (Zetasizer, 
ZEN3600, Malvern Instruments Ltd, Worcestershire, UK) and expressed as the average 
hydrodynamic diameter derived from the change of intensity of scattered light with time (laser 633 
nm, detection angle 173°). 
Zeta Potential (ζ) 
Emulsions were placed in the electrophoretic cell of the above-mentioned Zetasizer and ζ, which 
represents the charge on the surface of the droplets, was obtained from the electrophoretic mobility 
using the M3-PALS technique which is a combination of Malvern’s laser Doppler velocimetry 
method (M3 measurement technique) and the Phase Analysis Light Scattering technique (PALS). 
Viscosity 
Kinematic viscosity was measured with an Ubbelohde glass capillary viscometer (Schott Geräte, 
Mainz, Germany) of internal diameter 0.63 mm, taking as reference the viscosity of water at 25°C 
(η?=?0.89 cST (centistokes, mm2/s)) and the efflux time for water (81?±?0.1 s). Measurement was 
applied to inert emulsions without drug, which were not used for pellet preparation, and, for the 
twelve emulsions containing drug. To convert the values to cP (centipoise, g•s/cm2), multiplication 
by the average density, calculated from the density of the oil (0.95 g/cm3) and that of the surfactants 
(1.05 g/cc, Handbook of Pharmaceutical Excipients), was applied. 
Pellet Preparation and Characterization 
For the preparation of pellets by extrusion/spheronization, 30 g batches of MCC powder were 
mixed with 30 g emulsions (75% water and 25% w/w oil/surfactant/drug self-emulsifying mixture) 
for about 5 min in a 1-L cylindrical mixing vessel, fitted with a three-blade impeller [22]. The 
emulsions had milky appearance except for those containing FS and oil/surfactant ratio 1.5, which 
gave clear (RH40) or slightly turbid, translucent emulsions. Further addition of small amounts of 2 
to 5 g of water was required to obtain most spherical pellets. The resulting wet mass was extruded 
in a radial extruder (Model 20, Caleva Process Solutions, Dorset, UK) operated at 25 rpm and fitted 
with a 1-mm circular orifice and 1.75 mm thickness screen. The extrudate was immediately 
processed for 10 min at 1,360 rpm corresponding to a linear perimeter speed of 8.55 m/s in a 
spheronizer (Model 120, Caleva Process Solutions, Dorset, UK) fitted with a cross-hatch friction 
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plate. The produced pellets were dried for 12 h in an air-circulation tray oven (UT6, Heraeus 
Instruments, Hanau, Germany) at 40°C. The final dry pellets contained 0.4% drug, 19.6% 
oil/surfactant mixture, and 80% MCC and their properties were evaluated as follows: 
Size 
Size distribution was determined by placing approximately 10 g of pellets on a stack of 10 cm 
diameter sieves of 300, 425, 600, 850, and 1,200 μm aperture (DIN/ISO3310-1, Retch, Haan, 
Germany) and vibrating for 10 min (Fritsch Analysette 3, Oberstein, Germany). Median pellet 
diameter was derived from cumulative weight plots of the weight of remaining pellets on each 
sieve. 
Shape 
Pellet shape was determined by using an image processing and analysis system comprised of 
stereomicroscope, top cold light source (Olympus SZX9, Japan and Highlight 3,100, Olympus 
Optical), video camera (VC-2512, Sanyo Electric, Japan), and software (Quantimet 500, 
Cambridge, England). About 100 pellets were examined, in 3–4 optical fields, at a total 
magnification of 6.5?×?5?=?32.5. The shape was expressed as fullness index [FI%?=?100?×?(actual 
surface area?−?convex surface area)/actual surface area] which represents the surface irregularity, as 
aspect ratio (AR?=?length/breadth) and as shape factor eR which combines both geometrical and 
surface irregularity [24]. All shape parameters tend towards unity with increasing sphericity. 
Friability 
Friability was determined in a granule friabilator (Copley Scientific, type FRV 2000, Nottingham, 
UK) rotated at a speed of 25 rpm, for 10 min. Pellets (10 g) of the size fraction 600–1,200 μm were 
placed in the drum together with 20 g, 4 mm, glass beads. After rotation, the fines produced due to 
the shocks of the falling pellets were separated by sieving through a 600-μm sieve, for 5 min at 2 
mm vibration amplitude (Fritsch Analysette, Oberstein, Germany). Friability, FR%, was calculated 
from the weight difference of the pellets remaining on the sieve (Wf) compared to initial pellet 
weight (Wo) expressed as percentage: 
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Tensile Strength 
Pellets from the 1,000–1,200 μm fraction were diametrically loaded by using a modified CT-5 
testing machine (Engineering System, Nottingham, UK), at an upper platen speed of 1 mm/min. 
The tester was fitted with a 25 N load cell (model ELFM-T2M, Entran, USA) connected to a signal 
amplifier (RDP E308, UK). The signal was collected with a polymeter (Handyscope, Holland) and 
recorded in Microsoft Excel files. The tensile strength, σt, was calculated from the breaking force, 
F, and the pellet radius, R, by using the equation (25): 
σt=0.4?F/π?R2                                                                                                                                    (2) 
Disintegration 
The disintegration time of pellets, 1,000–1,200 μm in diameter, was determined in a modified 
reciprocating cylinder USP Apparatus 3 (Bio-Dis RRT9, G.B. Caleva, UK) as described previously 
[12]. 
Drug Migration 
Pellets (5 g) of the size fraction 850–1,200 μm were placed together with 20 g, 4 mm glass beads, in 
250 mL specially modified cylindrical glass jars in order to separate surface layers from the pellets 
and estimate drug content. The interior surface of the jars was covered by glued sand paper type 
P800 (FEPA classification) corresponding to about 16 μm grain size, which was selected after 
preliminary trials on the basis of the yield of outer layer removal from pellets. The jars were 
mounted on a Turbula mixer (Type T2C, Willy Bachofen AG, Basel Switzerland) and tumbled at a 
speed of 90 rpm. At 3-min intervals, the fines (<212 μm) were removed by sieving the jar content 
and tumbling was continued until collecting more than 250 mg fine powder. 
The drug content was determined in the two size fraction (<212 and >212 μm) applying a validated 
UV spectrophotometric method in five samples as follows. Samples (50 mg) corresponding to 200 
μg drug (nominal amount) were mixed for 5 min with 40 mL methanol, centrifuged for 3 min at 
4,500 rpm (Heraeus Labofouge 400R, Thermo Electron Corporation, Osterode, Germany), and the 
concentration of extracted drug in the supernatant was determined at 272 and 290 nm for FS and 
PR, respectively. The extraction process and UV determination was repeated once with 20 and then 
with 10 mL methanol until absorbance lower than 0.003 was obtained. 
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Validation of the method was based on linearity between absorbance, A, and concentration, C, 
(R2?>?0.999, in the range 0.5–20.0 μg/mL and 1.0–50.0 μg/mL for FS and PR, respectively). The 
relationships between concentration and absorbance were: C?=?16.8067?×?A?+?0.4403 and 
C?=?42.9185?×?A?+?0.4206. Considering the sensitivity of the spectrophotometer as A?=?0.001, the 
lower limit of detection (LLOD) was 0.45 and 0.55 μg/mL and the lower limit of quantification 
LLOQ was 1.0 and 1.5 μg/mL for FS (A?=?0.034) and PR (A?=?0.026), respectively, which 
corresponds to coefficient of variation <2% (for five samples). 
From the drug content in the two fractions (Douter and Dinner) the drug migration (M%) was 
expressed as: 
M%=100?(Douter-Dinner)/200                                                                                                         (3) 
On the basis of LLOQ (1.0 μg/mL for FS and 1.5 μg/mL for PR), any difference (Douter?−?Dinner) 
greater than 0.5% for FS and 0.75% for PR will be valid. 
Reconstituted Emulsions 
The evaluation of reconstituted emulsions was based on the determination of droplet size and zeta 
potential as already described for the emulsions used as wet massing liquids in the preparation of 
pellets. The reconstitution was evaluated using a USP II dissolution apparatus (Pharma-Test, 
Hainburg, Germany) by adding 3 g pellets corresponding to 0.6 g of oil/surfactant/drug mixture in 
200 mL distilled water, at 37?±?0.5°C, and stirring for 3 h at 100 rpm. These conditions ensured 
complete reconstitution for most pellet batches [22]. 
Experimental Design and Statistical Analysis 
A mixed level full factorial, completely randomized design (12 runs) with two factors at two levels 
(drug lipophilicity and oil/surfactant ratio) and one factor at three (type of surfactant), was 
employed to study their effects on the properties of emulsions and pellets. The prepared batches 
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Table 1. Mixed Level Full Factorial Experimental Design 
Formulation Drug Surfactant Oil/surfactant ratio 
1 FS ELP 1.5 
2 FS ELP 2.3 
3 FS RH40 1.5 
4 FS RH40 2.3 
5 FS RH60 1.5 
6 FS RH60 2.3 
7 PR ELP 1.5 
8 PR ELP 2.3 
9 PR RH40 1.5 
10 PR RH40 2.3 
11 PR RH60 1.5 
12 PR RH60 2.3 
 
For the statistical analysis, a 3-way analysis of variance (ANOVA) was applied and the statistical 
index adjusted coefficient of determination (Ra2) was used, representing the proportion of the 
variability in the data explained by the ANOVA, after adjusting for the number of experiments and 
the number of variables [26]. Furthermore, pairwise comparison of means (2-tailed t test) was 
applied for the estimation of the significance of the differences in the properties of emulsions due to 
the addition of drugs. For the analysis of the data, the SPSS 20.0 statistical software was used (IBM 
SPSS Statistics, Inc., Chicago, IL USA). Effects were considered significant at p value <0.05, less 
significant at p between 0.05 and 0.10, and without significance at p?>?0.10. 
RESULTS AND DISCUSSION 
The physicochemical properties of drugs, surfactants and oil are summarized in Table 2. From the 
physicochemical properties, it can be seen that the aqueous solutions of FS and PR have high 
surface tensions (64 and 66 mN/m) indicating minor surface activity compared to the surface 
tensions of surfactants (41.3–44.8 mN/m). The molecular size of drugs is similar (330.8 and 259.3), 
but they have different lipophilicities (log P 2.0 and 3.5, respectively) and different solubilities in 
the oil/surfactant mixtures (24.7–63.2 mg/mL; ref. 22). Therefore, the drugs are expected to be 
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distributed differently between the droplets and the external aqueous phase [15]. Similarly, the 
surfactants employed are expected to be distributed differently in the oil/water interface, due to their 
different hydrophilicity (HLB 13.9–15.7), and also to present different excess surface concentration 
in the water/air interface at the pellet surface during drying (Figure 1). Consequently, the 
combinations of different drug and surfactant types in altered proportions are expected to influence 
the formation of emulsions and the properties of the self-emulsifying pellets [12,13]. 
 
Table 2. Physicochemical properties of drugs, surfactants and oil 
Material Molecular weight LogP HLB




Furosemide 330.8 a 2.0 d n/a 219 a 64.0 (1.0) g 
Propranolol 259.3 a 3.5 e n/a 95 a 66.0 (1.0) g 
Surfactants 
Cremophor ELP 2,500 b n/a 13.9 20 c 41.3 (0.3) g 
Cremophor RH40 2,500 b n/a 14.3 30 c 44.0 (0.1) g 
Cremophor RH60 2,800 b n/a 15.7 30c 44.8 (0.3) g 
Oil 
Medium chain triglyceride 498 c n/a n/a −20 c 31.1 c 
aMerck index 
bBASF Technical Information May 2010 
cHandbook of Pharmaceutical Excipients 
dAlvarez-Nunez and Yalkowsky [31] 
eAvdeef et al. [29] 
fMatsaridouet al. [12] 
gSaturated drug and 0.1%?w/v surfactant solutions in distilled water measured after filtration (0.1 μm) with a du Nuoy 
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Figure 1. Schematic representation of drug, surfactant and oil in the MCC pellets 
 
Effect of Drug Incorporation on Emulsion Properties 
In Figure 2a–c, the properties of emulsions without (inert) and with drug are compared. It can be 
seen (Figure 2a) that the presence of FS decreases the droplet diameter in all cases (pairwise 
comparison of means, t test, p? =?0.009), whereas that of PR decreases the diameter of emulsions 
with ELP and RH40 but not with RH60. Since the surface activity of the drugs is minor compared 
to the surfactants, the decrease in droplet diameter caused by the presence of drug implies a co-
surfactant drug effect. 
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Figure 2. Comparison of a droplet diameter, b zeta potential, and c viscosity for inert and drug-
loaded emulsions used for the preparation of pellets 
 
Regarding the zeta potential (ζ), it can be seen in Figure 2b that for inert emulsions it is negative 
due to the free fatty acids present in the oil which confirms previously reported data for self-
emulsifying systems with nonionic surfactants [13,27]. In the case of inert emulsions with RH60, 
the zeta potential is less negative compared to the other surfactants probably due to their generally 
greater droplet diameter and its influence on droplet mobility (Figure 1a and ref. 12). Interestingly, 
in Figure 2b, it can be seen that ζ changes significantly due to the presence of drug, negatively for 
furosemide and positively for propranolol. These ζ changes should be related to the presence of 
drug in the oil/water interface affected by both, the surfactant type and the oil/surfactant ratio. 
More specifically, for furosemide which is a weak acid (pKa ?=?4.25), its carboxylic acid ionizes in 
the aqueous solution giving negatively charged carboxylate and negative overall droplet surface 
charge, which explains the decrease of zeta potential. Conversely, the characteristic turning to 
positive values by propranolol should arise from its basic character due to the presence of amino 
group (−NH, pKa?=?9.53) which neutralize the free fatty acids present in the oil of the self-
emulsifying mixture [28]. 
Regarding the emulsion viscosity, it can be seen from Figure 2c that in all cases, incorporation of 
drugs causes an increase. This can be attributed to the presence of drugs in the oil/water interface 
and the consequent alteration in the surrounding the droplet hydrated layer and hence in the 
shearing resistance [29]. In general, FS addition gave greater viscosity than PR, which is in 
agreement with its higher hydrophilicity and therefore increased presence in the oil/water interface 
[15]. Pairwise comparison of means, t test, gave p?=?0.012 for FS and p?=?0.006 for PR. The higher 
viscosity seen in Figure 2c for formulation with Cremophor RH40 with oil/surfactant ratio 1.5 and 
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furosemide in comparison with the formulation with ratio 2.3 is associated with the transparent 
appearance of the emulsion and its lower average droplet diameter (part of Pellet preparation in 
Materials and Methods and Table 3). Formation of transparent dispersions of RH40 with medium 
chain triglycerides was also previously observed for emulsions without drug [12]. 
 
Table 3. Droplet diameter, polydispersity index, and zeta potential of added and reconstituted 
emulsions together with the viscosity of added emulsions [mean, (SD), n?=?3] 
Cremophor/ratio 
Added emulsions Reconstituted emulsions 
Viscosity (cP) 
dv (nm) PDI ζ (mV) dv (nm) PDI ζ (mV) 
Furosemide 
ELP/1.5 240 (4) 0.264 −1.4 (2.7) 494 (43) 0.406 −25.7 (0.9) 4.94 (0.00) 
ELP/2.3 291 (4) 0.285 −1.3 (0.9) 562 (40) 0.468 −27.9 (1.8) 3.98 (0.03) 
RH40/1.5 182 (1) 0.283 −1.6 (3.3) 303 (16) 0.488 −24.3 (0.6) 7.75 (0.08) 
RH40/2.3 302 (4) 0.411 −1.7 (0.4) 632 (74) 0.498 −27.8 (0.4) 4.98 (0.02) 
RH60/1.5 227 (4) 0.262 −2.4 (1.4) 533 (30) 0.447 −28.5 (1.1) 4.86 (0.03) 
RH60/2.3 310 (18) 0.290 −1.8 (0.5) 643 (69) 0.487 −28.2 (0.8) 4.25 (0.01) 
Propranolol 
ELP/1.5 222 (4) 0.236 0.6 (0.2) 467 (52) 0.381 −19.2 (0.4) 3.89 (0.00) 
ELP/2.3 259 (4) 0.205 0.5 (0.2) 
596 
(119) 
0.447 −22.6 (0.2) 2.93 (0.03) 
RH40/1.5 200 (2) 0.236 0.4 (1.0) 552 (8) 0.407 −11.6 (0.3) 4.94 (0.02) 
RH40/2.3 263 (6) 0.212 1.2 (1.4) 349 (10) 0.452 −13.4 (0.4) 3.97 (0.01) 
RH60/1.5 311 (7) 0.371 0.0 (3.2) 401 (39) 0.418 −15.2 (0.3) 4.56 (0.01) 
RH60/2.3 499 (20) 0.406 0.6 (0.4) 405 (96) 0.411 −14.7 (0.7) 4.20 (0.03) 
dv average hydrodynamic droplet diameter, PDI polydispersity index, ζ zeta potential 
 
Effect of Surfactant Type and Ratio on Droplet Size, Zeta Potential, and Viscosity 
In Table 3 are presented the results of droplet diameter and polydispersity index (PDI) and of ζ for 
the added to the MCC during pellet preparation and for the reconstituted emulsions, together with 
the viscosity of the added emulsions. Viscosity of the added emulsions was evaluated in order to be 
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compared with the pellet properties. In Table 4 are given the results of ANOVA for the main effects 
and interactions of the studied factors on the properties of added emulsions and self-emulsifying 
pellets. 
 
Table 4. ANOVA of the main effects and interactions of the type of drug (A), the type of surfactant 
(B), and the oil/surfactant ratio (C) on the properties of added emulsions and self-emulsifying 
pellets 
Property 
Main and effects Interactions Ra2 
A B C A?×?B B?×?C A?×?C 
Added emulsions 
Droplet diam. (dv) 0.333 0.135 0.070 0.164 0.413 0.568 0.742 
ζ-potential (ζ) 0.006 0.213 0.202 0.481 0.486 0.562 0.943 
Viscosity (η) 0.066 0.096 0.059 0.240 0.324 0.349 0.822 
Pellets 
Median diameter 0.025 0.016 0.614 0.049 0.104 0.191 0.951 
Fullness index (FI%) 0.329 0.491 0.213 0.320 0.287 0.185 0.503 
Aspect ratio (AR) 0.121 0.254 0.201 0.250 0.535 0.405 0.594 
Shape factor (eR) 0.059 0.096 0.054 0.110 0.317 0.148 0.861 
Friability (%) 0.021 0.028 0.012 0.046 0.169 0.044 0.959 
Tensile strength 0.244 0.688 0.123 0.081 0.126 0.142 0.797 
Migration% 0.132 0.473 0.204 0.822 0.972 0.620 0.248 
Disintegration time 0.649 0.624 0.633 0.389 0.586 0.236 0.048 
Reconstituted emulsions 
Droplet diameter (dv) 0.025 0.259 0.095 0.084 0.777 0.641 0.858 
ζ-potential (ζ) 0.013 0.112 0.177 0.212 0.373 0.511 0.901 
Numbers in bold correspond to statistical significance p?<?0.05 and numbers in italics to statistical significance p 
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Droplet Size 
Comparing the droplet diameters of added to the MCC emulsions with those of the corresponding 
reconstituted, it can be seen that they are significantly smaller, except in the case of propranolol 
with RH60 at oil/surfactant ratio 2.3. The range of PDI values increase from 0.205–0.406 for the 
added emulsions (the majority between 0.205 and 0.290) to 0.381–0.498 for the reconstituted, 
which is still under 0.500, thus, allowing comparison of the droplet diameters of the different 
formulations [30]. The increase in reconstituted emulsions is by about a factor of 2, although still in 
the nano-size range (303–643 nm) which is desirable for absorption. The increase in the droplet size 
and the higher PDI values of the reconstituted emulsions, are attributed to the expected reduction in 
excess surface concentration of surfactant and drug in the oil/water interface due to the incomplete 
reconstitution of emulsions from pellets, as reported previously [12,22]. 
Regarding the effect of drug type on the droplet diameter of reconstituted emulsions, the more 
lipophilic PR appears giving emulsions with lower overall diameter (ANOVA p = 0.025, Table 4), 
implying better stability of the reformed emulsion due to the easier incorporation and more firmly 
bound lipophilic drug to the oil/surfactant and to the greater surfactant availability. Regarding the 
effect of oil/surfactant ratio on droplet diameter, from Table 3 appears that for the added emulsions 
and for the same drug and surfactant, the diameters for the high oil/surfactant ratio are greater than 
those of the low ratio (p = 0.070, Table 4) which should be attributed to decreased interfacial film 
formation due to the lower surfactant content. 
Zeta Potential (ζ) 
The effects of formulation variables on the ζ of the added emulsions have been already presented 
and discussed during the comparison of inert and pharmaceutical emulsions. Now, comparing the ζ 
of the reconstituted emulsions with that of the added, it can be seen from Table 3 that ζ in the 
reconstituted emulsions changes considerably towards negative values, which can be ascribed to the 
effect of dilution on the composition of oil/water interface, and consequently, in the diffuse 
electrical layer around the droplets. In particular, this change shows the predominance of the free 
acids in the oil of the self-emulsifying mixture. ANOVA (Table 4) shows significant effect of the 
type of drug on ζ values for both added and reconstituted emulsions (p?=?0.006 and p? =?0.013, 
respectively) which means that drug charges still exist after reconstitution, resulting in significant 
differences in the droplet charges of the reconstituted emulsions of the two drugs. In fact, bivariate 
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correlation analysis between the ζ values of added (1/10 dilution of oil/surfactant in water) and 
reconstituted emulsions gave linear relationship: 
ζreconstituted = 4.5626?ζadded-18.9680(R2=0.7626)                                                                                 (4) 
The higher dilution of droplets in the reconstituted emulsions is due to the volume of the 
reconstitution medium used in the test (200 mL in which 3 g pellets were suspended, corresponding 
to 0.6 g self-emulsifying mixture and 1/333 dilution instead of 1/10 in the prepared emulsions) and 
also due to the contact and adherence of the hydrophilic surfactants on the MCC fibrils of the dry 
pellets, resulting in incomplete reconstitution [12]. 
Viscosity 
Viscosity of the added emulsions was determined as a quantitative measure of the difficulty to flow, 
which is expected to vary, since their appearance varied from clear to translucent or milky liquid, 
due to the different composition and relatively high content (25% w/w) of the drug/oil/surfactant 
mixture. More importantly, emulsion viscosity may affect the micromeritic and particularly the drug 
migration during pellet drying [19]. The effect of drug addition on viscosity has already been 
discussed and now the surfactant type and oil/surfactant ratio will be considered. 
From Table 3, it appears that although the effect of surfactant on viscosity is of low statistical 
significance (p?=?0.096, Table 4) RH40 contributes highest in viscosity, followed by RH60 and ELP. 
Taking into account the surfactant properties, Table 2, we can see that their effect on emulsion 
viscosity should be a combination of molecular weight and HLB value, both of which (together 
with the surfactant content) affect their concentration in the oil/water interface. The increase of 
viscosity at lower oil/surfactant ratio is clear for all the emulsions studied and ANOVA confirmed 
this effect at significance p?=?0.059 (Table 4) which can be attributed to the increased surfactant 
content at the oil/water interface and hence greater hydration and shearing resistance. 
Pellet Properties 
In Table 5 are summarized the micromeritic together with the mechanical properties and in Table 6 
the pharmaco-technological properties of the pellets respectively. From Table 5 it can be seen that 
the extra amount of water required, additionally to the emulsion (30 g) for the formation of pellets 
with narrowest size distribution and most spherical shape, increases slightly with oil/surfactant ratio 
for half of the batches of both drugs. Also, for a fixed ratio it increases in the order ELP < RH40 < 
RH60, which is the same as the order of their HLB value or hydrophilicity. Therefore, the effects of 
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the surfactant content and type on the pellet properties should be ascribed to the hydration of MCC 
[12]. 
 
Table 5. Extra water required during MCC wet massing, micromeritic (size, shape) and mechanical 
(friability and tensile strength) properties of self-emulsifying pellets [mean, (SD), n = 3 and for 














FI(%) AR eR 
Furosemide 
ELP/1.5 2 79 1,071 3.34 1.09 0.53 3.6 0.81 
ELP/2.3 3 69 1,096 3.49 1.09 0.54 2.2 0.67 
RH40/1.5 2 70 1,083 3.45 1.11 0.47 3.6 0.88 
RH40/2.3 3 80 1,062 3.84 1.10 0.50 2.5 0.67 
RH60/1.5 5 87 1,000 3.47 1.09 0.52 2.3 1.10 
RH60/2.3 5 87 1,012 3.11 1.08 0.55 1.7 0.78 
Propranolol 
ELP/1.5 3 79 1,043 3.47 1.10 0.51 2.8 0.99 
ELP/2.3 3 84 1,037 3.34 1.08 0.54 2.4 0.72 
RH40/1.5 3 78 1,048 3.90 1.12 0.44 2.1 0.98 
RH40/2.3 4 86 1,018 3.18 1.11 0.50 1.6 0.65 
RH60/1.5 5 90 1,013 6.11 1.18 0.37 2.0 0.60 
RH60/2.3 5 89 1,019 3.22 1.10 0.49 1.9 0.52 
FI% fullness index, AR aspect ratio, eRshape factor 
aModal size fraction: 850–1,200 μm 
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Table 6. Pharmaco-technological properties of pellets (disintegration time, drug content in outer 




Drug (μg) in Migration 
(%) 
Drug solubilitya in 





ELP/1.5 6.2 (0.4) 210 (6) 193 (4) 9.0 26.0 (0.5) 
ELP/2.3 4.5 (0.7) 235 (8) 215 (2) 9.8 24.7 (0.9) 
RH40/1.5 4.5 (0.2) 214 (9) 209 (2) 2.5 40.7 (0.9) 
RH40/2.3 4.4 (0.4) 241 (5) 212 (3) 14.5 28.0 (2.0) 
RH60/1.5 4.8 (0.3) 206 (1) 197 (2) 4.3 29.9 (0.7) 
RH60/2.3 4.5 (0.1) 233 (1) 195 (1) 18.5 29.8 (2.5) 
Propranolol 
ELP/1.5 4.2 (0.1) 194 (2) 192 (1) 0.8 63.2 (2.7) 
ELP/2.3 3.7 (0.1) 210 (4) 189 (6) 11.0 47.6 (2.3) 
RH40/1.5 5.7 (0.1) 218 (1) 214 (2) 1.8 61.5 (1.3) 
RH40/2.3 4.9 (0.1) 220 (5) 211 (1) 4.3 49.6 (2.8) 
RH60/1.5 10.8 (0.3) 202 (1) 199 (1) 1.3 57.0 (2.5) 
RH60/2.3 4.3 (0.1) 220 (1) 217 (2) 1.8 49.9 (2.6) 
aData from Nikolakakis and Malamataris 2014 [22] 
 
Pellet Size 
The results in Table 5 show that most pellet batches have a high percentage (69–89%) in the modal 
size fraction 850–1,200 μm and median diameters in a narrow size range (1,000–1,096 μm). 
ANOVA (Table 4) showed interaction of the effects of drug type and surfactant type on the median 
diameter (p?=?0.049). This is depicted in Figure 3a by comparing the mean values of pellet diameters 
for the two drugs and the three surfactants. It can be seen that the difference between drugs are 
pronounced for pellets with ELP and RH40 but small for those with RH60. Also, for FS, the 
difference between ELP and RH60 or between RH40 and RH60 is large; whereas for PR, it is small, 
indicating that the effect of drug depends on the surfactant. The decreasing size of the pellets with 
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increasing surfactant hydrophilicity (Figure 3a) can be explained due to the greater extra water 
required for their preparation (Table 5) and hence greater water loss and decrease in diameter 
during drying. As can be seen in Table 5 the range of required extra water is smaller for propranolol 
compared to furosemide (2 to 5 compared with 3 to 5) which accounts for the different effect of 
surfactant type for the two drugs. 
 
 
Figure 3. Interaction plots of the effects of drug and surfactant on a pellet diameter and b friability, 
and c interaction plots of the effects of drug and oil/surfactant ratio on friability (solid symbols with 
solid lines for furosemide and open symbols with dotted lines for propranolol) 
 
Pellet Shape 
From Table 5, it can be seen that, except for formulation of PR with RH60 at oil/surfactant ratio 1.5, 
the values of the fullness index (FI% <3.90), aspect ratio (AR <1.12) and shape factor (eR>0.44) 
indicate production of spherical pellets. However, the values of eR for the different formulations 
vary considerably (0.37–0.55), meaning that eR is more discriminative. Comparing pellet batches of 
the two drugs, it can be seen that eR is lower for PR batches (drug effect significant at p?=?0.059, 
Table 5). For the different surfactants, the results in Table 5 do not show a certain trend, whereas 
for different oil/surfactant ratios eR increases clearly with the increase of oil/surfactant ratio or 
lower surfactant content (p?=?0.054, Table 5). Comparing the effects of the three studied factors on 
pellet shape and emulsion properties, we can see that viscosity and eR are both affected at similar 
significant level by the type of drug and the oil/surfactant ratio. Therefore, the differences in eR 
values should be related to the viscosity of emulsions used for the preparation of the pellets. 
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More specifically, considering the data in Tables 3 and 5, it can be seen that emulsions of 
furosemide with RH40 at oil/surfactant ratio 1.5 and 2.3 (denoted as FS/RH40/1.5 and 
FS/RH40/2.3) and emulsions of propranolol with RH40 and RH60 at ratio 1.5 (denoted as 
PR/RH40/1.5 and PR/RH60/1.5) with higher viscosity, correspond to more irregular pellets with 
higher FI% and AR and lower eR. Accordingly, the relationship between pellet shape and emulsion 
viscosity was examined by plotting data of the more established shape parameters aspect ratio (AR) 
and shape factor (eR) against emulsion viscosity. The plots in Figure 4a, b show that except for 
formulation PR/RH60/1.5, AR increases linearly with viscosity (R2?=?0.711 and 0.893 for FS and 
PR, respectively, Figure 4a), whereas eR decreases (R2?=?0.740 and 0.977, Figure 4b). 
 
 
Figure 4. Plots of a aspect ratio and b shape factor (eR) with the viscosity of emulsions used for the 
preparation of pellets (round symbols for furosemide and square for propranolol) 
 
The increased sphericity with decreasing viscosity should be due to even spreading of emulsions in 
MCC powder resulting in more homogeneous wet mass and improved distribution of the self-
emulsifying oil/surfactant/drug mixture in the pellets. The deviation of formulation PR/RH60/1.5 
representing high drug lipophilicity, high surfactant hydrophilicity and content, may be ascribed to 
the difficulty of spreading of the respective emulsion in MCC, resulting in high FI% and low eR 
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Pellet Friability and Tensile Strength 
From the results in Table 5, it appears that all batches of self-emulsifying pellets exhibit friability 
>1.6%. This is expected considering the relatively high proportion of self-emulsifying mixture 
(20% w/w), resulting in weaker MCC interparticle bonding and less coherent pellets. More 
specifically, from Table 5, it appears that overall, furosemide pellets show higher friability than 
propranolol and that for the same drug and surfactant, the friability of pellets with higher 
oil/surfactant ratio is always lower. This should be related to the greater deformability of pellets due 
to the higher oil content and hence their greater ability to absorb shocks during tumbling in the 
friabilator and also to lubricating action of the oil. From the results of ANOVA (Table 4), it is seen 
that all studied formulation factors affect friability and there are significant interactions between the 
effect of drug and surfactant type (p?=?0.046) as well as between the effect of drug type and 
oil/surfactant ratio (p?=?0.044). 
The former of the two interactions is depicted in Figure 3b, where the differences in friability for 
the two drugs are seen to be greater for Cremophor RH40, with FS showing highest and PR lowest 
friability, whereas there are no differences for Cremophor RH60. The latter of the two interactions 
is depicted in the plots of Figure 3b, where the decrease in friability with oil/surfactant ratio is seen 
to be steeper for FS. The greater friability of FS pellets compared to PR and, in particular, those 
made with Cremophor RH 40 (Figure 3b) can be ascribed to the higher viscosity of the added 
FS/RH40 emulsions (7.75 and 4.98 cP at oil/surfactant ratios 1.5 and 2.3 for FS compared with 4.94 
and 3.97 cP for PR, Table 3). The higher viscosity impairs the movement of emulsions and 
distribution into MCC powder, as manifested by high extrusion forces [18], and consequently the 
efficiency of incorporation of oil/surfactant in the dry pellet, which adversely affects pellet 
deformability or the ability to absorb stresses during friability testing. The low and similar friability 
of the pellets of both drugs made with RH60 could be ascribed to the increased presence of the 
highly hydrophilic surfactant (HLB?=?15.7) on the pellet surface, migrating along with the water 
during drying and also, to its high molecular weight and solid nature (Table 2), resulting in harder 
pellet surface. The different effect of oil/surfactant ratio for the two drugs on friability (interaction 
shown in Figure 3c) can be ascribed to the greater difference in the viscosities of the emulsions of 
the two drugs at ratio 1.5 (1.39 cP, Table 3) compared with ratio 2.3 (1.33 cP) and consequently 
greater difference in pellet deformability as explained above. 
From the data in Table 5, it appears that the type of drug and the surfactant do not have an effect on 
tensile strength. However, for the same drug and surfactant type, tensile strength clearly decreases 
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with the increase in oil/surfactant ratio which should be attributed to the weakening of the 
interparticle MCC bonds due to the masking action of the oil [12]. 
Pellet Disintegration 
From Table 3, the disintegration time does not seem to be influenced by the type of drug or 
surfactant. However, for the same drug and surfactant type, there is a general decrease with the 
increase in oil/surfactant ratio. This is in agreement with the weaker MCC interparticle bonding 
which is responsible for the tensile strength reduction due to the increased oil content and, 
additionally, it can be ascribed to lesser gel formation due to the lower surfactant content [11,12]. 
The nearly double disintegration time of formulation PR/RH60/1.5 can be ascribed to the inefficient 
spreading and uneven distribution of oil/surfactant in the pellets which probably limits the presence 
of surfactant and wetting at certain parts of the pellet surface only, resulting in less efficient liquid 
penetration and longer disintegration time. This is also indicated by the lowest sphericity of 
PR/RH60/1.5 pellets (highest FI% and AR and lowest eR, Table 5). 
Drug Migration in Pellets 
The results of drug content in outer and inner part of pellets together with the calculated migration 
(%) and solubility of drug in the corresponding oil/surfactant mixture are given in Table 6. 
Migration appears greater for the less lipophilic furosemide and particularly for higher oil/surfactant 
ratio. 
The drug lipophilicity and oil/surfactant ratio should affect migration due to their combined 
influences on the solubilization of drug in the oil of droplets and on capillary flow (viscosity) of the 
emulsion used. In pellets, before drying, drug may exist as solubilized in the oil droplets and as 
dissolved or suspended in the continuous aqueous emulsion phase, Figure 1. Since the solubilities 
of the two studied drugs in water at the ambient temperature of pellet preparation, are similar (0.063 
mg/mL for FS and 0.051 mg/mL for PR) and remarkably lower (about 3 orders of magnitude) than 
those in oil/surfactant mixtures (24.7–63.2 mg/mL), the drug lipophilicity should determine 
partitioning in the two emulsion phases and the concentration in the droplets [13,15]. During 
drying, instability of the emulsion and deposition of drug dissolved in the aqueous phase may occur. 
Therefore, in dried pellets the drug exists as solubilized in the oil/surfactant mixture dispersed in the 
MCC particles, and/or as solid particles, mainly in the outer part of the pellets, carried there by the 
migrating aqueous phase of the emulsion during drying. 
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In addition, viscosity affects capillary flow of liquid phase towards the pellet surface and drug 
deposition due to water evaporation during drying together with surface tension as has been already 
reported for wet granulations dried in conventional oven [19]. The contribution of surface tension 
on migration is not expected to be significant for the examined formulations, since it is similar for 
the aqueous solutions of the two drugs (64.0 and 66.0 mN/m) and the three surfactants (41.3–44.8 
mN/m, Table 2). 
Comparing the effects of drug lipophilicity and oil/surfactant ratio on emulsion viscosity and drug 
migration (%) (Tables III and VI), there is apparently some controversy. As expected, decreased 
emulsion viscosity due to increase of oil/surfactant ratio (for the same drug) corresponds to 
increased migration (%) but decreased viscosity due to increased drug lipophilicity corresponds to 
decreased migration (%). This controversy reveals predominance of drug lipophilicity and solubility 
in oil droplets on migration (%) over that of capillary flow. 
From the above discussion, it is clear that both the viscosity of the emulsion (η) and drug solubility 
in oil/surfactant mixture (S) should control drug migration towards pellet surface. Accordingly, 
from the drug migration (M%) plots against the product [η•S], Figure 5, it can be seen that M% 
decreases exponentially with the product [η•S], following the simple equation (R2?=?0.856): 
?? ? ???????????????? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????(5) 
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Regarding the emulsion properties, viscosity is affected by the type of drug and oil/surfactant ratio, 
the droplet size by the oil/surfactant ratio, while zeta potential is affected by the drug. 
For the micromeritic properties and mechanical strength of pellets, pellet shape is affected by the 
studied formulation variables and there was significant interaction between the effects of the drug 
and surfactant type on pellet diameter. There were also significant interactions between the effects 
of drug and surfactant type and between the effects of drug and oil/surfactant ratio on pellet 
friability. 
Regarding the pharmaco-technological properties of pellets, drug migration is higher for furosemide 
of lower lipophilicity and for higher oil/surfactant ratio. The droplet size of the reconstituted 
emulsions and the zeta potential of both added to the MCC (for the preparation of pellets) and 
reconstituted emulsions are affected by the type of drug. Linear relationships between the emulsion 
viscosity and shape parameters of pellets (aspect ratio and shape factor) and exponential 
relationship between drug migration (%) and the product of viscosity and solubility of drug in 




Polysaccharides as Drug Delivery Systems for different Administration Routes 
Tesi di Dottorato in Scienze e Tecnologie Chimiche-Scienze Farmaceutiche 
Università degli Studi di Sassari 
References 
1. Bechgaard H, Hegermann NG. Controlled-release multiple-units and single-unit doses. Drug 
Dev Ind Pharm. 1978;4:53–67. 
2. Schulz P, Kleinebudde P. A new multiparticulate delayed release system. Part I: dissolution 
properties and release mechanism. J Control Release. 1997;47:181–9. 
3. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral 
absorption: physical and biopharmaceutical aspects. Pharm Res. 1995;12(11):1561–72. 
4. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev. 
1997;25:47–58. 
5. Newton M, Petersson J, Podczeck F, Clarke A, Booth S. The influence of formulation 
variables on the properties of pellets containing a self-emulsifying mixture. J Pharm Sci. 
2001;90(8):987–95. 
6. Serratoni M, Newton JM, Booth S, Clarke A. Controlled drug release from pellets 
containing water-insoluble drugs dissolved in a self-emulsifying system. Eur J Pharm Biopharm. 
2007;65:94–8. 
7. Newton JM. Gastric emptying of multi-particulate dosage forms. Int J Pharm. 2010;395:2–8. 
8. Tuleu K, Newton M, Rose J, Euler D, Saklatvala R, Clarke A, et al. Comparative 
bioavailability study in dogs of a self-emulsifying formulation of progesterone presented in a pellet 
and liquid form compared with an aqueous suspension of progesterone. J Pharm Sci. 
2004;93(6):1495–502. 
9. Iosio T, Voinovich D, Grassi M, Pinto JF, Perissutti B, Zacchina M, et al. Bi-layered self-
emulsifying pellets prepared by co-extrusion and spheronization: Influence of formulation variables 
and preliminary study on the in vivo absorption. Eur J Pharm Biopharm. 2008;69:686–97. 
10. Wang Z, Sun J, Wang Y, Liu X, Liu Y, Fu Q, et al. Solid self-emulsifying nitrendipine 
pellets: Preparation and in vitro/in vivo evaluation. Int J Pharm. 2010;383:1–6. 
11. Nazzal S, Smalyukh II, Lavrentovich OD, Khan MA. Preparation and in vitro 
characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) 
of ubiquinone: mechanism and progress of emulsion formation. Int J Pharm. 2002;235:247–65. 
12. Matsaridou I, Barmpalexis P, Salis A, Nikolakakis I. The Influence of Surfactant HLB and 
Oil/Surfactant Ratio on the Formation and Properties of Self-emulsifying Pellets and 
Microemulsion Reconstitution. AAPS PharmSciTech. 2012;13(4):1319–30. 
53 
Andrea Salis 
Polysaccharides as Drug Delivery Systems for different Administration Routes 
Tesi di Dottorato in Scienze e Tecnologie Chimiche-Scienze Farmaceutiche 
Università degli Studi di Sassari 
13. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Self-emulsifying drug delivery 
systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral 
absorption of lipophilic drugs. Int J Pharm. 1994;106(1):15–23. 
14. Nielsen FS, Gibault E, Ljusberg-Wahren H, Arleth L, Pedersen JS, Mullertz A. 
Characterization of prototype self-nanoemulsifying formulations of lipophilic compounds. J Pharm 
Sci. 2007;96(4):876–92. 
15. Chidambaram N, Burgess DJ. Effect of nonionic surfactant on transport of surface-active 
and non-surface-active model drugs and emulsion stability in triphasic systems. AAPS Pharm Sci. 
2000;2(3):1–11. 
16. Sznitowska M, Janicki S, Dabrowska E, Zurowska-Pryczkowska K. Submicron emulsions 
as drug carriers. Studies on destabilization potential of various drugs. Eur J Pharm Sci. 
2001;12(3):175–9. 
17. 17.Ktistis G. A viscosity study on oil-in-water microemulsions. Int J Pharm. 1990;61:213–8. 
18. Podczeck F, Maghetti A, Newton JM. The influence of non-ionic surfactants on the 
rheological properties of drug/microcrystalline cellulose/water mixtures and their use in the 
preparation and drug release performance of pellets prepared by extrusion/spheronization. Eur J 
Pharm Sci. 2009;37:334–40. 
19. Kapsidou T, Nikolakakis I, Malamataris S. Agglomeration state and migration of drugs in 
wet granulations during drying. Int J Pharm. 2001;227:97–112. 
20. Poutiainen S, Honkanen M, Becker J, Nachtweide D, Järvinen K, Ketolainen J. X-ray 
microtomography analysis of intragranular drug migration during fluidized bed and oven tray 
drying. J Pharm Sci. 2012. doi:10.1002/jps.23051. 
21. Schrank S, Hodzic A, Zimmer A, Glasser JB, Khinast J, Roblegg E. Ibuprofen-loaded 
calcium stearate pellets: drying-induced variations in dosage form properties. AAPS PharmSciTech. 
2012;13(2):686–98. 
22. Nikolakakis I, Malamataris S. Self-emulsifying pellets: relations between kinetic parameters 
of drug release and emulsion reconstitution, influence of formulation variables. J Pharm Sci. 
2014;103(5):1453–65. 
23. Ktistis G, Niopas I. A study on the in-vitro percutaneous absorption of propranolol from 
disperse systems. J Pharm Pharmacol. 1998;50(4):413–8. 




Polysaccharides as Drug Delivery Systems for different Administration Routes 
Tesi di Dottorato in Scienze e Tecnologie Chimiche-Scienze Farmaceutiche 
Università degli Studi di Sassari 
25. Shipway PH, Hutchings IM. Attrition of brittle spheres by fracture under compression and 
impact loading. Powder Technol. 1993;76:23–30. 
26. Montgomery DC. Design and analysis of experiments. 4th ed. New York: Wiley; 1987. p. 
108–10. 
27. Thi TD, Van Speybroeck M, Barillaro V, Martens J, Annaert P, Augustijns P, et al. 
Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS. Eur J 
Pharm Sci. 2009;38:479–88. 
28. Avdeef A, Box KJ, Comer JEA, Hibbert C, Tam KY. pH-Metric logP 10. Determination of 
Liposomal membrane-water partition coefficients of ionizable drugs. Pharm Res. 1998;15(2):209–
15. 
29. Florence AT, Attwood D. Physicochemical principles of pharmacy. 2nd ed. New York: The 
Macmillan Press; 1988. p. 239–40. 
30. Zetasizer Nanoseries User Mannual MANO 317 Issue 1.1 Feb. 2004 page 5.6. Malvern 
Instruments Ltd, Worcestershire. 
31. Alvarez-Nunez FA, Yalkowsky SH. Relationship between polysorbate 80 solubilization 














Polysaccharides as Drug Delivery Systems for different Administration Routes 
Tesi di Dottorato in Scienze e Tecnologie Chimiche-Scienze Farmaceutiche 
Università degli Studi di Sassari 
CHAPTER 2: 
Development of thermosensitive chitosan/glicerophospate injectable in situ gelling solutions 
for potential application in intraoperative fluorescence imaging and local therapy of 
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is an important cause of cancer deaths: each year > 600,000 
people die from HCC in the world [1]. The hepatic resection represents the initial treatment for 
localized HCCs in patients without vascular invasion and with preserved hepatic functions [2]: the 
precise imaging of HCC nodules is clearly important for the success of the surgical procedure. 
HCC is classified as a highly chemoresistant disease and conventional systemic chemotherapy plays 
almost no role in the treatment of advanced HCCs. For these reasons, localized anticancer therapies 
must be taken into account [3]. Among several locoregional ablative methods, transarterial 
embolization (TAE) consists of embolization of the artery feeding the tumor, which results in 
ischemia and subsequent tumor necrosis, whereas transarterial chemoembolization (TACE) implies 
the localized delivery of chemotherapeutic drugs combined with the use of embolic materials. The 
rationale is based on the fact that normal liver tissue receives its blood supply from the portal vein, 
whereas liver tumors mostly from the hepatic artery [4,5]: a combination of concentrated 
chemotherapy and local ischemia within the tumor can be synergistic in achieving tumor necrosis 
[6]. 
Nowadays, microparticles are used both as embolic agents (TAE), and as embolic drug carriers 
(TACE). In humans microparticles of size larger than 10 μm are used considering that the capillary 
diameter is ? 6 – 8 μm. Diameters from 40 to almost 1000 μm are suitable. Particles greater than 
1000 μm can determine catheter clogging during the intra-arterial administration [3]. 
The microparticles can be classified as non-biodegradable (e.g., polyvinyl-alcohol [PVA] 
microspheres) or biodegradable (e.g., microspheres based on natural polymers such as starch, 
gelatin, chitosan or on synthetic polymers such as polylactic-co-glycolic acid. Commercial products 
are available constituted by calibrated microspheres (drug empty particles to be loaded before use) 
that have changed the conditions of embolization: radiologists can adapt the size of microspheres to 
the size of the vessels to be occluded, in such a way to obtain an accurate targeting [7]. Several 
agents can be used for hepatic embolization; they have been recently reviewed [8]. Briefly, there are 
microspheres available on the market for so-called bland embolization or TAE. These include Bead 
Block®, Embospheres®, Embozene® and Contour SE®. DC Bead® was designed to load 
therapeutic agents to enable one-step TACE and consists of PVA hydrogel modified with sulfonate 
groups that were first to demonstrate the ability to load and release chemotherapeutics in a 
controlled manner – a concept known as a drug-eluting bead (DEB). Other DEB systems are also 
now commercially available but based on microspheres with carboxylic acid functionality instead 
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(HepaSphere® and Tandem®) [9]. All these commercial products are quite successful in the clinic, 
even if the intra-arterial local administration of microparticles can present some difficulties (such as 
catheter clogging). There is therefore the need of new embolizing systems, possibly not based on 
the intra-arterial administration of particles. 
Indocyanine green (ICG) is a water-soluble, amphiphilic tricarbocyanine dye that has a broad range 
of clinical applications due to its low toxicity and capacity to absorb and emit in the near-infrared 
(NIR) spectral range [10]. Human tissue has the lowest absorption coefficient in the NIR part of the 
spectrum; therefore this dye is utilized for diagnostic and therapeutic applications. 
Recent studies report the usefulness of ICG-based intraoperative fluorescence imaging for the 
detection of HCC nodules. HCC tumors show very strong fluorescent signals in patients who had 
been given an ICG bolus several days before surgery as a routine preoperative liver function test 
[11-14]. The real mechanisms that mediate the preferential accumulation of ICG in HCC nodules 
instead of the normal liver tissue are still unknown. A hypothesis could be that ICG accumulates in 
regions of tissue possessing leaky capillaries of vessels [15] or disturbance of bile secretion [11]. 
As reported in the literature [11,12,16], fluorescent nodules can be examined by an NIR camera 
system named PDE (photo dynamic eye, Hamamatsu Photonics K.K. Hamamatsu, Japan), that 
activates ICG with emitted light at a wavelength of 760 nm and filters out light with a wavelength < 
820 nm [17]. The light source is a light emitting diode, and the detector is a charge-coupled device 
camera. The camera unit of the device is directly handled and real-time fluorescence images can be 
observed on the monitor in the operating room. Thus, either nodules detection or hepatic resection 
could be performed under the guide of the PDE. 
‘Smart’ hydrogels are constituted by polymer solutions, which exhibit sol–gel phase transition in 
response to environmental stimuli such as pH, temperature, ionic strength, electric field, magnetic 
fields [18]. 
In situ thermo-sensitive hydrogels use temperature as the trigger of the gelation. Hence, it is 
possible to obtain hydrogels that are solutions at room temperature, but under physiological 
conditions (i.e., the body temperature) they form gels [19]. They can be designed as fluids that can 
be introduced into the desired tissue, organ or body cavity by simple syringe injection. 
The viscosity of solutions can be low enough to allow direct blood administration. Thus after intra-
arterial injection the solutions quickly form a gelled structure able to embolize the tumor [8,20] and 
to deliver imaging agents and/or drugs (if loaded in the precursor solution) [21]. Chitosan (C) is a 
cationic polysaccharide obtained by partial N-deacetylation of chitin. This polymer is widely used 
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in the field of controlled drug release for its gelling properties, biodegradability and high 
biocompatibility [22-24]. 
The major issue concerning the applicability of C formulations is the impossibility of maintaining C 
in solution up to physiological pH due to its pKa (? 6.3). Above pH 6, C has no charge and it forms 
a gel-like precipitate [25]. 
Chenite et al.[25] developed a thermosensitive neutral aqueous solution based on C and 
glycerophosphate (GP), which exhibit sol–gel transition around body temperature. The addition of 
polyol salts, such as GP, leads to the transformation of pH-dependent C solutions into thermally 
sensitive pH-dependent solutions. In the presence of GP, C solutions remain liquid below room 
temperature, even with pH values within a physiologically acceptable neutral range from 6.8 to 7.2 
[25]. These nearly neutral C/GP aqueous solutions gel when heated [26]. The neutralization 
behavior of GP determines C/GP solubility and phase transition phenomena. GP presents a mild 
alkalinity (pKa ? 6.34) providing correct buffering without inducing immediate precipitation or 
gelation when the temperature provided is between 4 and 15°C [26]. 
Taking into account these considerations, the aim of this work was the design and preparation of 
polymeric platforms based on C/GP and loaded with ICG that might be used in the field of TAE 
and following intraoperative fluorescence imaging of HCC. 
MATHERIALS AND METHODS 
Materials 
C was obtained from Primex ehf (Oslo, Norway). The deacetylation degree was 94% and the 
molecular weight was 103 kDa. GP, hydrated disodic salt, was purchased from Sigma Aldrich (St. 
Louis, USA). ICG Pulsion was obtained from SEDA (Trezzano, Italy). The molecular weight was 
774.96 Da. All other chemicals were of analytical grade. 
Preparation of C/GP blank solutions 
C/GP blank solutions at different concentrations (Table 1) were prepared according to the method 
of Kashyap et al. [27]. C was dissolved in 18 ml HCl 0.1 N and GP was solubilized in 2 ml of 
bidistilled water, at room temperature. The two solutions were put into an ice bath until the 
temperature of 4°C was reached. Thereafter, the GP solution was dropwise added, under vigorous 
magnetic stirring, into the C solution. The final solution was then left under stirring into the ice bath 
for 15 min, at 4°C. As reported in the literature, in order to obtain liquid C/GP systems below room 
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temperature a pH range of 6.8 – 7.2 is required [25]. For this reason the pH of all solutions was 
measured (pH meter 510, XS instruments) (Table 1). 
 
Table 1.Composition and pH of C/GP blank solutions prepared for the evaluation of gel formation. 
C (%w/v) GP (%w/v) pH 
2.0 12.0 7.31 
2.0 10.0 7.25 
2.0 7.0 7.21 
2.0 6.0 7.17 
2.0 5.0 6.98 
2.0 4.0 6.98 
2.0 3.5 6.95 
2.0 3.0 6.95 
1.6 18.0 7.42 
1.6 15.0 7.34 
1.5 7.0 7.29 
1.5 6.0 6.98 
1.5 5.0 6.96 
1.5 4.0 6.96 
1.5 3.5 6.85 
1.5 3.0 6.81 
1.0 7.0 6.89 
1.0 6.0 6.88 
1.0 5.0 6.86 
1.0 4.0 6.84 
1.0 3.5 6.80 
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In order to assess their thermo-sensitivity at 37°C, the C/GP blank solutions obtained (Table 1) 
were placed inside a plastic syringe, conveniently cut and isolated with a rubber cap and Parafilm®. 
The syringe was then emerged in a temperature-controlled water bath at 37°C (±1°C). The solutions 
were left there for 20 min in order to make a preliminary assessment of their gelation behavior. 
Gelation time of C/GP blank solutions 
Gelation time of C/GP blank solutions was studied using the inverted tube test method, according to 
the methodology described by Gupta et al. [28]. The inverted tube test was performed with the 
solutions that exhibited gel formation in 20 min with the previous method (Table 2). Two ml 
chromatographic glass tubes were thermo-stabilized in a temperature-controlled bath at 37°C 
(±1°C). Five hundred μl of the sample solution were placed into the tubes and incubated in the bath. 
At predetermined time intervals of 30 s, the tubes were taken out of the water bath and horizontally 
inverted in order to verify the solution flowability. If the solution did not flow within 15 s, the time 
is recorded as gelation time. Inverted tube tests were carried out immediately after the preparation 
of the solutions, which were then stored at 4°C. New measurements were taken the day after the 
preparation and every week through 3 weeks, in order to evaluate the solution stability and the 
possible changes of the gelation time over that period. 
 
Table 2.Composition and gelation time of C/GP blank solutions (S) and formulations (F) performed 
with inverted tube test. 





after prep. 1 day 1 week 2 weeks 3 weeks 
S F S F S F S F S F 
2.0 12.0 06:00 06:00 06:00 06:30 06:00 06:00 05:30 05:30 05:00 05:30 
2.0 10.0 07:00 07:00 07:00 07:00 07:00 07:30 04:30 04:30 04:00 04:00 
2.0 7.0 14:00 14:30 03:00 03:00 02:00 02:30 01:30 01:30 01:00 01:00 
2.0 6.0 16:30 16:00 04:30 05:00 01:00 01:00 00:30 00:30 00:30 00:30 
2.0 5.0 18:00 18:00 07:30 07:30 00:30 01:00 00:30 00:30 00:30 01:00 
1.6 18.0 02:00 02:00 02:00 02:00 02:00 02:00 02:00 02:00 01:30 01:30 
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Preparation of formulations and determination of their gelation time 
ICG was incorporated in the C/GP solutions; composition is reported in Table 2. About 5 mg of 
ICG were dissolved in each C/GP solution (20 ml) under stirring condition at 4°C. Gelation time of 
formulations was determined following the inverted tube test method previously reported. The 
rationale was the assessment of the dye influence in the gelling properties of these thermosensitive 
fluids. Inverted tube tests were performed considering the same time intervals carried out for C/GP 
blank solutions. 
Biodegradability 
The leader solutions and formulations that exhibited the best gelation time were selected for further 
studies and named as reported in Table 3. 
Biodegradability studies were conducted following the method of Zang et al. [29]. Hydrogels 
formed from blank solutions and formulations were prepared at 0.6 cm3 volume and 1 cm diameter 
and immersed in 2 ml of DMEM medium with 0.1% sodium azide containing 1.91 µg/ml chicken 
egg white lysozyme. Samples were placed in incubator thermostabilized at 37°C for 14 days. The 
medium was replenished every week of storage. Dried weights of the samples were measured on the 
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Table 3.Composition of leader solutions and formulations.  
Code C (% w/v) GP (% w/v) ICG (% w/v) 
C2/GP12 2.0 12.0 - 
C2/GP12d 2.0 12.0 25 
C2/GP10 2.0 10.0 - 
C2/GP10d 2.0 10.0 25 
C2/GP7 2.0 7.0 - 
C2/GP7d 2.0 7.0 25 
C1.6/GP18 1.6 18.0 - 
C1.6/GP18d 1.6 18.0 25 
C1.6/GP15 1.6 15.0 - 




Leader solutions (Table 3) and their corresponding hydrogels were analyzed by rheological 
methods. The gelling and rheological properties were performed with a Physica MCR101 rheometer 
(Anton Paar, Austria). The measuring system was parallel-plate type (diameter 50 mm, gap 0.2 
mm). Each type of rheological measurement was performed immediately after the preparation of 
solutions and after 1 week of storage at 4 and 20°C. Data were expressed as mean ± standard 
deviation (n = 3). 
Viscosity measurements 
Viscosity measurements of solutions were carried out at 4°C applying a shear rate from 0 to 100 
1/s. For all curves the slope (n) was determined in order to evaluate the changes of the viscosity 
increasing the shear rate. 
Frequency sweep measurements 
Dynamic frequency sweep tests were performed at constant temperature (37°C) and strain (1%) in 
the limit of the linear viscoelastic region. The storage (G′), and loss moduli (G″) damping factors 
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were determined for angular frequencies (ω) between 0.1 and 100 1/s. The viscoelastic behavior on 
the hydrogels was analyzed via their corresponding damping factors (tan(δ)) at ω = 10 1/s. 
Gelation time performed with rheometer 
Gelation time was determined at 37°C at a constant angular frequency (ω) of 1.0 1/s at a constant 
strain of 1 % measuring the G′ and G″ as a function of time. Gelation time of the samples was 
established at the time of the intersection of G′ and G″, where tanδ = 1. The differences between 
gelation time values gained by the rheometer and the inverted tube test were assessed. 
In vitro dye release studies 
Each formulation (Table 3) was filled in a dialysis bag previously activated with ethylene diamine 
tetra-acetic acid. The molecular weight cut off of the dialysis bag was 12,000 – 14,000 and higher 
than the molecular weight of the dye. The dye release was studied by using the USP dissolution 
apparatus (DT70, Erweka GmbH, Germany). Each dialysis bag was fixed to the rotating bar of the 
dissolution tester and lowered into the dissolution vessel containing 900 ml of phosphate buffer 
(PBS) at pH = 6.5, 37°C (±1°C). The rotation speed of the dialysis bag was 100 rpm. The 
dissolution test was performed up to 16 h. At each prefixed time point, the medium (1 ml) was 
removed for analysis and it was replaced with the corresponding volume of fresh PBS. The samples 
removed from the medium were immediately analyzed spectrophotometrically (λ = 779 nm) 
(ThermoSpectronic, Helios, UK). The dissolution studies were conducted in triplicate (mean values 
are reported). The dye contents of the samples were measured from the reference absorption–
concentration curve of the dye that was constructed by using standard solutions of known ICG 
concentration in PBS. The same test was performed filling 10 mg of ICG in the aqueous solution in 
another dialysis bag in order to make a comparison with the release behavior of C/GP systems 
loaded with ICG. 
Dye uptake from a preformed hydrogel 
The eventual ability of blank hydrogels to up-take ICG dispersed in the liver was investigated 
filling a preformed blank hydrogel (C1.6/GP15) into a solution of known ICG concentration (0.01 
mg/ml) in PBS pH = 6.5, 37°C (±1°C). The variation of ICG concentration in the medium was 
analyzed via the UV spectrophotometer (λ = 779 nm) (ThermoSpectronic, Helios, UK) removing 
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samples (1 ml) from the medium at 15, 30, 45, 60 and 90 min. The medium removed for analysis 
was always replaced with the corresponding volume of fresh PBS. 
Ex vivo embolization procedure 
Ex vivo studies were carried out on a bovine liver (weight of ? 8 kg), thermostabilized at 37°C in a 
saline bath. The experiments were carried out in standard conditions, with the organ preserved 
outside of the body. It was flushed at a low pressure saline solution (NaCl 0.9%) and immersed into 
? 10 – 15 cm of H2O. 
The leader formulations were selected for these studies (Table 3). 
The hepatic artery was surgically exposed and then catheterized with a catheter (CVC 14 Gauge). 
Successively, 5 ml of formulation was slowly injected till a predetermined area of the organ through 
the distal branches of the hepatic artery (in the right lateral lobe) to selectively embolize an area of 3 
– 4 cm2. Selective visualization of the injection site with an NIR fluorescence imaging system 
(PDE; Hamamatsu Photonics K.K. Hamamatsu, Japan) and intraoperative ultrasound (Flexfocus 
800, BK medical) were performed in order to assess the localization and gelation of the solutions 
and the occlusion of the artery. Our group has previously described the combined use of ICG 
fluorescence and ultrasounds as a useful combine technique to detect small nodules into a liver [16]. 
In this experiment the probe could allow us to confirm the site of gelation shown by fluorescence 
detection. The site visualized by PDE was then cut open in order to evaluate the hydrogel 
formation. 
RESULTS 
Preparation of C/GP blank solutions and gel formation 
Twenty-two C/GP blank solutions, characterized by different C/GP weight ratios, were prepared 
(Table 1). Solutions with the highest concentrations of GP (12 – 18% w/v) were clear solutions at 
4°C when polyol salt was dropwise added. On the contrary, solutions with the lowest concentration 
of GP (3.0 – 7.0% w/v) showed a different behavior at 4°C: the formation under stirring of a milky 
suspension was observed, whereas a gel-like milky precipitate formed without stirring. However, by 
shaking or intense stirring, the milky suspension was again obtained. 
Gelation of the solutions was assessed through their incubation in a plastic syringe inside a thermo-
stabilized bath (37 ± 1°C) and left there for 20 min. Solutions which displayed gelation within that 
time interval are showed in Table 2. An increase in the hydrogel compactness was found by rising 
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the concentration of C and GP. For the same amount of C, hydrogels with higher amounts of GP 
were more opaque and they presented a stronger milk coloration, which was in conformity with the 
observations reported by Ahmadi and De Bruijn [30]. 
 
Gelation time of C/GP blank solutions and formulations 
Figure 1 shows gel set in the inverted tube of a formulation chosen as an example Gelation time 
results following the inverted tube test method are presented in Table 2. After the preparation, 
solutions with 2% of C showed the increase of gelation time as the GP concentration decreases from 
6 min (12% w/v) to 18 min (5% w/v). When C concentration is lowered to 1.6%, higher GP 
concentrations are necessary to obtain more rapid gelation time: 2 min (18% w/v) and 3 min (15% 
w/v) were gained. 
A decrease in the gelation time values taken 1 day after the preparation was observed for 2% C 
solutions with the lowest amount of GP (5.0 – 7.0%) till 7 – 3 min, respectively; this behavior was 
observed also along the time as a further remarkable decrease in the gelation time from the first to 
the third week was observed. 
The incorporation of ICG into C/GP blank solutions did not display any significant change in the 
gelation rates of these systems (Table 2). Even after 3 weeks of storage at 4°C, all of the C/GP 
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Figure 1. Photographs of the gelation process observed by the inverted tube test. Formulation is a 
flowable liquid at room temperature (A) and it is transformed to a rigid hydrogel at 37°C (B). 
 
Biodegradability 
Figure 2 shows the degradation rate of blank hydrogels or containing ICG. The degradation rate was 
independent of dye loading and decreased as the C concentration in the solution increased. Over the 
14 days of degradation, formulations with 2% C concentration were degraded no more than 54%, 
whereas formulations with 1.6% C concentration exhibited a degradation rate > 60% (Figure 2B). 
Nevertheless, the cross-link density between C and GP did not affect the degradation rate in the 
case of formulations with 2% C concentration. The only exception was formulation C2/GP7d that 
exhibited the lowest degradation rate despite the lowest concentration of GP (lowest cross-link 
density between C and GP). As concerning 1.6% C concentration, the formulation degradation rate 
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Figure 2. Degradation of hydrogel obtained from blank solutions (A) and formulations (B) > 14 
days. Data are depicted as mean ± SD (n = 3). 
 
Rheological characterization: 
Viscosity measurements  
For all solutions, the viscosity curve was determined at 4°C. In this type of diagram, viscosity is 
plotted versus shear rate in order to get information about the flow behavior of polymer solutions. 
Figure 3 shows viscosity of C1.6/GP18, chosen as example. This formulation exhibited a shear-
thinning behavior showing viscosity decreases when the shear rate has increased. Furthermore, the 
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Figure 3. Viscosity curves of C1.6/GP18, chosen as example, after preparation and after 1 week of 
storage at 4 and 20°C. 
 
Data in Table 4 show the viscosity values at the shear rate of 100 1/s. Solutions with high cross-link 
density between C and GP (formulation C1.6/GP18 and C1.6/GP 15) exhibited an increase of the 
viscosity during the storage, as already reported in the literature [31]. 
For all viscosity curves, the slope (n) was determined. Table 4 shows that the solution with the 
lowest cross-link density between C and GP (C2/GP7) exhibited the highest value of n. Solutions 
with the highest cross-link density (formulation C1.6/GP18 and C1.6/GP15) displayed the lowest 
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Table 4. Viscosity, η, at shear rate of 100 1/s of solutions stored at 4°C and 20°C.  
Solution 
η (Pa × s) 
Slopes (n) after 
preparation Storage at 4°C Storage at 20°C 
after preparation 1 week 1 week 
C2/GP12 0.476 ± 0.06 0.412 ± 0.05 1.040 ± 0.07 0.379 ± 0.09 
C2/GP10 0.358 ± 0.03 0.302 ± 0.08 0.710 ± 0.10 0.333 ± 0.08 
C2/GP7 0.205 ± 0.02 0.370 ± 0.03 0.152 ± 0.03 1.163 ± 0.10 
C1.6/GP18 0.157 ± 0.02 0.244 ± 0.03 0.317 ± 0.05 0.125 ± 0.01 
C1.6/GP15 0.160 ± 0.01 0.274 ± 0.03 0.270 ± 0.07 0.129 ± 0.01 
 
 
Frequency sweep measurements 
Figure 4 displays the frequency dependency of G′ of hydrogels. High gel strengths (high G′) were 
obtained increasing the cross-link density between C and GP. The only exception was solution 
C2/GP7 that exhibited a good gel structure despite the lowest cross-link density. Data in Table 5 
show the damping factor of hydrogels at ω of 10 1/s. The lowest values of tan (δ) are related to 
solutions with the highest molar ratio GP/C. This tendency was general at 4 and 20°C. The tan (δ) 
slightly changed during the storage time (at 4 and 20°C) except for C2/GP7 whose tan (δ) was 
similar and even lower than tan (δ) plotted for C2/GP10 and C2/GP12, made with the same 
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Figure 4. Frequency dependence of hydrogels after preparation. 
 




Storage at 4°C Storage at 20°C 
after preparation 1 week 1 week 
C2/GP12 0.28 ± 0.01 0.29  ± 0.02 0.26 ± 0.01 
C2/GP10 0.29 ± 0.03 0.30  ± 0.01 0.28 ± 0.01 
C2/GP7 0.30 ± 0.03 0.27  ± 0.02 0.24 ± 0.01 
C1.6/GP18 0.19 ± 0.02 0.17  ± 0.03 0.16 ± 0.04 
C1.6/GP15 0.22 ± 0.03 0.24  ± 0.03 0.22 ± 0.03 
 
 
Gelation time performed with rheometer 
The dynamic viscoelastic functions G′ and G″ were measured as a function of time at 37°C. 
Gelation time (tg) is defined as the crossing point between G′ and G″. Figure 5 shows the changes 
of the storage and the loss modulus as a function of time at 37°C of C1.6/GP18, chosen as an 
example. The gelation point of the samples was established at the intersection of G′ and G″. 
71 
Andrea Salis 
Polysaccharides as Drug Delivery Systems for different Administration Routes 
Tesi di Dottorato in Scienze e Tecnologie Chimiche-Scienze Farmaceutiche 
Università degli Studi di Sassari 
 
 
Figure 5. Sol–gel transitions versus time of C1.6/GP18 at 37°C after preparation, chosen as 
example. 
 
Values of tg of all samples extrapolated from sol–gel transitions versus time curves (data not 
shown) are quite similar to gelation time values carried out with inverted tube test. Thus, there was 
a good correspondence between the two methodologies. 
For C2/GP7, it was not possible to identify the crossing point, and consequently the tg because G′ 
was always higher than G″ during the time. 
From G′ versus time curves (Figure 6), the gelation speed of the samples necessary to reach an 
adequate gel structure can be evaluated, through the slopes of those curves (Table 6). The slopes 
were dependent on the cross-link density between C and GP and on C and GP concentrations. The 
only exception was C2/GP7 that exhibited a rapid gelling despite the lowest cross-link density 
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Figure 6. Comparison of the slopes of solutions after preparation. 
 
Table 6. Slopes (n) of G′ versus time curves of solutions after preparation. 
Solution Slope (n) 
C2/GP12 21.75 ± 6.53 
C2/GP10 13.80 ± 4.00 
C2/GP7 47.70 ± 4.31 
C1.6/GP18 16.80 ± 2.11 
C1.6/GP15 6.84 ± 1.05 
 
 
In vitrodye release studies 
Release of ICG from hydrogels into PBS at 37°C over the course of 16 h was measured 
spectrophotometrically. The results are displayed in Figure 7. The dye in the aqueous solution was 
able to diffuse across the membrane. On the contrary, no significant release of ICG from 
C1.6/GP15d hydrogel occurred. Indeed, ICG cross through the cutoff of the dialysis bag neither in 
the first minutes when formulation was still in solution, nor when it gelled. No difference in the 
release profile was found in the case of other formulations. 
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Figure 7. In vitro release profile of ICG from C1.6/GP15d, chosen as example, compared with that 
of diffusion from the ICG water solution. Data were expressed as mean ± SD (n = 3). 
 
Dye uptake from preformed hydrogel 
Considering the results from in vitro release studies, which showed the ability of hydrogels to retain 
ICG, the present test was done to confirm the strong affinity between ICG and hydrogels. A 
preformed hydrogel (C1.6/GP15) was immersed into the PBS solution of known ICG concentration 
(Figure 8A); the variation of ICG concentration was measured spectrophotometrically at different 
time intervals. It was observed a loss of dye absorbance in the PBS solution just only after 15 min 
from 0.952 to 0.294 and decreased till 0.092 after 60 min (Figure 8B). The observed loss of dye 
absorbance could be correlated with the strong interaction between C and ICG [32]. As the 
hydration of C1.6/GP15 hydrogel occurs, an interaction between chitosan and the dye could be 
hypotized: in fact, green gelled clots were observed suspended into the PBS solution, which 
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Figure 8. Absorbance curve of ICG solution versus time during dye uptake from preformed 
hydrogel; picture of ICG solution immediately after the immersion of C1.6/GP15 hydrogel. (A) and 
after 90 min (B). 
 
Ex vivo embolization procedure 
The injection of the leader formulations (Table 3) through the hepatic artery was performed as 
previously described. Considering the results gained from the inverted tube test, C2/GP7d was 
injected the day after the preparation in order to achieve a faster gelation inside the artery. 
In all cases the formation of a stable gelled clot was macroscopically observed at the site of 
embolization in the hepatic parenchyma, due to the rapid gelation of the injected solution, 
containing the thermosensitive polymer. In this set of experiments, the hydrogel was apparently 
completely stabilized after 1 – 5 min at 37°C. The same clot was evident at PDE examination 
(Figure 9). Furthermore, sections of the liver in correspondence of the injected site confirmed the 
presence of the gelled clot (Figure 10). 
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Figure 9. Selective visualization of the injection site with a near-infrared fluorescence imaging 
system PDE. The embolizing formulation was injected through the hepatic artery in the right lateral 
lobe. The figure shows the bright fluorescence of ICG under the infrared PDE camera and its neat 
localization into the injection site. The dotted line indicates the limit of the organ. 
 
 
Figure 10. Section of the liver after the in situ gelation of C1.6/GP15d. The picture demonstrates 
gelled clots at the site of injection after cutting open the area previously localized by PDE and 
showed in Figure 9. 
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DISCUSSION 
C/GP solutions were prepared to develop a class of ICG-loaded injectable hydrogels, whose 
potential application is the loco-regional detection and treatment of HCC nodules. Particularly, the 
solution should be injected down a catheter, which is selectively placed into the arterial branches of 
a predetermined liver area, similarly to the technique used for superselective TACE. The polymeric 
compound should be delivered close to the tumor and saturate its vessels. The sol–gel transition 
should be fast enough to allow a saturation of the microcirculation. These solutions should be able 
to exhibit an adequate viscosity to be injected and gelation behavior at physiological temperature 
(about 37°C). The formed gel should have suitable viscosity to embolize and avoid that hydrogel 
fragments can flow in the blood circulation. Any peripheral escape of the dye should not be 
observed. 
Most of the solutions prepared are characterized by low concentrations of GP, ranging from 3 to 7% 
w/v (Table 1); in spite of its endovenous use being approved by the Food and Drug Administration, 
certain GP toxicity issues have been arisen: after gelation GP starts diffusing out of the physically 
cross-linked network, resulting in a linear increase of the extraction medium osmolality, which 
results in possible local cytotoxic effects [33]. Therefore the rationale was the preparation of in situ 
gelling solutions containing the minimum GP amount. In C/GP systems three types of interactions 
may be involved in the gelation process: i) hydrogen bonding between C chains, as a consequence 
of reduced electrostatic repulsion after neutralization with GP; ii) electrostatic attraction between C 
ammonium groups and GP phosphate groups; iii) C–C hydrophobic interactions [25,34]. Although 
sol–gel phase transition is driven by hydrophobic interactions, gelation would not occur without 
mechanisms i) and ii). This explains the role of pH in the temperature-controlled gelation of C/GP 
aqueous systems [25]. At low temperatures, C/GP solutions with a pH around 7 do not immediately 
turn into a gel suggesting that repulsive forces between the C chains are stabilized at low 
temperatures and destabilized at high temperatures. Ruel-Gariépy et al.[35] hypothesized that GP 
prevents or slows down gelation at low temperature. In fact, polyols are known to stabilize several 
compounds in aqueous solutions, promoting the formation of a shield of water around some 
macromolecules in polyol-water mixtures [36]. Accordingly, the presence of GP into the C solution 
promotes the protective hydration of C chains, preventing at low temperatures their association and 
consequently gelation. C chain hydration is then dependent on the amount of GP added to the C 
solution. If GP concentration is too low, as in the solutions prepared, the formation of a water shield 
around C chains and their neutralization is only partial, preventing just part of their association and 
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leading to a gel-like precipitate at low temperatures. The gel-like precipitate formation at 4°C is 
reversible. At 4°C hydrogen bonding between C–C and C–water are predominant and there is not 
enough energy for hydrophobic bonds to be established, resulting in a reversible gelation process. 
Gelation time values obtained immediately after the preparation of the final solutions (Table 2) are 
in accordance with the results reported by Chenite [25]. In order to achieve a physiologically 
acceptable pH range and fast gelation at 37°C, high concentrations of C and GP are required. As a 
consequence, gelation time increased with the decreasing of GP and C amounts. The increase of the 
gelation rate observed for solutions with the lowest amount of GP (5.0 – 7.0%) during the storage, 
at 4°C, could be explained in the following way: as we previously reported, low proportions of GP 
lead to a reversible gelation of C solutions at low temperature even if the pH of the formulations is 
neutral. Although the hydrogels turned back into a solution under stirring, the presence of small gel 
nucleus dispersed into the C/GP solutions was observed. As a result, shear stress allows the 
breaking of the gel network and the formation of small gel nucleus of C/GP, which are suspended in 
the aqueous solution. Gel nucleus can aid and accelerate the final gelation induced by temperature 
through a mechanism of nucleation and growth. The small increase in the gelation rate for the 
formulations with the highest GP concentrations after 3 weeks of storage was also dependent on the 
high deacetylation degree of C used for the preparation of these formulations. The combination of 
high deacetylation degree with high GP concentration leads to high cross-link density between the 
phosphate groups of GP and the ammonium groups of C [34]. 
Although all solutions and formulations (Table 2) gel at body temperature, the solutions that 
exhibited slow gelation cannot be considered suitable for local treatment of HCC as embolic agents. 
The C/GP solution should form a gel quickly in order to provide good occlusion of blood flow [37]. 
The viscosity and compactness of the corresponding hydrogels that strictly depend on C and GP 
concentrations could be further critical parameters [36]. High viscosity may help to control 
injection, to avoid dilution of the solution and to limit the possibility of migration into collateral 
arteries [31]. In the latter case, if the arterial blood flow disperses the embolic agent, 
cardiopulmonary embolism may occur [38-42]. However, too fast gelation may be problematic 
because it could determine catheter occlusion. Accordingly, five leader solutions and formulations 
were selected for further in vitro and ex vivo studies (Table 3). By virtue of the high viscosity, high 
compactness and adequate gelation rate, these formulations are supposed to remain in the injection 
site, filling and gelling in vessel cavities. In all cases, formulations remained easily injectable 
through (CVC 14 Gauge) catheters. Data in Table 4 show the viscosity values at the shear rate of 
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100 1/s in order to make a comparison with the high shear rate evolving during a hypothetical 
injection of our solutions. Thus, it is possible to evaluate the injectability of these systems 
immediately after the preparation and after 1 week of storage. These systems could be considered 
still injectable, nevertheless an increase of the viscosity during the storage was observed for 
solutions with high cross-link density between C and GP. The determination of the slope (n) of 
viscosity curves is a useful approach to understand the resistance to flow of our solutions and 
consequently the injectability of such systems. The high slope determines low resistance to flow, 
which indicates a good injectability for these pseudoplastic liquids and, in terms of applicability, a 
good fit to the desired blood vessel or body cavity. As shown in Table 4 the solution with the lowest 
cross-link density between C and GP (C2/GP7) exhibits the best injectability despite the formation 
of a gel-like precipitate at 4°C. This because the gel-like precipitate structure is quite easy to be 
destroyed during the injection procedure. 
Frequency sweep tests were used to characterize the final gel-structure of the five solutions at body 
temperature. The gels can be described as systems in which the G′ are higher than the G″ and/or 
they are relatively independent from frequency. Lapasin and Pricl [43] classified gels into two 
classes: strong gels, where the moduli are relatively independent from frequency and weak gels, 
where the moduli are slightly dependent from frequency. Frequency sweep measurements were 
carried out in the limit of the linear viscoelastic range, in order to evaluate the frequency 
dependency of the G′ and G″. The high gel strengths (high G′) showed by solutions with high cross-
link density between C and GP were in conformity with the results previously reported in the 
literature [35]. The unexpected result of C2/GP7, which exhibited a good gel structure despite the 
lowest cross-link density, could be explained with the presence of the gel-like precipitation at 4°C. 
The gel-like precipitate can aid the reaching of a strong gel structure thanks to a nucleation 
mechanism. 
The damping factor reveals the ratio of the viscous and the elastic portion of the viscoelastic 
deformation behavior. In the hydrogel field, the determination of this value is an important criterion 
to assess gel formation and the hardening process. Therefore, tan (δ) > 1 defines the liquid state and 
tan (δ) < 1 defines the gel state. Furthermore, tan (δ) indicates the elasticity property of the 
hydrogels: the low tan (δ) determines strong gel structure and, as a consequence, good gel resistance 
and stability inside the desired tissue, organ, or body cavity. 
Data in Table 5 show that the lowest values of tan (δ) are related with solutions with the highest 
molar ratio GP/C, due to a better neutralization of C chains that leads to an improvement of the 
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interactions involved in the gelation process (hydrogen bonding and hydrophobic interactions). The 
unexpected tan (δ) of C2/GP7 displayed during the storage time (at 4 and 20°C) could be explained 
by the nucleation growth mechanism previously supposed. As previously reported, it was not 
possible to extrapolate the tg from sol–gel transitions versus time curves for C2/GP7: G′ was always 
higher than G″ during the time. This comportment is probably due to the presence of the gel-like 
precipitation at 4°C that leads to an elastic response of the material and that is stronger than the 
viscous response. As described before, low proportions of GP lead to a reversible gelation of C 
solutions at low temperature. 
The unexpected result for formulation C2/GP7 is found and it is in contrast with the theories 
reported in the literature [25,35]. C2/GP7 exhibited a rapid gelling despite the lowest cross-link 
density between C and GP. This performance could be explained by the gel-like precipitation at 
4°C. For the other solutions, the slopes are dependent on the cross-link density between C and GP 
and on C and GP concentrations as we expected. 
The degradation rate of C/GP hydrogels with lower concentration of C was faster than those with 
higher concentrations of this polymer. This behavior was in accordance with previous studies 
[29,44]. As concerning as the cross-link density, the literature reports that hydrogels with high 
cross-link density have strong gel intensity prohibiting enzyme permeation and causing less 
degradation [44,45]. However, our results demonstrated that C concentration mainly affects the 
degradation rate as C1.6/GP15d and C1.6/GP18d (although they have high cross-link density) 
showed higher weight loss compared to 2% C formulations. It can be attributed to the susceptibility 
of C toward lysozyme [46]. The lowest degradation rate observed for formulation with the lowest 
cross-link density (C2/GP7d) was also supported by our frequency sweep experiments. This 
hydrogel exhibited a good gel structure that can be attributed to the nucleation growth mechanism 
previously mentioned. 
The release of ICG from formulations analyzed was not significant. This behavior could be due to 
an electrostatic interaction between C and ICG [32]. In the aqueous solution, the dye is negatively 
charged thanks to its sulphonic groups, whereas C is cationic. Therefore, the molecular weight of 
the ionic complex is bigger than cutoff of dialysis membrane used in our release study and ICG is 
not quantified in the dissolution medium. 
A final consideration must be done about the sterilization of these systems: the formulations 
described in this preliminary work are not sterile because the kind of experiments performed (in 
vitro and ex vivo) does not require sterile systems. The literature shows that steam sterilization of 
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chitosan may have different effects depending on whether sterilization was performed during its dry 
state or after it was in solution. Results show that autoclaving the dry chitosan power had no effect 
on viscosity and thus chitosan dry after sterilization does not undergo any structural changing. Thus, 
sterile hydrogel can be obtained by treating the dry material and working in aseptic environment 
[29]. 
At the current point of this research, we have demonstrated that a polymeric platform can be loaded 
with a dye to mark a liver area. Considering the results gained from the ex vivo procedure, these in 
situ gelled C/GP formulations have the potential to remain in correspondence of the injected site for 
a long period of time. As we reported before, the time of gelation of these hydrogels was a matter of 
second, and the process starts immediately at contact with the warmth of blood resulting in an 
embolization effect of the tumor. Such an approach could stop the growth and shrink the tumor 
burden, while leaving on site a marker, to help the following intraoperative detection of the cancer. 
At the same time, the removal of the fluorescent tissue would be guided throughout the operation by 
a real time observation of the parenchymal margins. The final result could be a better outcome for 
the patients, with an advantage offered by the pre-treatment of the tumor and a resulting aid during 
the resection. However, this preliminary study is a ‘proof of concept’ and its clinical use still 
requires further experiments. 
CONCLUSIONS 
Thermosensitive C/GP platforms were prepared and loaded with ICG, which did not interfere with 
their gelation process. C2/GP7d thanks to a gel-like precipitation, rapidly forms in situ compact gels 
and represents a good candidate for filling vessels. Taking into consideration the obtained results, 
formulations could be injected through a catheter into tumor nodules; as the solution gels in these 
areas, a prolonged visualization of these nodules can be achieved in ‘real time imaging’ during the 
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INTRODUCTION 
Combination antiretroviral therapy (cART) has made a significant impact against HIV infection. 
However, the efficacy of this therapy is limited by the poor bioavailability of anti-HIV drugs at 
viral reservoir sites, such as the central nervous system (CNS) [1,2], particularly in cerebrospinal 
fluid (CSF) subarachnoid spaces that contain macrophages, which constitute the only site of HIV 
replication in the brain [3,4]. The lack of drug penetration into these “HIV sanctuaries” occurs 
primarily due to the expression of active efflux transporters (AETs) on the blood–brain (BBB) and 
blood−cerebrospinal fluid (BCSFB) barriers [5,6]. In vivo, these transporters induce the asymmetric 
transport of anti-HIV drugs across these barriers, where the rate of drug efflux from the CNS to the 
blood is greater than the influx rate [7]. 
We recently proved that the conjugation of zidovudine (AZT), which is an antiretroviral drug used 
in cART protocols [8], with the bile acid ursodeoxycholic acid (UDCA) generates a prodrug 
(UDCA−AZT) that can elude the AET systems [9]. We have therefore proposed that when this 
prodrug is taken up in the CNS, it should not be extruded into the bloodstream because it is able to 
elude the AET systems. Accordingly, we demonstrated that the nasal administration of solid lipid 
microparticles loaded with the UDCA–AZT prodrug facilitates its uptake into the CSF of rats [10]. 
Nasal administration constitutes a potentially efficacious way of achieving the brain uptake of 
neuroactive agents [11-14]. Indeed, drugs deposited on the olfactory epithelium of the nose can gain 
direct access to the CNS, particularly the CSF, via transcellular transport through olfactory 
epithelial cells. The drugs absorbed in the CSF can then diffuse into the interstitial fluid (ISF) and 
subsequently penetrate the brain parenchyma [13,15,16]. Moreover, drugs deposited on the 
olfactory epithelium can be transported into the brain parenchyma by olfactory neurons or 
trigeminal nerves that reach the nasal cavity [16-18]. Finally, nasally administered drugs can be 
absorbed into the systemic circulation from the respiratory epithelium [19] and can then reach the 
CNS if they are able to cross the BBB [13]. 
In general, appropriate strategies are required to improve the brain delivery of drugs, such as the 
addition of penetration enhancers and mucoadhesive materials to formulations or the preparation of 
micro- and nano-particulate delivery systems [20-24]. In this regard, chitosan is a polysaccharide 
derived from the alkaline deacetylation of chitin that is used in different formulations for the nose-
to-brain delivery of drugs [20] due to its biocompatibility, nontoxicity and high charge density, 
which confers mucoadhesive properties [25,26]. Chitosan is poorly soluble in water at physiologic 
pH values, but it forms salts with inorganic or organic acids, such as hydrochloride and glutamic 
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acid, that are soluble in water and possess better characteristics than chitosan itself, such as 
mucoadhesiveness and the ability to enhance the penetration of neuroactive agents into the CNS 
[21,27,28]. Chitosan is also characterized by the ability to reversibly open tight junctions, which is 
associated with a potential increase in the transcellular transport of drugs across the olfactory 
mucosa [29]. Nasal formulations obtained in the presence of water have drawbacks, such as the risk 
of chemical and physical instability and microbiological growth. In addition, the residence time of 
the liquid formulation in the nasal cavity is short, as the liquid is often rinsed into the 
gastrointestinal tract (GIT) or out of the nose [30]. These disadvantages can be overcome by using 
powder-based formulations [31,32]. 
The purpose of the present work was first to demonstrate that UDCA–AZT can permeate and 
remain in macrophages more efficiently than its parent drug AZT and then to prepare microspheres 
based on chitosan chloride in order to increase the nose-to-brain delivery of UDCA–AZT by using a 
particulate formulation that is suitable for nasal administration. The characterization of 
microparticles was performed in vitro and in vivo. All in vitro and in vivo measurements performed 
for the loaded microparticles were also performed for a parent physical mixture of chitosan chloride 
and UDCA–AZT in order to verify the efficacy of the microparticulate system for the brain delivery 
of the prodrug. 
MATERIALS AND METHODS 
Materials 
The prodrug UDCA−AZT was synthesized as described previously [9]. Chitosan chloride (Protasan 
UP CL 113, molecular weight and degree of deacetylation of 160,000 g/mol and 83%, respectively) 
was purchased from FMC BioPolymer AS (Drammen, Norway). Dow Corning 345, which is a 
blend of polydimethylcyclosiloxane, was obtained from Dow Corning (Brussels, Belgium). AZT, 7-
n-propylxanthine (7n-PX), and bovine serum albumin (BSA) were obtained from Sigma Aldrich 
Italy (Milan, Italy). Methanol, acetonitrile, ethyl acetate and water were high performance liquid 
chromatography (HPLC) grade and obtained from Sigma Aldrich Italy. Monopowder P® 
insufflators were furnished by Valois Dispray (Mezzovico, Switzerland). Male Wistar rats were 
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Uptake of AZT and UDCA–AZT in macrophages 
The J774A.1 murine macrophage cell line was obtained from the American Tissue Type Culture 
Collection (LGC Standards, Milan, Italy). J774A.1 macrophages were grown as adherently cultured 
cells in Dulbecco’s modified Eagle’s medium + Glutamax supplemented with 10% fetal bovine 
serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C. All cell culture reagents 
were provided by Invitrogen (Life Technologies, Milan, Italy). Briefly, a total of 5 × 105 cells 
J774A.1 cells were seeded in 12-well culture plates, and when semi-confluent, the cells were 
exposed to 100 μM AZT and 10 or 100 μM UDCA–AZT in growth medium for 30 min. At the end 
of the treatment, the cells were washed and lysed. The cell lysates were dried under a nitrogen 
stream, resuspended in methanol and centrifuged to remove cell debris. The supernatant (10 μl) was 
used to measure the levels of AZT and UDCA–AZT via HPLC analysis. All of the values obtained 
from experiments with J774A.1 cells are the mean of three independent experiments. 
Toxicity texts (MTT assay) 
J774A.1 cells were seeded in 96-well plates at a density of 8000 cells per well and reached an 
optimal population density within 48–72 h. The cells were then incubated for 15, 30 and 60 min in 
200 μL of culture medium in the presence and absence of 100 μM UDCA–AZT. At the end of the 
time-course, the incubation medium was removed and replaced with 200 μL of fresh culture 
medium, and 20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) stock 
solution (5 mg/mL) were added to each well and incubated at 37°C for 4 h. A negative control of 20 
μL of the MTT stock solution added to 200 μL of medium alone was included. Then, 100 μL of 
DMSO were added to each well and incubated at 37°C for 2 h in an orbital shaker incubator. 
Finally, the absorbance of each well was measured at 570 nm using a microtiter plate reader. 
Preparation of loaded and unloaded chitosan microspheres 
Chitosan microspheres containing UDCA−AZT (named CP) were prepared using the spray-drying 
method. Chitosan chloride (400 mg) was dissolved in water (15 mL), whereas UDCA−AZT (100 
mg) was dissolved in methanol (35 ml). The drug solution was dispersed into chitosan one (solid 
concentration: 1% w/v of UDCA−AZT and chitosan). Due to the very low solubility of the drug, a 
fine suspension was obtained and spray-dried using a mini spray-dryer equipped with a high 
performance cyclone (Büchi B-191, Büchi Labortechnik AG, Flawil, Switzerland) and with a 0.7 
mm two-fluid nozzle. The following standard operating conditions were utilized: inlet and outlet 
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temperature, 100°C and 73°C, respectively; spray flow rate, 500 L/h; pump setting, 8% (2.00 
mL/min); and aspirator setting, 90%. Aqueous solutions of chitosan chloride (0.8% w/v) were 
sprayed under the same conditions to obtain drug-free microspheres (CH). The microparticles were 
stored in a desiccator at room temperature. 
HPLC analysis 
The prodrug UDCA−AZT and its hydrolysis product AZT were quantified using HPLC. The 
chromatographic apparatus consisted of a modular system (model LC-10 AD VD pump and model 
SPD-10A VP variable wavelength UV–vis detector; Shimadzu, Kyoto, Japan) and an injection 
valve with a 20 μL sample loop (model 7725; Rheodyne, IDEX, Torrance, CA, USA). Separations 
were performed at room temperature on a 5 μm Hypersil BDS C-18 column (150 mm × 4.6 mm 
i.d.; Alltech Italia Srl, Milan, Italy) equipped with a guard column. Data acquisition and processing 
were accomplished with a personal computer using CLASS-VP Software, version 7.2.1 (Shimadzu 
Italia, Milan, Italy). The detector was set to 260 nm. The mobile phase consisted of a mixture of 
water and methanol that was regulated by a gradient profile programmed as follows: isocratic 
elution with 20% (v/v) MeOH in H2O for 10 min; a 1-min linear gradient to 75% (v/v) MeOH in 
H2O; and the mobile phase composition was then maintained at 75% MeOH for 10 min. After each 
cycle, the column was conditioned with 20% (v/v) MeOH in H2O for 10 min. The flow rate was 1 
mL/min. The xanthine derivative 7n-PX was employed as an internal standard for the analysis of rat 
blood (see below). The retention times for 7n-PX, AZT and the prodrug UDCA−AZT were 6.5, 8.4, 
and 19.6 min, respectively. The HPLC assay of UDCA–AZT alone was performed isocratically 
with 80% (v/v) MeOH in H2O. In this case, the retention time of UDCA–AZT was 4.8 min. The 
chromatographic precision was evaluated. 
Characterization of microspheres 
The prepared microspheres were characterized in terms of production yield, drug content and 
encapsulation efficiency, particle size and particle size distribution, particle morphology, true 
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Production yields 
The production yields (YP) were calculated as a percent weight of microspheres obtained with 
respect to the initial amounts of UDCA−AZT and chitosan that were employed for the preparation 
of the feed suspension. 
UDCA−AZT content in CP 
The UDCA–AZT content in the microparticulate powders was determined. The microparticles 
(approximately 0.95 mg) were accurately weighed and dissolved in 3 ml of water to which 300 μl of 
0.2% H3PO4 was added; the final volume of the solution was adjusted to 10 mL with methanol. 
Then, 10 μL of the filtered solutions (0.45 μm) were injected into the HPLC system for the UDCA–
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All of the obtained values are the mean of four independent experiments. 
Particle size measurement 
The size and size distribution of the microspheres were analyzed via the light diffraction method 
using a Coulter LS 100Q (Beckman Coulter Particle Characterization, Miami, FL, USA). A sample 
(2 mg) of unloaded and drug-loaded microspheres was suspended in silicon oil, sonicated for 
approximately 3 s and analyzed. The reported results are the averages of triplicate averages. For 
comparison, a test was also performed on the physical mixture containing UDCA−AZT and 
chitosan chloride (87:13 w/w) (MIX) that was prepared by geometric dilution using an agate mortar 
pestle, as well as on chitosan chloride and UDCA–AZT alone, before and after grinding. 
Particle morphology 
The shape and surface characteristics of the powders were studied using scanning electron 
microscopy (VP-SEM; Zeiss EVO40XVP, Arese, Milan, Italy). The samples were placed on 
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double-sided tape that had previously been secured to aluminum stubs and then analysed under an 
argon atmosphere at an 18 kV acceleration voltage after gold sputtering. 
True density 
The true density of the microspheres was measured via helium pycnometry (Micromeritics Accupyc 
II 1340 Analysis system, Peschiera Borromeo, Italy) at 21 C [34]. The density (ρ) of the powder 
was determined in triplicate for each batch. 
Determination of water uptake capacity 
Investigations of the water uptake capability of CP and CH were carried out using a modified Enslin 
apparatus, as described previously by Rassu et al. [35]. Briefly, the dried microspheres were spread 
uniformly on the filter paper, which was previously soaked with phosphate buffer, pH 6.5. The 
volume of fluid absorbed from the microspheres during the time of the experiment (0–60 min) was 
recorded. The values (mean of at least 3 experiments) were expressed as μl of fluid absorbed per 
gram of microspheres during the time of the experiment. For comparison, the test was also 
performed using MIX. 
In vitro release and dissolution studies 
The release tests were performed using the flow-through dissolution method (European 
Pharmacopoeia, Apparatus 4), with a modified glass cell that is useful for organic solvents. The CP 
formulation (20 mg) was placed into the glass cell. The dissolution medium was warmed to 37 ± 
0.1 C and introduced through the bottom of the cell to obtain a suitable continuous flow. A 
methanol–water blend (70–30 v/v) was used as the dissolution medium. The test solution (10 μL) 
was analyzed via HPLC to evaluate the amount of UDCA–AZT released from the microspheres, 
which was calculated as a percentage of the initial amount of UDCA−AZT incorporated into the 
microspheres prior to the dissolution test. For comparison, the test was also performed using MIX. 
All experiments were performed with at least three replicates. 
In vivo UDCA–AZT administration and quantification 
Male Wistar rats (200–250 g) were anesthetized during the experimental period and received a 
femoral intravenous infusion of 0.1 mg/mL of UDCA–AZT dissolved in a medium constituted by 
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20% (v/v) DMSO and 80% (v/v) physiologic solution, at a rate of 0.2 mL/min for 10 min. At the 
end of the infusion and at fixed time points, blood samples (100 μL) were collected and CSF 
samples (50 μL) were withdrawn using the cysternal puncture method described by van den Berg et 
al. [36], which requires a single needle stick and allows the collection of serial (40–50 μL) CSF 
samples that are virtually blood-free [10]. A total volume of approximately 150 μL of CSF was 
collected during the experimental session. Four rats were employed for femoral intravenous 
infusions. The CSF samples (10 μL) were immediately injected into the HPLC system for AZT and 
UDCA–AZT detection. The blood samples were hemolysed immediately after their collection with 
500 μL of ice cold water, and 50 μL of 10% sulfosalicylic acid and 100 μL of internal standard (30 
μM 7n-PX) were then added. The samples were extracted twice with 1 mL of water-saturated ethyl 
acetate, and after centrifugation, the organic layer was reduced to dryness under a nitrogen stream. 
Two hundred microliters of a water–methanol mixture (70:30 v/v) were added, and after 
centrifugation, 10 μL were injected into the HPLC system for AZT and UDCA–AZT detection. 
The precision of the analytical method was determined. The in vivo half-life of AZT in the blood 
was calculated by nonlinear regression (exponential decay) of concentration values in the time 
range within 3h after infusion and confirmed by linear regression of the log concentration values 
versus time. 
Nasal administration of UDCA–AZT was performed on anesthetized rats laid on their backs, 
following two main procedures. The first procedure consisted of the introduction of 50 μL of an 
aqueous suspension of UDCA–AZT (2 mg/mL) into each nostril, as described previously [10]. 
After administration, blood (100 μL) and CSF samples (50 μL) were collected at fixed time points 
and analysed using the same procedures described above. Four rats were employed for nasal 
administration of the UDCA–AZT suspension. 
The second procedure was based on the insufflation of CP microparticles into each nostril of 
anesthetized rats using single dose Monopowder P® insufflators (Valois Dispray SA, Mezzovico, 
Switzerland). These devices were constituted by a pump, a nasal adapter and a solid formulation 
reservoir [37]. The insufflators were loaded with approximately 0.8 mg of UDCA–AZT-loaded 
microparticles (corresponding to approximately 100 μg of UDCA–AZT), or with approximately 0.8 
mg of the corresponding physical mixture (MIX). The rats received this amount in each nostril. The 
amount of powder emitted during administration was determined based on the difference between 
the insufflator weights before and after each insufflation. After administration, blood (100 μL) and 
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CSF samples (50 μL) were collected at fixed time points and analysed using the same procedures 
described above. Four rats were employed for nasal administration of the microparticulate powder. 
All in vivo experiments were performed in accordance with the guidelines issued by the Italian 
Ministry of Health (D.L. 116/92 and D.L. 111/94-B), the Declaration of Helsinki, and the Guide for 
the Care and Use of Laboratory Animals as adopted and promulgated by the National Institute of 
Health (Bethesda, Maryland, USA). The protocols for all in vivo experiments were approved by the 
Local Ethics Committee (University of Ferrara, Ferrara, Italy). All efforts were made to reduce the 
number of animals and their suffering. 
The areas under the concentration curves of UDCA–AZT in the CSF (AUC, μg mL−1 min) were 
calculated using the trapezoidal method. The in vivo half-life of UDCA–AZT in the CSF was 
calculated by linear regression of the log concentration values versus time between 1 and 3 h after 
nasal administration of the loaded microparticles. All calculations were performed using the 
computer program Graph Pad Prism (GraphPad Software, Incorporated, La Jolla, CA, USA). 
Statistical analysis 
Statistical comparisons of the amounts of water uptake of the powder samples and the UDCA–AZT 
Cmax and AUC values obtained in the CSF of rats were made using the Student’s t test or one-way 
ANOVA (GraphPad Prism). P values <0.05 were considered to be statistically significant. 
RESULTS 
Uptake of AZT and UDCA–AZT in macrophages 
The incubation of 100 μM zidovudine or its prodrug with the macrophages for 30 min allowed us to 
detect 0.054 ± 0.007 nmoles of AZT and 1.12 ± 0.16 nmoles of UDCA–AZT in 106 cells, as 
reported in Figure 1. The amount of AZT detected in the cells after incubation with UDCA–AZT 
for 30 min was 0.081 ± 0.009 nmoles/106 cells (Figure 1). The cell counter measured the volume of 
macrophages as 1.7 ± 0.1 pL; as a consequence, the amount of AZT released by the macrophages 
after incubation with 100 μM UDCA–AZT incubation corresponds to a concentration of 47 ± 5 μM. 
No toxicity was observed for cells incubated with 100 μM UDCA–AZT. These data indicate not 
only that the prodrug is able to permeate and remain in the macrophages with an efficiency twenty 
times higher than that of its parent drug (P<0.001) but also that the macrophages hydrolyze the 
prodrug, facilitating intracellular AZT release (Figure 1). Moreover, the incubation of macrophages 
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with 10 μM UDCA–AZT allowed us to detect 0.21 ± 0.03 nmoles of the prodrug in 106 cells 
(Figure 1). In this case, the AZT amounts were lower than the limit of detection of the analytical 
system. Therefore, the ability of UDCA–AZT to elude the AET systems [9] appears to be useful for 
inducing uptake into macrophages. According to the data reported in Figure 1, the presence of the 
prodrug in the CSF should allow its permeation and permanence in the macrophages, therefore 
making the prodrug an efficient carrier for AZT. 
 
Figure 1. Intracellular levels of AZT and its prodrug UDCA–AZT after incubation (30 min) with 
J774A.1 murine macrophages. The incubation concentrations were 100 μM for AZT and 10 and 
100 μM for UDCA–AZT. The graph also reports the intracellular levels of AZT after the incubation 
of the macrophages with 100 μM UDCA–AZT. The data are reported as the mean ± S.D. of three 
independent experiments. *: P< 0.001 versus 100 μM AZT. 
 
Characterization of microspheres 
Production yields 
The spray-drying technique proved to be suitable for preparing loaded and unloaded chitosan 
microparticles; in fact, these microparticles were obtained with good production yields of between 
61.7% (CP) and 64.7% (CH). Generally, the yields obtained with the spray-drying at laboratory 
scale with conventional spray-dryers are in the range of 20–70% due to the loss of product on the 
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walls of the drying chamber and the low capacity of the cyclone to separate fine particles [38,39]. 
However, the yield strongly depends on the work scale; the yield is high in larger scale setups 
because large batch sizes and separators (e.g., filter systems) are used. 
UDCA−AZT content in CP 
The amount of encapsulated UDCA−AZT in the CP sample was found to be 13 ± 0.3% (w/w), 
showing that chitosan, which is characterized by hydrophilic properties, was able to encapsulate the 
lipophilic prodrug with a good encapsulation efficiency (64.9 ± 1.5%). 
Particle size measurement 
Table 1 reports the volume-surface diameters (dvs) obtained for the loaded (CP) and unloaded 
microparticles (CH), for MIX and for chitosan chloride and UDCA–AZT before and after grinding 
using an agate mortar and pestle. The loading of UDCA−AZT into chitosan microparticles caused 
an increase in the particle size: CP microspheres had a dvs of 3.59 ± 0.1 μm in comparison to a dvs of 
2.32 ± 0.01 μm for CH (P<0.0001). Furthermore, the presence of the drug resulted in a change in 
the particle size distribution: loaded microparticles showed a larger curve than drug-free 
microspheres (Figure 2 up). In particular, CH showed a Gaussian curve while the CP curve 
appeared to be leptokurtic, right skewed and wide, with the presence of small shoulders. 
Table 1. Volume-surface diameters (dvs, μm) of unloaded (CH) and loaded (CP) microparticles 
together with dvs values of the parent mixture (MIX) of chitosan chloride and UDCA-AZT and its 
single components before and after grinding by agate mortar and pestle. Data are reported as the 
mean ± SD of three independent experiments. 
Sample dvs (μm) 
CP 3.59 ± 0.14 
CH 2.32 ± 0.11 
MIX 6.11 ± 0.02 
Grinded Chitosan HCl 12.67 ± 0.82 
Grinded UDCA–AZT 5.12 ± 0.02 
Chitosan chloride before grinding 19.98 ± 0.06 
UDCA–AZT before grinding 23.33 ± 0.06 
96 
Andrea Salis 
Polysaccharides as Drug Delivery Systems for different Administration Routes 
Tesi di Dottorato in Scienze e Tecnologie Chimiche-Scienze Farmaceutiche 
Università degli Studi di Sassari 
 
 
Figure 2.Size distribution of loaded (CP) and unloaded (CH) chitosan microspheres (up), MIX and 
chitosan chloride and UDCA–AZT alone, before and after grinding (down). The particle size 
distribution was graphically expressed as curves obtained by plotting the volume of the particles as 
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MIX had a dvs of 6.11 ± 0.022 μm, which was significantly higher than the values obtained for 
microspheres (P<0.001) and UDCA–AZT alone but significantly lower than the value obtained for 
chitosan chloride alone, which were both analyzed after grinding. The grinding of the drug and the 
polymer in an agate mortar reduced the particle size and shifted the size distributions to lower 
values (Figure 2, lower panel). In fact, the dvs of chitosan chloride changed from 19.98 ± 0.24 μm to 
12.67 ± 0.819 μm due to aggregate breaking. The size reduction of UDCA–AZT crystals was even 
more pronounced: the dvs decreased from 23.33 ± 0.06 μm to 5.12 ± 0.018 μm after grinding. 
Particle morphology 
Figure 3A presents an SEM image of MIX obtained by geometric dilution using an agate mortar 
and pestle. This picture reveals not only particles characterized by a round morphology and a 
relatively smooth surface but also the presence of fragments characterized by an irregular shape. 
For comparison, Figure 3B and C present SEM images of chitosan chloride and UDCA–AZT, 
respectively, which were ground using an agate mortar and pestle. Figure 3B shows particles 
characterized by a round morphology and a smooth surface. These morphologic characteristics did 
not appear to be significantly different from those of chitosan chloride before grinding, as 
evidenced by the SEM image presented in Figure 3E. The SEM picture of ground UDCA–AZT, 
Figure 3C, showed fragments characterized by an irregular shape (details are evident in the SEM 
image reported in Figure 3D) and a high aptitude to aggregate. These morphologic characteristics 
appeared to be significantly different from those of the prodrug UDCA–AZT before grinding, as 
evidenced in Figure 3F, where fragments of an irregular shape are shown to be characterized by 
diameters at least one order of magnitude higher than those of the ground UDCA–AZT particles. 
Taking into account these aspects, we can conclude that the SEM image of the physical mixture of 
chitosan chloride and UDCA–AZT (Figure 3A) allows us to discriminate its two components; in 
particular, the particles with a round morphology can be attributed to chitosan chloride, whereas the 
fragments of irregular shape can be attributed to UDCA–AZT. 
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Figure 3.Scanning electron microscopy (SEM) micrographs of the mixture of chitosan chloride and 
UDCA–AZT (87:13 w/w, magnification of 3610 times) [A]; ground chitosan chloride 
(magnification of 3140 times) [B]; ground UDCA–AZT with magnifications of 512 times [C] and 
10,000 times [D]; chitosan chloride before grinding (magnification of 2740 times) [E]; and UDCA–
AZT before grinding (magnification of 505 times) [F]. 
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Figure 4A and B present SEM images of CP, which is constituted by the loaded UDCA–AZT 
microparticles based on chitosan chloride. The pictures reveal the presence of spherical particles 
characterized by a smooth surface and several fragments characterized by an irregular shape and 
high porosity, similar to spongy balls, with some degree of aggregation. For comparison, a SEM 
image of the unloaded microparticles (CH) [21] reveals their round shape and smooth surfaces. 
Taking into account these aspects, we can hypothesize that the spherical particles presented in 
images 3A and 3B are constituted by unloaded chitosan chloride, whereas the spongy balls were 
obtained from the interaction between chitosan chloride and UDCA–AZT, which gave rise to the 
highly porous structures. 
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Figure 4. Scanning electron microscopy (SEM) micrographs of the loaded microparticles (sample 
CP) with magnifications of 11,250 times [A] and 3620 times [B]. 
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True density 
The true density of the microspheres was 1.48 ± 0.02 g/cm3, which is comparable to the ρ of nasal 
microspheres [34]. 
Determination of water uptake capacity 
Figure 5 shows the water uptake of both loaded and unloaded formulations. The drug-free 
formulations absorbed a greater amount of water than the loaded microparticles. Drug loading 
decreased the water absorption capability of chitosan microspheres (P<0.05). UDCA−AZT and the 
chitosan chloride physical mixture also exhibited water uptake capabilities stronger than that of CP 
but weaker than that of CH after 15–60 min (P<0.05). 
 
 
Figure 5. Water uptake profiles of loaded (CP) and unloaded (CH) microspheres over 60 min in 
comparison to that of the physical mixture (MIX, chitosan chloride and UDCA−AZT (87:13 w/w). 
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In vitro release and dissolution studies 
The dissolution and release studies of UDCA−AZT were performed in a MeOH/H2O (70:30, v/v) 
mixture. The employment of methanol as a cosolvent was necessary to increase the low solubility of 
the prodrug in water (0.0030 ± 0.0001 mg/ml; [9]), thus ensuring sink conditions. 
Figure 6 reports the release profile of UDCA−AZT from the loaded CP sample. The release pattern 
is compared with that of UDCA–AZT dissolution from its physical mixture with chitosan chloride. 
The dissolution rate of the prodrug included in MIX appeared to be significantly lower than that of 
UDCA–AZT loaded in the CP sample. Indeed, after 2 h of incubation, 38.4 ± 1.6% of the prodrug 
loaded in the dissolution apparatus appeared to have dissolved, whereas in the case of CP loaded 
microparticles, the amount of dissolved UDCA–AZT was 86.2 ± 3.4%. As a consequence, the 
dissolution half-life of UDCA–AZT loaded in CP sample appeared to be approximately 15 min, 
whereas for the prodrug in the physical mixture (MIX), the dissolution half-life was greater than 2 
h. These profiles suggest that the employment of the CP sample as a nasal formulation should be 
appropriate, as this formulation is able to release the prodrug UDCA–AZT in a relatively short time, 






Polysaccharides as Drug Delivery Systems for different Administration Routes 
Tesi di Dottorato in Scienze e Tecnologie Chimiche-Scienze Farmaceutiche 
Università degli Studi di Sassari 
 
Figure 6. In vitro release of UDCA−AZT from CP microparticles based on chitosan chloride. The 
release profile is compared with the dissolution profile obtained for the parent physical mixture of 
chitosan chloride and UDCA–AZT (87:13 w/w) (MIX). The data are reported as the mean ± SD of 
three independent experiments. 
In vivo UDCA–AZT administration 
Taking into account the fact that the CP microparticles were characterized not only by a satisfactory 
encapsulation efficiency but also by the ability to induce relatively rapid dissolution of 
UDCA−AZT, we tested these microparticles for nasal administration of the prodrug in order to 
verify potential uptake in the CNS. The nasal administration of UDCA−AZT was performed using 
three different formulations: (I) a suspension of the raw UDCA–AZT powder in water, (II) the 
powder constituted by loaded CP microparticles and (III) for comparison, the parent physical 
mixture of chitosan chloride and UDCA–AZT (87:13 w/w). The results were compared with those 
obtained after the intravenous infusion of UDCA−AZT into rats. 
Intravenous administration of UDCA−AZT 
The prodrug was undetectable in rat blood samples following intravenous infusion. This result is in 
agreement with the very fast hydrolysis of UDCA−AZT in rat blood at 37°C [9]. Significant 
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amounts of AZT were therefore detected following the intravenous administration of the prodrug, as 
evidenced in Figure 7. In particular, after the infusion of 0.200 mg of UDCA−AZT into the rats, the 
AZT concentration in the bloodstream was 4.50 ± 0.31 μg/mL. This concentration decreased over 
time with apparent first order kinetics, as confirmed by the linearity of the semilogarithmic plot 
reported in the inset of Figure 7 (n = 9, r = 0.990, P<0.0001), and a half-life of 60.4 ± 3.8min. 
These data are in good agreement with those obtained from previous studies of in vivo UDCA–AZT 
pharmacokinetics [10]. No AZT or UDCA−AZT was detected in the CSF within 180 min after the 
intravenous administration of UDCA−AZT. 
 
 
Figure 7. Elimination profile of AZT after the infusion 0.200 mg of UDCA−AZT into rats. The 
data are expressed as the mean ± SD of four independent experiments. The elimination followed 
apparent first order kinetics, as confirmed by the semilogarithmic plot reported in the inset (n = 9, r 
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Nasal administration of UDCA−AZT 
The nasal administration of pure UDCA–AZT as a water suspension did not allow us to obtain 
detectable amounts of AZT or the prodrug in the blood or in the CSF, respectively, within 180 min 
of administration, as reported previously [10]. In contrast, the nasal administration of the powders 
constituted by MIX or by the CP microparticles (0.8 mg, approximately 100 μg of UDCA−AZT in 
each nostril) produced detectable amounts of UDCA−AZT in the CSF of the rats, as reported in 
Figure 8. In particular, the UDCA−AZT Cmax was obtained after 60 min, with a value of 1.96 ± 0.29 
μg/mL (3.1 ± 0.4 μM), after nasal administration of the mixture. 
 
Figure 8. UDCA−AZT concentrations (μg/mL) detected in the CSF after the nasal administration 
of dry powders constituted by loaded CP microparticles and its parent mixture (MIX) of chitosan 
chloride and UDCA–AZT. Each dose contained 200 μg of the prodrug. The inset reports the 
semilogarithmic plot of the UDCA–AZT concentrations (μM) in the CSF after the nasal 
administration of the CP sample. The elimination of UDCA–AZT from the CSF followed apparent 
first order kinetics, as confirmed by the linear regression of the points ranging from 60 to 180 min 
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The nasal administration of the same amount of CP microparticles increased the rate of uptake of 
the prodrug into the CSF of rats. Indeed, the UDCA−AZT Cmax was obtained at 60 min, with a 
value of 2.99 ± 0.31 μg/mL (4.7 ± 0.5 μM), which was significantly higher than the Cmax value 
obtained for the MIX sample (P<0.001). 
No AZT was detected in the bloodstream or in the CSF within 180 min after nasal administration of 
the powders constituted by MIX or the CP microparticles. 
The areas under the concentration (AUC) curve values obtained for UDCA−AZT in the CSF after 
the nasal administration of MIX and CP microparticles (Figure 8) were 201.39 ± 13.51 μg mL−1 
min and 354.4 ± 13.3 μg mL−1min, respectively. The ratio between the AUC of the CP sample and 
the AUC of the mixture was 1.76, indicating that the nasal formulation constituted by the CP 
microparticles allowed an uptake of UDCA−AZT into the CSF that was 76% higher than that 
obtained after the administration of the parent mixture (P<0.001). 
The UDCA–AZT concentration in the CSF after nasal administration of CP microparticles 
decreased over time with apparent first order kinetics, as confirmed by the linearity of the 
semilogarithmic plot reported in the inset of Figure 8 (n = 4, r = 0.998, P< 0.05), and a half-life of 
80.4 ± 9.2 min. 
DISCUSSION 
Although antiretroviral nucleoside derivatives are largely used against HIV infection for their 
efficacy at the peripheral level, the total eradication of this virus from the body is currently difficult 
to achieve. Indeed, antiretroviral drugs are unable to reach the CNS [40,41]; in contrast, the CNS is 
easily reached by HIV through infected monocytes [42,43] that differentiate into macrophages and 
microglia in the brain [44]. Therefore, the CNS and those macrophages constitute sanctuaries for 
HIV, where drug resistance is induced and from which the periphery can be re-infected [1,2]. These 
phenomena are attributed primarily to the expression of AETs on the membranes of macrophages 
[45,46] and blood brain barrier (BBB) cells [5,6], whose activity prevents the penetration of 
antiretroviral drugs into HIV sanctuaries. 
Among numerous nucleoside antivirals, AZT was the first to be approved and remains the most 
widely used for the treatment and prophylaxis of HIV/AIDS [47]. Unfortunately, long-term clinical 
use of AZT is associated with significant side effects, but despite these drawbacks, AZT is 
considered to be one of the more potent inhibitors of the HIV DNA polymerase (reverse 
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transcriptase) [48,49]. Currently, tenofovir (TDF) is known to be a more potent and less toxic 
antiretroviral (ARV) drug than AZT; however, a higher virological failure rate was observed after a 
clinical TDF-containing ARV regimen in comparison to AZT-containing ARV therapy [50]. 
AZT activity in the CNS appears to be necessary not only in the brain tissue but also in the CSF 
subarachnoid spaces that contain macrophages and constitute the only site of HIV replication in the 
brain [3,4]. It is therefore important to obtain formulations that are able to target AZT to the CSF, 
but it is equally important to induce the ability of AZT to elude the AET systems in order to avoid 
its extrusion from the CNS and the associated macrophages. In this regard, we know that the 
prodrug UDCA–AZT, which was obtained by the conjugation of AZT to ursodeoxycholic acid 
(UDCA), is able to elude the AET systems [9]. Moreover, the results reported in this paper 
demonstrate for the first time that the prodrug UDCA–AZT is more efficient than AZT in 
permeating and remaining inside the murine macrophage-like J774A.1 cell line, which is commonly 
used as model system for studying the internalization process of macrophages [51]. Human cells 
can be used for in vitro studies of inflammation and infection, and many similarities between 
immortalized human monocytic cell lines (e.g., U937 and THP-1) and primary human blood 
monocytes have been reported [52]. However, these immature cells often require the addition of 
stimulant factors to promote their differentiation to a mature, adherent phenotype [53]. This 
requirement complicates the study of inflammatory outcomes related to these cell types, as 
stimulant factors exert specific effects on cellular behaviour. Additionally, maturation protocols 
vary across studies. In contrast, murine cell lines offer the advantage of an immortalized, relatively 
stable, mature, adherent macrophage phenotype. The murine cell lines J774A.1, RAW 264.7 and 
IC-21 exhibit the maturity markers F4/80 and Mac-1, indicating their macrophage-like phenotypes, 
and have been used as models of macrophage activation in numerous studies [54]. As an example, 
J774 mouse macrophages have been successfully used to demonstrate the uptake of azidothymidine 
triphosphate (AZT-TP)-loaded nanoparticles and the related efficient delivery of AZT-TP into the 
cell cytoplasm [55]. 
Moreover, our results demonstrate that the prodrug UDCA–AZT is hydrolysed in macrophages, 
facilitating intracellular AZT release. Interestingly, no toxicity was observed in the macrophages 
during their incubation with UDCA–AZT. We demonstrated previously that this prodrug is not a 
substrate of human AETs [9]. This result suggests that UDCA–AZT should not be subject to efflux 
from human macrophages. Furthermore, AZT is known to induce anti-HIV activity in the HTLV-1-
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transformed cell line MT-4, which is highly susceptible to and permissive for HIV infection [56], 
thus suggesting that AZT is able to induce anti-HIV activity in human macrophages. 
It is important to note that the prodrug UDCA–AZT is quickly hydrolysed in whole blood, so 
intravenous administration is not suitable for its permeation across the BBB. Indeed, following this 
type of administration, we detected only AZT, which exhibited concentration values that decreased 
over time with a half-life of approximately 1 h. No AZT or UDCA−AZT were detected in the CSF 
of rats after intravenous administration. In contrast, the nasal administration of this prodrug appears 
promising for achieving uptake into the CNS and particularly the CSF. We demonstrated that the 
nasal administration of chitosan-based microparticles can induce the selective uptake of neuroactive 
agents into the CSF of rats, probably by promoting drug permeation across the olfactory nasal 
mucosa [21,24,27]. Very recently, the poor water solubility of UDCA–AZT encouraged us to 
encapsulate this prodrug in solid lipid microparticles [10]. In particular, the nasal administration of 
UDCA–AZT loaded in stearic acid-based microparticles induced the selective uptake of the prodrug 
into the CSF of rats, with amounts of up to approximately 0.4 μg/ml within 60 min after 
administration [10]. These amounts increased (up to approximately 1.50 μg/mL within 120 min 
after administration) when the same quantity of microparticles were administered nasally as a water 
suspension in the presence of chitosan chloride [10]. This result was attributed to the good 
mucoadhesive properties of chitosan [21] and to its ability to transiently open the tight junctions in 
the epithelial membranes [57,15]. 
Nasal formulations obtained in the presence of water can be associated with the risk of chemical 
and physical instability and microbiological growth. Moreover, in the nasal cavity, liquid 
formulations are often rinsed into the GIT or out of the nose, so their residence time is generally 
short [58]. These disadvantages can be overcome by using powder-based formulations [32,59]. For 
this reason, we prepared microspheres based on chitosan chloride in order to increase the nose-to-
brain delivery of UDCA–AZT. The efficacy of the microparticulate system for the brain delivery of 
the prodrug was verified by comparing the properties of the microparticles with those of their parent 
physical mixture, which was obtained by geometrical dilution of the components using an agate 
mortar and pestle. The grinding process induced a reduction of the dvs diameters of chitosan 
chloride and the UDCA–AZT particles. The chitosan chloride particles were characterized by a 
round morphology and a relatively smooth surface before and after grinding, whereas UDCA–AZT 
appeared as fragments with an irregular shape. These two different morphological characteristics 
were distinctly apparent in the SEM picture of the physical mixture, where small irregular 
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fragments of UDCA–AZT appeared on the surface of larger and rounder chitosan chloride 
microspheres. 
The spray-drying process allowed us to obtain unloaded microparticles of chitosan chloride (CH) 
with the “classical” round morphology and a small dvs diameter. The loaded microparticles (CP) 
evidenced a slight increase in size and a morphology characterized by spherical particles mixed 
with fragments of irregular shape and high porosity, similar to spongy balls, with some degree of 
aggregation. We can conclude that the spherical particles are attributable to pure chitosan chloride 
that has not interacted with UDCA–AZT during the spray-drying process, whereas the “spongy 
balls” were obtained by a combination of the prodrug with polymer, inducing the formation of the 
highly porous structures. The different degrees of water solubility between UDCA–AZT and 
chitosan can justify these characteristics of the CP formulation. The description of the CP 
formulation’s morphology appears to be consistent with the observed dissolution and water uptake 
profiles. Indeed, we observed that the dissolution rate of UDCA–AZT from the CP sample was 
significantly higher than that of the parent physical mixture. This phenomenon can be attributed to 
the highly porous structures observed in the CP sample, which allows a faster dissolution of 
UDCA–AZT with respect to its fragments included in MIX. Moreover, as demonstrated previously 
by Gavini et al. [27], water soluble chitosans, such as salts, are more able to completely amorphize 
poorly soluble drugs into the polymer matrix compared to the chitosan base; as a consequence, the 
dissolution rate and bioavailability of poorly soluble drugs improve. 
Moreover, we observed that the water uptake rate of the CH sample was significantly reduced if 
chitosan chloride was mixed with UDCA–AZT, but a drastic decrease was observed in the case of 
the CP sample. The presence of UDCA–AZT, which is a very poorly water soluble molecule, in the 
physical mixture can explain its reduction of water uptake with respect to the CH sample, but the 
drastic reduction observed for the CP microparticles can be attributed to their porous structures, in 
which the presence of the prodrug and chitosan chloride together contributed to dramatically 
reducing the water uptake aptitude of the polymer. 
Therefore, the CP sample appeared to be a valuable formulation for the nasal administration of 
UDCA–AZT. In particular, we hypothesized that the size and density of the microparticles should 
induce their deposition on the nasal mucosa, which should not be dehydrated by their presence, 
given the poor the water uptake of this sample. Moreover, the ability of the loaded microparticles to 
increase the dissolution rate of UDCA–AZT suggested their potential aptitude for inducing prodrug 
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permeation across the nasal mucosa, a phenomenon that is probably potentiated by the ability of 
chitosan to transiently open tight junctions [20]. 
The nasal administration of raw UDCA−AZT to rats did not produce any detectable levels of 
UDCA−AZT or AZT in the bloodstream or the CSF, whereas the nasal administration of the CP 
sample and its parent physical mixture allowed us to obtain relatively high levels of UDCA–AZT in 
the CSF of rats 60 min after administration. The relative bioavailability of the CP sample was 176% 
of that of its parent physical mixture (P<0.001). No AZT was detected in the bloodstream of rats 
after nasal administration of the CP sample and its parent physical mixture, confirming the 
existence of a direct nose−CNS pathway for this prodrug [10]. Our results demonstrate that the role 
of chitosan in inducing selective UDCA–AZT uptake into the CSF is potentiated when the prodrug 
is formulated as a microparticulate system by spray-drying. This phenomenon is illustrated in 
Figure 9, which presents a comparison of the AUC values obtained in the CSF after nasal 
administration of the same dose of UDCA–AZT (200 μg) to rats using different formulations (i.e., 
the solid lipid microparticles (SLMs), their water dispersion in the presence of chitosan (SLMs + 
Ch), which was obtained previously by Dalpiaz et al. [10], MIX and CP, which was described here). 
In particular, CP was able to induce an uptake of UDCA–AZT into the CSF of rats that was 1.8, 3.2 
and 18.6 times greater than that of its parent physical mixture (MIX), the dispersion of solid lipid 
particles in the presence of chitosan (SLMs + Ch) and the SLMs in solid form, respectively. 
 
 
Figure 9. A comparison among the AUC values obtained in the CSF of rats after the nasal 
administration of 200μg of UDCA–AZT using different formulations (i.e., loaded solid lipid 
microparticles (SLMs), their water dispersion in the presence of chitosan (SLMs + Ch), the physical 
mixture of chitosan and prodrug (MIX) and the loaded microparticles based on chitosan chloride 
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(CP)). The data pertaining to SLMs and the SLM + Ch formulations were reported previously [10]. 
The data are expressed as the mean ± SD of four independent experiments. 
To summarize, after nasal administration, chitosan microspheres induce the efficient uptake of 
UDCA–AZT into the CSF. We demonstrated previously that this prodrug is able to elude the AETs 
and avoid their inactivation [9]; as a consequence, the ability of the prodrug to elude the AET 
systems can prevent its extrusion into the bloodstream and induce AZT transport in the 
macrophages located in the subarachnoid spaces of the CSF. Consistent with these findings, it was 
demonstrated previously that the nasal co-administration of AZT and probenecid (an inhibitor of 
AETs) increased AZT uptake into the CSF of rats [60]. 
Taking into account the observations that the UDCA–AZT Cmax obtained in the CSF after the nasal 
administration of the sample CP was approximately 5 μM and that the half-life of the prodrug in the 
CSF was approximately 90 min, we can hypothesize that multiple nasal administrations every 90 
min will allow rats to obtain UDCA–AZT concentrations ranging between approximately 5 and 10 
μM in their CSF [61]. We demonstrated that the incubation of macrophages with 10 and 100 μM 
UDCA–AZT allowed us to detect prodrug amounts ranging from approximately 0.2–1 nmoles in 
106 cells. We also demonstrated that the AZT concentration in macrophages after incubation with 
UDCA–AZT was 47 μM. AZT exhibits anti-HIV activity in the HTLV-1-transformed cell line 
MT4, with an IC50 value of approximately 30 nM [56], which is more than three orders of 
magnitude lower than the concentration of AZT that we detected in the macrophages after 
incubation with 100 μM UDCA–AZT. Therefore, it seems reasonable to deduce that incubation 
with 5 or 10 μM UDCA–AZT can allow the macrophages to attain AZT concentrations sufficient to 
induce anti-HIV activity. As a consequence, taking into account the aspects we described above, we 
predict that the amount of UDCA–AZT taken up in the CSF following the nasal administration of 
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CHAPTER 4 
Composite Chitosan/Alginate Hydrogel For Controlled Release Of Deferoxamine: A System 
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INTRODUCTION 
Iron is a redox active metal, essential for life and indispensable for several biological reactions [1]. 
Nevertheless, its excess is toxic due to the release of reactive oxygen species (ROS) [1-3]. The 
hydroxyl radical is very reactive and can cause oxidative damage to various cell components, 
including lipid membranes, DNA, and proteins, thereby causing cell damage [2,4].Disruption of 
iron regulation plays a key role in the etiology of neurological disorders, cancer, stroke, muscle 
diseases such as Duchenne's muscular dystrophy, and aging [3,5]. Iron overload in the cytoplasm of 
hepatocytes contributes to hepatocellular damage and hepatocarcinogenesis [4]. In the skin, excess 
iron combined with UV radiation exerts pro-oxidant effects [3]. Furthermore, it is hypothesized that 
iron may contribute to the pathogenesis of ocular diseases [2]. 
Iron chelators are currently being investigated for their benefit in limiting iron-induced oxidative 
damage. The best known iron chelator in clinical use is deferoxamine (DFO, Desferal™) [2]. DFO 
as mesylate salt is the treatment of choice for acute iron intoxication and chronic iron overload due 
to transfusion-dependent anemia [6]. Data to support DFO use in other disorders associated with 
iron overload are growing. Several studies have shown the beneficial effects of DFO in reducing 
skin necrosis [7-11]. DFO appears to mitigate radiation-induced hypovascularity and improve tissue 
elasticity in a rat model [12]. DFO can prevent liver injury and development of preneoplastic 
lesions in rats [13,14], and it was proposed as an anticancer agent for the therapy of advanced 
hepatocellular carcinoma (HCC) [4,15]. Over the past few years, a variety of studies have been 
conducted on DFO demonstrating some positive effects on fracture healing [16-21]. Unfortunately, 
DFO has properties that significantly limit its usefulness in a clinical setting. Administration of this 
drug is limited to the parenteral route due to its poor absorption in the gut. Furthermore, DFO has a 
very short plasma half-life because of rapid renal excretion; thus, repetitive or continuous 
subcutaneous infusions are necessary to maintain its effective therapeutic levels [1,22]. These are 
associated with toxic effects [23]. Furthermore, repeated injection of DFO at the bony injury may 
not be practical or effective clinically [19]. In most studies DFO was administered in solution 
[4,12,15,16], and to date, very few formulation strategies have been developed in order to improve 
DFO biopharmaceutical properties: (i) conjugation to hydroxyethyl starch (Hespan) [24] or to 
hyperbranched polyglycerol (HPG) [25] for increasing plasma half-life; (ii) formulation in nasal 
microparticulate delivery systems to improve the nose to brain transport [26]; (iii) loading in 
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Hydrogels are widely used as debriding agents, moist dressings, components of pastes for wound 
care, as well as ocular drug delivery carriers, and subcutaneous inserts. Furthermore, hydrogels are 
able to both locally embolize the hepatic tumor and deliver drugs in a controlled manner [28,29]. 
Tissue engineering is one of the most recent applications of hydrogels as space filling agents, 
delivery vehicles for bioactive substances or as three-dimensional structures that organize cells and 
ensure the development of a required tissue [30]. Composite hydrogels are a co-formulation of 
particulate systems incorporated into the hydrogel matrix forming “plum pudding” hydrogel 
networks [31]. Incorporating degradable micro- or nanoparticles loaded with a drug in the hydrogel 
can further extend the possibilities for controlling drug delivery [32]. This can have the added 
benefits of reducing burst release commonly displayed in microsphere formulations and can prevent 
microsphere displacement away from the site of action [31]. 
In order for DFO therapy to progress to clinical treatment, methods of delivery, timing, and dosage 
need to be considered and optimized [14,18,20]. In this study, the feasibility of hydrogel as 
prolonged delivery systems of DFO, useful for solving the criticalities common to several iron 
dysregulation diseases, was investigated. Physical chitosan/alginate hydrogel was selected in order 
to obtain a carrier able to control the delivery of this drug to the target site, and at the same time, 
depending on the disease, to serve as structural support (e.g. on fracture healing) or embolic agent 
(e.g. in the therapy of advanced hepatocellular carcinoma). Finally, it should be reabsorbed after it 
has served its function. This system should be entirely biocompatible and biodegradable, no toxic, 
injectable or implantable. The materials used well correspond to the characteristic quality of the 
required drug delivery systems making alginate and chitosan more suitable carriers than others. The 
advantages of chitosan/alginate hydrogel alone or co-formulated with PLGA microparticles were 
evaluated in vitro. 
MATERIALS AND METHODS 
Materials 
Sodium alginate (Protanal LF 120 L, batch: 907788; MW: 221 kDa; viscosity (1% sol): 93 cP; 
Seaweed species: Lessonia nigrescens; FG: 0.41; FM: 0.59; FGG: 0.22; FGM: 0.19; FMM: 0.40; FGGM: 
0.05; FMGM: 0.14; FGGG: 0.17; NG>1: 5.6 [33] was purchased from FMC BioPolymer, now FMC 
Health and Nutrition (Philadelphia, USA). Chitosan (ChitoClear TM 1358, deacetylation degree: 
95%; viscosity (1% sol): 63 cP; MW: 103 kDa; ash residue: 0.9% (according to the manufacturer's 
specifications)) was acquired from PRIMEX EHF, Siglufjordur, Island. Poly(d,l-lactide-co-
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glycolide) (PLGA) RG502 (viscosity: 0.16–0.24 dl/g (50:50), MW: 7000–17,000), RG504 
(viscosity: 0.45–0.60 dl/g, MW: 38,000–54,000), and deferoxamine mesylate salt (DFO) were 
purchased from Sigma–Aldrich, St. Louis, USA. All other solvents and chemicals were of 
analytical grade. 
Hydrogel preparation 
Unloaded hydrogel characterized by a molar ratio 1/1 between alginate and chitosan and 2.5% (w/v) 
concentration of polymers, in the final volume, were prepared. Sodium alginate solution (2.44% 
w/v) was made dissolving alginate powder in water with the aid of a magnetic stirrer at room 
temperature. Separately, chitosan (2.75% w/v) was dissolved in hydrochloric acid solution pH 0.7, 
under magnetic stirring. Then, 1.25 mL of chitosan solution was added to 3.75 mL alginate solution 
(pH 7.0) and stirred vigorously in order to obtain the final pH of 3.0. Loaded hydrogels were 
prepared by dissolving DFO (3 mg) in chitosan solution before mixing polymer solutions. 
Microsphere preparation 
Microspheres, composed by PLGA, hydrophobic polymer, and DFO, hydrophilic drug, were 
prepared by using the emulsification/spray drying method previously described [34]. After 
preliminary studies, the total solid (drug + polymer) concentrations of 4% w/v was selected; drug to 
polymer ratios of 1:4 and 1:10 were considered. Table 1 lists the formulations prepared. Briefly, 
w/o emulsion was prepared by dissolving DFO in water and PLGA in 25 mL of dichloromethane. 
The aqueous solution was added dropwise to the organic one within 5 min, under homogenization at 
10,000 rpm (Ultra-Turrax T25 basic, IKA, Germany). The w/o emulsion was then sprayed through 
the nozzle (0.7 mm) of a spray-dryer, co-current flow type (Buchi Mini Spray Dryer B-191, Milano, 
Italy). The process conditions are shown in Table 1. The temperature of emulsion was maintained at 
about 5°C throughout the process. No phase separation during the spray-drying process was 
observed in the emulsion, thus rendering unnecessary the use of surfactants (Figure S1). 
Microspheres were collected and kept under vacuum for 48 h at room temperature. 
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Table 1. Microsphere formulations: composition and spray-dryer manufacturing parameters. Mean 


















502 - - 50 41 5.63±0.31 8.33 
504 - - 50 41 8.19±2.09 15.95 
D502 4 0.250 5 80 55 33.13±23.75 10.37 
D504 4 0.250 5 80 51 66.38±11.86 9.10 
D502 10 0.100 1.5 50 39 18.21±3.2 8.62 
D504 10 0.100 1.5 50 42 21.93±17.76 13.08 
aDrug to polymer ratio of 1:4 and 1:10 were used; The following conditions were also used during 
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Composite hydrogel preparation 
Composite hydrogels were prepared by combining the microspheres and the hydrogel. Two 
methods were tested: (1) PLGA microspheres (30mg) were added into the chitosan solution; which 
was then loaded onto the alginate solution and stirred vigorously; and (2) the addition of 
microspheres was performed after the formation of chitosan/alginate hydrogel. 
Microsphere characterization 
Yield of production 
The yield of production was calculated as percentage of the weight of the final product with respect 
to the total solid (drug and polymer) solubilised in the feed solutions. 
Particle size analysis using a suspension method 
The particle size and particle size distribution of the microspheres were determined with a Coulter 
LS 100Q Laser diffractometric equipment (Beckman Coulter Particle Characterization, Miami, FL, 
USA). For particle size analysis using a suspension method, microspheres (2 mg) were suspended 
in 1 mL of Tween 80 solution (0.1% w/v); the suspension was further diluted and dispersed by 
vortexing for 10min in case of formulation based on RG502 and vortexing for 10 min and 
sonication for 2 min in case of RG504. Values reported are the averages of three determinations for 
five samples of each formulation (standard deviation, SD, n = 15). 
Powder particle size analysis 
The particle size in the dry powder was measured by an HELOS Particle Size Analyser from 
Sympatec GMbH, fitted with an Aspiros doser (pressure, 2.00 bar; vacuum, 36.00 mbar; feed 
velocity; 25.00 mm/s). A lens able to detect particles in the size range 0.9–175 μm was fitted. 
Drug content 
DFO loaded microspheres (15 mg) were dissolved in 2–4 mL dichloromethane with the aid of 
magnetic stirring. The solution was then diluted with 40 mL of water and the organic phase was 
evaporated using a rotavapor at 35°C before transferring the remaining aqueous solution into a 
volumetric flask (50 mL) and analyzed by HPLC as described below. One extraction was enough 
for complete DFO recovery. 
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Loading efficiency (LE), as percentage, was calculated by using the following equation: 
                                                                                                                               (1) 
where DCA and DCT are the amount of drug loaded into the polymer matrix and the expected 
theoretical value, respectively. DCA was calculated as previously reported [35]. 
Drug burst test 
Microspheres (15 mg) were suspended in 50 mL of water, at either 37 °C or at room temperature. 
The samples were then vortexed for 10 s before centrifugation (3000 rpm for 5 min) and then 
analyzed by HPLC. 
HPLC analysis of deferoxamine mesylate 
For the quantification of DFO in buffer samples, a Varian ProStar 210 with AutoSampler 410 and a 
PDA photodiode array detector (Varian Inc Scientific Instruments, Walnut Creek, CA, USA) was 
employed. The chromatographic separation was performed as previously reported [26]. Briefly, 
separation was performed at room temperature on a C18 column with polar endcapping 
(Phenomenex Synergi Hydro-RP 80A, 150 × 4.6 mm I.D. and 4 μm of particle size). Twenty 
microliters of samples were directly injected into the column and eluted with a binary mixture 
consisting of acetonitrile (pH 4.6 with 0.5 M H3PO4) and a 0.1 M KH2PO4 (3.4 g/250 mL), 120 
mg/L (30 mg/250 mL) 1-eptane sulfonic acid sodium salt solution ratio 17:83 (v/v) adjusted to pH 
4.6 by 0.5 M phosphoric acid. DFO was detected by UV at 210 nm wavelength. Concentrations of 
analyte were calculated by interpolation of DFO standard curves. 
Hydrogel characterization 
Viscosity measurement 
Viscosity of unloaded hydrogel as well as polymer solutions was measured, at room temperature, by 
rotational viscometer (Alpha-L, Fungilab, Barcelona, Spain) at a constant rotation speed of 60 rpm 
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Porosity measurement 
The solvent replacement method was used to determine the porosity of the hydrogel samples [36]. 
Freeze-dried hydrogels (unloaded, loaded and composite) were immersed in absolute ethanol 
overnight and weighed after blotting excess ethanol on the surface. The porosity was calculated 
from the following equation: 
                                                                                                          (2) 
whereM1 and M2 are the masses of the hydrogel before and after immersion in ethanol, respectively, 
ρ is the density of absolute ethanol and V is the volume of the hydrogel. 
Water uptake and swelling 
Hydrated and freeze-dried hydrogels (unloaded, loaded and composite) were weighed and fully 
immersed in a sealed container with phosphate buffered saline (PBS; pH 7.4) for 24 h at 37°C [37] 
to study the water uptake (WU%) and swelling characteristics. Then, samples were taken out, wiped 
with paper and weighed. The water uptake percentage was determined gravimetrically using 
following equation: 
                                                                                                                 (3) 
whereM1 is the dry weight and M2 is the saturated weight.  
Similarly, the swelling ratio was calculated from the volume of dry and saturated hydrogel. 
Dynamic vapor absorption (DVS) studies 
Dynamic vapor sorption (DVS) analysis of the freeze-dried hydrogels (unloaded, loaded and 
composite) was carried out with a Surface Measurement Systems DVS Advantage instrument. 
Using nitrogen as the carrier gas; the mass change of samples subjected to a changing water vapor 
partial pressure at 25°C was recorded. The partial pressure was increased from 0 to 90% in 10% 
increments; the partial pressure was increased to the next step either after equilibrium or after a 
maximum time of 360 min. A full adsorption/desorption cycle was performed; the data collected 
were used to calculate the adsorption and desorption isotherms as well as the hysteresis. The data 
were further analyzed according to the following equation: 
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Wp=Kptnp                                                                                                                                            (4) 
whereWp is the weight gain; Kp is the kinetic constant of water penetration into the composite 
material; np is the exponent describing the mechanism of water penetration. 
Biodegradability 
The weight loss of the composite hydrogels was monitored as a function of incubation time in PBS 
(pH 7.4) at 37°C for 24 days [37]. Weights of the samples were measured at 10, 17 and 24 days of 
incubation, after freeze-drying. Degradation was determined by percentage of weight loss (WL) 
using following equation: 
                                                                                                                (5) 
whereW0 was the initial weight and WL was the weight after degradation. Each experiment was 
repeated three times, and the value is reported as mean ± SD (n = 3). No significant change in pH 
was found during the test. 
Drug release studies 
Release studies of DFO from microspheres, loaded and composite hydrogels were carried out. 
Microspheres or hydrogels were put in 50 mL of PBS containing 0.01% Tween 80 and shaken at 80 
rpm, 37°C for 10 days. 
At predetermined time points, 1 mL of medium was withdrawn and centrifuged at 13,000 rpm for 
10 min, the supernatant was removed and stored at −20°C until HPLC analysis. Pellets eventually 
obtained after centrifugation were resuspended in 1 mL PBS and poured back into the release 
medium to restore the initial volume. Standard DFO solutions (60 mg/L) were stored in the same 
conditions in order to check the possible degradation of DFO during the time. 
Release profiles were corrected to remove the degradation aspect and analyzed with regards to 
release kinetics and mechanism of release. The following equation describes the method used for 
the corrections. Ftn is the corrected percentage release, Ft is the cumulative percentage release, t is 
the time at which Ft level was taken. 
                                                                                             (6) 
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The corrected data were then investigated for fit into various release models. Zero order is 
demonstrated by plotting the corrected cumulative release fraction versus time. Zero order describes 
the concentration-independent drug release rate from a formulation: 
C=k0t                                                                                                                                                  (7) 
First order release is described by plotting log cumulative drug fraction versus time and describes 
concentration-dependent drug release from the system: 
                                                                                                                    (8) 
The Hixson–Crowell cube root law describes the release from systems where there is a change in 
surface area and diameter of particles (therefore applies to microsphere only formulations). As 
described by Eq. (9), a straight line will confirm this type of release. 
                                                                                                                          (9) 
The Korsmeyer–Peppas equation as shown in Eq. (10), describes the mechanism of drug release. 
The release exponent can be used to characterize different release mechanisms[38]. 
                                                                                                                                    (10) 
whereMt/M∞ is the fraction of drug released at time t, Kkp is the rate constant and n is the release 
exponent. 
At the end of test, the microspheres, loaded and composite hydrogel were recovered, frozen at 
−80°C and freeze-dried for morphological examination. 
Scanning electron microscope (SEM) studies 
The morphology of microspheres and freeze-dried hydrogels was analyzed by SEM. A Jeol JSM-
6060LV Scanning Electron Microscope was used and samples were coated with gold using a 
Quorum Q 150RES spatter coater. 
Statistical analysis 
Data were analyzed using the nonparametric Kruskal–Wallis test; individual differences were 
evaluated using a post hoc Dunn's multiple comparison test (GraphPad Prism, version 6.02; 
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GraphPad Software Incorporated). When suitable, analysis of variance (ANOVA) followed by a 
Tukey test was done. 
RESULTS 
Microsphere preparation and characterization 
Yield of production 
Microspheres were produced by spray-drying technique using RG502 and RG504 as polymers. 
Spray-drying appears to be a suitable method for the preparation of unloaded and DFO loaded 
microspheres, but with yield of production ranging from 34% to 67%. Loss of yield was due to 
deposition in the spray-drying apparatus. This is a common problem with small drying chambers 
and does not normally occur in industrial scale spray-drying due to the large cyclone area [39]. 
Particle size analysis 
The particle size and particle size distribution of the microspheres were determined by analyzing the 
powder in the dry state or in suspension. When measured in suspension (Table 1) there was no 
significant difference in particle size between the two unloaded formulations (502 versus 504, p = 
0.423), that differed only in molecular weight of the polymers used. The skewness in 502 is slightly 
more to the right with almost double the leptokurtic value compared to 504. 502 also had smaller 
d90/d10 showing reduced distribution (Table 1). The loading of DFO in the polymer matrix 
determined an increase of particles size regardless of the PLGA used mainly when the highest drug 
amount was employed. In fact, the loaded D502 4 and D504 4 compared to the unloaded samples, 
502 and 504, were significantly larger in size (p<0.05). Significant difference between particle sizes 
of 502 versus D502 10 and 504 versus D504 10 were also observed (p> 0.05) (Table 1). Both 
unloaded and loaded samples were skewed to the right with leptokurtic properties. 
The increase in particle size of all 504 formulations can be attributed to the increase in water/DCM 
ratio (p = 0.0029) (Figure S2). The distribution also narrows with increasing water content (d90/d10 
= 15.95, 14.00 and 8.74). Less evident but significant is the change of size of 502 formulations 
according to the ratio drug polymer used (Table 1, p<0.05). 
In order to observe whether an improvement in particle size distribution with reduced aggregation 
was observed using a dry method, samples were analyzed using this method as a qualitative 
assessment. The mean particle size was mostly larger using the dry method (Figure S3), which 
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could indicate that sample preparation for the suspension method for 502, 504, D502 4 and D502 10 
broke aggregates and reduced the average particle size. 
In comparison of the two particle size analysis methods, it is evident that suspending the 
microspheres in solution containing surfactant as well as vortexing and sonicating is beneficial in 
reducing aggregation which is advantageous to creating a true distribution curve of particle sizes. 
 
 
Figure S2. Comparative overlay of 504 (blue), D504 10 (green) and D504 4 (red) in order of 
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Figure S3. Comparison of mean particle size diameter of microsphere formulations using the 
suspension and the dry methods. 
 
Drug content and drug burst release 
In order to accurately determine drug loading efficiency and drug release of PLGA particles, the 
actual drug content of the microspheres was investigated as well as the burst release. Burst release 
as a proportion of actual drug content will help to determine which formulation manages to sustain 
drug release. All loading efficiency (LE) were above 83% of theoretical values (Figure 1). LE 
depends on factors such as kind of PLGA and drug to polymer ratio. When 1:4 drug to polymer 
ratio was used, LE increased if PLGA with high molecular weight was used (D502 4 versus D504 4 
p = 0.0068); no significant differences were observed when high concentration of polymer was used 
(D502 10 versus D504 10 p>0.05). The drug to polymer ratio affected the LE only in the case of 
502 formulations (D502 4 versus D502 10 p = 0.0310). Higher molecular weight formulations 
tended to have a significant reduction in burst release (D504 4 versus D504 10, p>0.05). Figure 1 
shows a significant difference between D502 4 and D504 4, D502 10 and D504 10 and between 
D502 4 versus D502 10. Temperature did not significantly affect the burst test. 
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Figure 1. Loading efficiency (LE) of formulations and the percentage of DFO released during the 
burst test. 
Microspheres morphology by (SEM) 
The image of unloaded 502 microspheres in Figure 2A and C concurs with the particle size 
distribution profiles discussed above. Figure 2 shows not only the wide range of particle size 
present in the formulations but it also provides evidence that agglomeration is the cause for 
anomalous spikes that occur in the distribution graphs (Figure S2). In contrast, 504 presented less 
visible aggregation between the microspheres which is likely due to the higher glass transition 
temperature of the polymer. Figure 2 also shows the presence of fibrous polymer between 
microspheres; this could be due to the difficulty in separating the longer strands of polymer for 
incorporation in individual spheres during the preparation process. Studies found that increasing the 
drying gas flow rate will reduce this fibrous formation and therefore increase efficiency due to 
better separation in the cyclone [40]. 
504 microspheres also had a comparatively more textured surface than 502. As all other 
manufacture and formulation parameters, apart from the molecular weight of the polymer, were 
kept constant, it is hypothesized that the more amorphous nature of the RG502 allowed the 
formation of a smoother surface. 
Regardless of the polymer used, unloaded microspheres appeared to have a better spherical 
appearance compared to loaded microspheres (Figure 2A–D). The difference could be due to the 
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use of water in the formulation of loaded microspheres, this could cause disruption during structural 
formation [41]. On examination of the manufacturing parameters, the increase in outlet temperature 
from unloaded batches to loaded batches could also contribute to the large morphological change. 
The surface of loaded microspheres appeared to be smooth with pores and did not show presence of 
crystallized drug on the surface. This opposes theories that indicate drug deposited on the surface as 
the reason for the burst release observed. The filamentous appearance of 504 is still present in the 
loaded microspheres D504 10 (Figure 2D). 
Morphology of D504 10 was observed also after drug release studies. Samples analyzed after 
release tended to show more agglomerated and fused particles (Figure 2E). This occurrence is 
explained by the reduction in glass transition temperature and therefore the increase in rubbery 
nature of the PLGA in the presence of water. The filamentous structures disappeared after 
dissolution, possibly due to degradation. Pores are present in this formulation which alongside 
microsphere collapsing is the primary cause for burst release. There is some evidence of the 
presence of drug after dissolution, indicating there is good internalization of the drug in the dry 
microspheres (Figure 2F). 
Drug release studies 
Release studies of DFO from microspheres were carried out. Standard deferoxamine solutions (60 
mg/L) were stored in the same conditions in order to check the degradation of DFO in solution 
during the time. 
Degradation of DFO over time was observed in DFO solution. Whereas D502 4 and D504 4 curves 
displayed concomitant release and degradation and had no significant difference in gradient (1–250 
h) when compared to the standard (Figure S4). The high initial release of the microspheres (86% 
and 90%) indicated a burst release, followed by a negative correlation to the same degree as the 
DFO standard indicative of drug degradation with time. 
In an attempt to reduce the burst release of the microspheres, an increase in the ratio of polymer to 
drug was used as well as a reduction in water content in the preparation process. D504 10 shows a 
high initial release followed by non-significant difference in degradation gradient (time 1–240 h, p 
= 0.11629) when compared to the DFO solution. 
D502 10 was not tested because of the very high percentage of DFO released during the burst test. 
Even though the release profile was similar, they could be the result of a different ratio of drug 
being released and being degraded. In order to examine the release profile, data points were 
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corrected to remove the degradation aspect. Most microsphere batches on their own exhibited very 
little correlation with any of the kinetic or mechanistic equations (R2<0.9). It was found that D502 4 
had strong correlation with first order (concentration dependent), Hixson–Crowell and Korsmeyer–
Peppas at 1–6 h. The application of the Hixson–Crowell equation shows that there is a change in 
surface area and diameter of particles in the time frame 1–6 h and from the close fit to the 
Korsmeyer–Peppas equation, it can be deduced that D502 4 releases the drug with diffusion as the 
rate controlling factor (n<0.45). 
 
 
Figure S4. DFO release from microspheres and concomitant degradation of DFO solution, without 
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Preparation of hydrogels and characterization 
Unloaded and DFO loaded hydrogels as well as composite hydrogel were prepared. The molar ratio 
1/1 and pH of 3.0 were found to be critical to formation of alginate and chitosan hydrogel. The 
gelation was immediate after vigorously stirring the chitosan and alginate solutions at room 
temperature (Figure S5). 
 
 
Figure S5.Photographs of chitosan solution added to alginate solution (left) and gel instantaneously 
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Viscosity measurement 
The viscosity of alginate and chitosan solutions employed for hydrogel formation was 460.3 ± 8.7 
cP and 658.1 ± 59.1 cP, respectively. The viscosity of hydrogel was 10-fold higher (4470.1 ± 458.9 
cP). 
Porosity measurement 
Porosity of unloaded, loaded and composite hydrogels was measured by the solvent replacement 
method. Results demonstrate that the porosity of the system remains unchanged regardless the 
presence of DFO and microspheres and the preparation method of composite hydrogel (p>0.05). 
The porosity of unloaded and loaded hydrogels was 84.86 ± 4.23%, and 82.11 ± 7.32% 
respectively. D502 hydrogel produced by 2nd method, showed a porosity of 78.68 ± 2.00%. No 
significant differences in porosity were found in case of other composite hydrogels. 
Water uptake and swelling 
In order to study the water uptake (WU, %) and swelling characteristics, the weight and volume 
variations of hydrated and freeze-dried hydrogels were measured (Table 2). Freeze-dried hydrogels 
absorbed a considerable amount of water and the unloaded ones showed the highest WU 
percentage. The presence of microspheres reduces the WU value compared with the unloaded 
hydrogel (p<0.05). After water absorption, the hydrogels obtained have a bigger volume than 
freeze-dried forms. In particular the hydrogels containing DFO showed a 54% volume increase, a 
much higher value compared to any other (p<0.05). 
 
Table 2. Water uptake (WU, %) and swelling ratio (SW, %)of unloaded, loaded and composite 
hydrogels both hydrated and freeze-dried. 
Hydrogel freeze-dried hydrated 
WU (%) ± SD SW (%) WU (%) SW (%) 
unloaded 2759.9 ± 246.9$ 3.6 ± 0.7* -16.9 ± 2.2$* -8.3 ± 2.8* 
loaded 2379.2 ± 151.4 54.2 ± 6.7*§ -1.04 ± 1.5*§ -32.3 ± 3.0*§ 
D502(2ndmethod) 1954.1 ± 139.8$ 16.1 ± 1.5§ 7.9 ± 0.2$§ -0.3 ± 3.7§ 
$ § *P< 0.05 
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When the test was performed with the hydrated hydrogel, no water absorption was observed. On the 
contrary, weight loss was observed as well as volume contraction. As a consequence, negative WU 
and SW values were obtained. As concerning the preparation method, the composite hydrogel 
obtained by 1st method did not differ from loaded hydrogel. On the contrary, the composite 
hydrogel from the 2nd method absorbed smaller amount of water but did not change in volume. 
No significant differences in water uptake and swelling were observed when different microspheres 
were incorporated. 
Dynamic vapor absorption (DVS) studies 
Dynamic vapor sorption (DVS) studies describe the mechanism of water sorption by the gels. The 
unloaded hydrogel (Figure 3A) showed a profile typical of bulk water absorption; the hysteresis is 
due to the reversible and elastic swelling deformations caused by the introduction of water 
molecules within the polymeric network. This hydrogel fits the type II model according to the 
BDDT classification, indicative of a multilayer mechanism of absorption. Loaded and composite 
hydrogels (Figure 3B and C), presented a type III isotherm: this profile is generally observed when 
the interaction between vapor/surface and vapor/vapor are similar so only a few molecules of vapor 
adsorb on the surface at low partial pressure followed by condensation when higher humidity is 
reached. For all hydrogels, hysteresis was greatly reduced for RH values greater than 60%, 
indicating this value as a critical RH after which no further structure deformation is occurring. 
 
 
Figure 3. Isotherm curves for unloaded (A), loaded (B) and composite (C) hydrogels. 
 
By applying the Korsmeyer–Peppas equation to the plots of percentage water sorbed versus time, 
the mechanism of hydration can be further understood. By comparing the diffusion exponent, it is 
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evident that the unloaded hydrogel (np = 1.018) presents a Case-II transport mechanism where the 
rate limiting factor is relaxation and chain disentanglement. For all loaded hydrogels (0.45 
<np<0.89) diffusion is controlled by a combination of Fickian diffusion and gel deformation. 
Hydrogels morphology by SEM 
The morphology of the hydrogels was evaluated in order to observe their overall structural 
characteristics, the presence of microspheres, the presence of the drug and also the changes after 
drug release. 
The unloaded hydrogel (Figure 4A) presented a layered structure, whereas porous appearance was 
observed for the loaded hydrogel. Furthermore, crystals of DFO were evident on the structure of the 
loaded hydrogel (Figure 4B). 
Observing the composite hydrogel prepared with the two methods, the included microspheres were 
clearly visible. Figure 4C shows the composite hydrogel produced by the 1st method, chosen as 
example; it can be seen that particles included in the gel showed integral spherical shape without 
collapse phenomena. After dissolution, crystals were found in the hydrogel indicating that the 
composite hydrogel is able to entrap the drug released from the microspheres further delaying its 
release (Figure 4D). Greater drug crystallization on composite hydrogel obtained with the 2nd 
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Figure 4. SEM pictures showing morphology of unloaded (A) and loaded (B) hydrogel 
(magnification 500× and 1000×). SEM pictures showing morphology of D502 10 composite 
hydrogel, produced by 1st method, before (C) and after (D) drug release studies (magnification 
100× and 230×), chosen as examples. 
 
Drug release studies 
Figure 5 shows the release of DFO from loaded and composite hydrogels. Loaded chitosan/alginate 
hydrogel was able to control the release of DFO incorporated: 46% of the drug was quickly released 
within 1 h, the release continued gradually till reaching a plateau at 72% after 48 h. After 144 h, no 
statistical differences are observed between profiles of loaded hydrogel and standard DFO solution. 
Data obtained are affected by the degradation process of DFO and therefore Figure 5 shows release 
profiles corrected and not corrected to account for the degradation. The release of DFO from the 
composite hydrogels was affected by the method of incorporation of the microspheres. If 
microspheres were added into the chitosan solution before hydrogel formation, the resulting 
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hydrogel showed a DFO release profile superimposable to the loaded hydrogel (p>0.05) during the 
first 48 h. Afterwards, the concentration of released DFO from the composite hydrogel declined 
indicating degradation exceeding release. 
 
Figure 5. DFO release from composite hydrogel with incorporated D502 10 prepared adding 
microspheres into the chitosan solution before hydrogel formation (1st method) or at preformed 
hydrogel (2nd method). Data corrected (dotted lines) and not corrected (continuous lines). 
 
When microspheres were incorporated into the preformed hydrogel, a much more sustained release 
profile was observed (Figure 5): 4% of drug incorporated in the microspheres was released within 
1 h and no further release was observed until 216 h. The ability of this composite hydrogel to 
provide a more sustained release was attested also by the higher amount of DFO observed by SEM 
after dissolution test, as above described. 
It must be kept in mind that the release profile of all systems is the result of two different 
phenomena occurring at the same time: release and degradation. 
140 
Andrea Salis 
Polysaccharides as Drug Delivery Systems for different Administration Routes 
Tesi di Dottorato in Scienze e Tecnologie Chimiche-Scienze Farmaceutiche 
Università degli Studi di Sassari 
In order to examine the release profile, data points were corrected to remove the degradation aspect 
using Eq. (6). The D502 10 composite hydrogel formulation prepared with the 1st method did not 
show a strong relationship with either zero or first order overall, however, there was indication of a 
first order release (concentration dependent) after 48 h. This hydrogel also fits with Korsmeyer–
Peppas to show Fickian diffusion as the mechanism of drug release (n< 0.45) (Table 3). 
 
Table 3. Table showing significant R2 values for the release kinetics and mechanism of release 
models for microspheres and composite hydrogels. R2 was taken for the whole experimental time 
frame, from points at the beginning and toward the end of the dissolution duration. 





D502 4 1≤ t <240 0.0857 0.0727 0.1345 0.0465 
1≤ t <6 0.969 0.9724 0.9581 0.9940 
1≤ t <24 0.4785 0.483 0.4651 0.8401 
48≤ t <240 0.6221 0.6165 0.6359 0.4182 
D502 10 1st 
method 
1≤ t <216 0.8658 0.8474 - 0.9437 
1≤ t <24 0.7934 0.78 - 0.9918 
48≤ t <216 0.947 0.9477 - 0.9568 
D502 10 2nd 
method 
1≤ t <216 0.7562 0.6873 - 0.9612 
1≤ t <24 0.8017 0.7368 - 0.978 
48≤ t <216 0.6816 0.7115 - 0.7183 
 
 
D502 10 composite hydrogel obtained with the 2nd method did not fit strongly to either zero or first 
order overall or at selected time intervals. Korsmeyer–Peppas in this composite hydrogel shows 
overall Fickian diffusion as the mechanism of drug release (n< 0.45) (Table 3). 
No statistical differences were observed regardless the microspheres formulation employed. 
The different behavior of the composite hydrogel, can be attributed to the diverse water uptake and 
swelling capability. The hydrated hydrogel from 2nd method, indeed, absorbed water but did not 
reduce in volume whereas the other formulations significantly decreased in volume loosing water 
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entrapped into the hydrogel network. As a consequence the drug dissolved in water is released from 
the hydrogel. 
Biodegradability 
Since ionically crosslinked alginate hydrogels do not specifically degrade but undergo slow, 
uncontrolled dissolution [42], biodegradability in PBS (pH 7.4) at 37°C was studied. Figure S6 
shows the percentage of degradation measured for the composite hydrogel obtained with the 1st 
method, containing microspheres characterized by 1:10 drug–polymer ratio. At the end of the drug 
release studies, the hydrogel biodegraded by approximately 32–34% on the first day. No significant 
difference was observed regardless the kind of microspheres included in the hydrogel (p>0.05) at 
each time point. Concerning D502 10 and D504 10 composite hydrogels, a significant increase of 
degradability was observed between 10 and 24 days (p<0.05), reaching 53% and 49% respectively. 




Figure S6. Degradation degree of composite hydrogels obtained with the 1st method 
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Conclusion 
In this work, we proposed a new application of physical chitosan/alginate hydrogel and PLGA 
microspheres for the modified release of DFO, for which there is a therapeutic demand. These 
formulations produced can represent one of the few formulative approaches of DFO exploited. 
DFO, highly water soluble drug, can be encapsulated in biodegradable microspheres of PLGA; 
nevertheless, formulation into a composite hydrogel is necessary in order to obtain sustained drug 
release: hydrogel is better capable to control the DFO release compared to PLGA microspheres and 
thus absolutely necessary for achieving the prearranged aim; the composite chitosan/alginate 
hydrogel gave the most efficient delivery system. Furthermore, the preparation method affected the 
performance of the obtained systems, the DFO release from them and consequently the kind of 
therapeutic application. As example, hydrogel prepared by the first method can be formed in situ 
after injection of both solutions/suspension; on the other hand, the second method gives an 
implantable hydrogel. 
In conclusion, disruption of iron regulation plays a key role in the etiology of several diseases 
(neurological disorders, cancer, stroke, skin, muscle and bone diseases), which require different 
approaches, methods and time of treatment. The prepared systems not only could solve the 
criticalities common to several iron dysregulation diseases, but show versatility and usefulness with 
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CHAPTER 5 
Engineered microparticles based on drug–polymer coprecipitates for ocular-controlled 
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INTRODUCTION  
Topical eye drops represent a remarkable part of ophthalmic medications present in the market for 
treating diseases of the anterior segment of the eye. The rapid ocular clearance is however a 
remarkable limit of this kind of formulations. The bioavailability of the drug administered topically 
is consequently very low because once the drops are placed onto the eye surface, they are rapidly 
diluted and washed out by tearing and blinking. Most of the liquid ocular formulations are 
consequently drained away from the precorneal area in few minutes. The preparation of ocular 
solutions containing a drug overdose can be a method to compensate these effects, but this is not the 
optimal choice because greater doses can also determine increased side effects and toxicity [1].The 
therapeutic effect of an ocular drug formulation can be improved by prolonging its contact with the 
corneal surface. 
Fluoroquinolones are characterized by a remarkable activity against the most frequent Gram-
positive and Gram-negative ocular pathogens. They are broad spectrum bactericidal agents with 
activity against many important corneal pathogens including staphylococci, Neisseria gonorrhea, 
Haemophilus influenzae, Enterobacteriaceae and Pseudomonas aeruginosa [2,3]. Bacterial keratitis 
is an important infective pathology because it may arise secondary to corneal epithelial breakdown 
associated with dry eye, use of contact lens and trauma. The optimal therapeutic approach should 
firstly require the identification of the causative microorganism; however, the etiological agent 
could be rarely identified in time for the selection of the correct antibiotic therapy. For a rapid and 
successful therapeutic treatment, the empirical choice of a wide broad-spectrum agent can therefore 
be very important3. Recently, an interesting paper has been published regarding the surveillance of 
the activity of fluoroquinolones against ophthalmic pathogens in Europe in the 2010–2011 period 
[4]. Ciprofloxacin, a fluoroquinolone antibiotic, is active against a broad spectrum of aerobic Gram-
positive and Gram-negative bacteria. Its partition coefficient (log P, octanol-Tris model) is –1.31 
[5]. The resistance to this drug is developed slowly, with aminimal toxicity associated with its use. 
For all these reasons, this drug can be currently considered the anti-bacterial agent of choice for the 
eye [6,7] and it is often utilized for the treatment of ocular pathologies, such as bacterial infections 
and/or corneal ulcers. However, the ocular treatment with this antibiotic is characterized by low 
compliance because it requires frequent drug administrations. It is reported that ciprofloxacin eye 
drops need to be administered every 15–30 min in acute infections and at least 6–7 times daily in 
severe pathologies [8]. Furthermore, ciprofloxacin presents a pH-dependent solubility, which 
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becomes very low at the pH of tears [9,10] with consequent possible problems of low 
bioavailability. 
The development of topical controlled release formulations of ophthalmic drugs can be a way to 
improve their low ocular bioavailability with respect to the traditional eye drops, in particular by 
decreasing the clearance rate of the formulation from the precorneal area [11] and by controlling as 
much as possible drug release in this more prolonged time of contact. Therefore, ciprofloxacin is a 
good candidate for the preparation of ocular controlled release formulations to be administered in 
the precorneal site. The preparation of drug delivery systems for the sustained release of actives to 
the precorneal regions of the eye is a field of general and remarkable interest for the design of an 
ocular therapy. The main challenge of such treatments is to sustain sufficiently high concentrations 
of the drug in the corneal region. 
In order to enhance the bioavailability of the drugs administered by the ocular route and to improve 
their compliance, the design and preparation of different delivery systems and/or new strategies are 
possible. Early examples of improvement of the ocular bioavailability concerned the use of 
hydrogels or solutions that change to a gel after instillation, such as those based on Gelrite [12,13] 
or poly(vinylalcohol) and polymethacrylic acid 
Derivatives [14]. Vesicular systems, such as liposomes [14–19], chitosan coated liposomes [20] and 
niosomes [11] have also been prepared. Recently, gel-forming ocular films based on xyloglucan for 
the ocular delivery of ciprofloxacin have been proposed [21]. Moreover, the preparation of 
microparticles with suitable size can be a way to achieve a precorneal prolonged residence time. 
These microparticles are polymeric microspheres, constituted by biodegradable and/or 
mucoadhesive polymers [22–30]. Microspheres based on ion-exchange resins for ocular drug 
administration have been used, even if until now there are very few examples of this kind of 
controlled release formulations designed for the ophthalmic route [31–33]. The ionic interaction 
between polymers (polyelectrolytes) and oppositely-charged drugs has been previously proposed by 
our group as a way to develop ocular controlled release drug formulations. The drug–polymer 
interaction results in insoluble coprecipitates that dissociate only in the presence of the medium’s 
counterions, thus slowly releasing the drug. Once the drug is released, the polymer dissolves, 
leaving no residues in the site of administration [34–37]: this is particularly important in the case 
the route is constituted by the eye. 
The aim of this work was the study of the influence of the technological parameters on the particle 
size of drug/polymer 
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coprecipitates obtained by a procedure of ionic interaction and engineered for ocular 
administrations. Ciprofloxacin was chosen as a model alkaline drug. The polyelectrolytes used are 
two anionic polymers able to interact with alkaline drugs: lambdacarrageenan and chondroitin 
sulfate. Lambda carrageenan is anatural hydrocolloid, already proposed as viscolyser in eye-drop 
formulations [38]. Chondroitin sulfate is a polysaccharide similar to hyaluronic acid in its properties 
[36,37], already used as lubricant for the treatment of dry eye [39]. The final goal was to obtain 
aqueous suspensions containing microparticulate coprecipitates engineered with a size suitable for 
ocular controlled drug administrations. This size should be lower than 25 mm40 limit that fulfills 
requirements of American Pharmacopeia for ophthalmic formulations. 
In some suspensions, Carbomer (Carbopol 934P) was added to improve the mucoadhesive behavior 
of the microparticles. This polymer has good and well-known mucoadhesive properties and it has 
been already used for the preparation of ocular formulations [41,42]. 
Different technological parameters were taken into account for the preparation of the suspensions: 
concentration of the solutions of drug and polymer, temperature, kind and concentration of 
surfactant(s), stirring. A light scattering technique was used for the studies of particle size of the 
coprecipitates. Mucoadhesion tests were carried out using the ‘‘inclined plane’’ method [43,44], in 
order to characterize the capability of these systems to be retained in the precorneal region. 
MATHERIALS AND METHODS 
Materials 
Ciprofloxacin HCl (CPX) was a generous gift from Bayer, Milan, Italy. Chondroitin 6 sulfate (CS) 
was purchased from Fluka Chemie (Buchs, AG CH). Lambda-carrageenan (CR) Viscarin GP Q1 
109 NF (FMC Corporation) was donated by Prodotti Gianni, Q1 Milan, Italy. Carbomer (CB) 
(Carbopol 934P, BF Goodrich, Brecksville, OH).Polyoxyethylene 20 sorbitan monooleate (Tween 
80), Aldrich Chemie Gmbh, Steinheim, Germany. Sorbitan monooleate (Span 80) Aldrich Chemie 
Gmbh, Steinheim, Germany. Mucin type II crude from porcine stomach was purchased from Sigma 
Chemical Co., St Louis, MO. All of the other solvents and chemicals used were of reagent grade. 
Preparation of the CPX/CS and CPX/CR microparticle systems 
Solutions of the two polyelectrolytes, CS and CR, were prepared separately in distilled water at the 
concentration of 0.5% w/v. These solutions were then slowly added dropwise into an equal volume 
of 1% w/v CPX solution in distilled water, under magnetic stirring and at room temperature. This 
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slow addition determined the formation of microparticles represented by coprecipitates, due to the 
ionic interaction that happens between drug and polyelectrolytes. 
The resulting formulations (constituted by suspensions) are named hereafter as COP 1 and COP 2, 
respectively. An aqueous solution of CB at the concentration of 0.25% w/v (pH 7.5, adjusted with 
triethanolamine) was then added at room temperature to samples of the two suspensions, achieving 
two other suspensions named COP 3 and COP 4, respectively. Table 1 summarizes the 
compositions (expressed as percentage w/v) of all the suspensions prepared. 
On the basis of the experimental results obtained in the particle size characterization (carried out as 
below described), the suspension more suitable in terms of size of particles for ocular 
administration (COP 1, based on CS), was used as reference formulation for the further studies of 
formulation parameters. 
 










1 0.50    
2 0.50  0.25  
3 0.25   0.125 
4 0.25  0.125 0.125 
 
 
The influence of the following parameters on the particle size of the coprecipitates in suspension 
was studied: (a) concentrations of drug (CPX) and polymer (CS) solutions; (b) possible use of 
surfactants (kind and concentration); (c) temperature; (d) stirring. Concentrations of the solutions: 
aqueous solutions of CPX and CS at different concentrations (w/v) were prepared and mixed 
together with the method previously described, in such a way to obtain suspensions (named A1–4) 
of drug/polymer (CPX/CS) coprecipitates of different final concentrations. The concentrations of 
the solutions are reported in Table 2, while the concentrations of the corresponding suspensions 
obtained from these solutions are reported in Table 3. In all these preparations, the drug/polymer 
weight ratio was always maintained 2/1. 
Use of surfactants: the kind and amount of surfactant(s) were evaluated as a possible formulation 
parameter. Tween 80 was used alone or in combination with Span 80 in two different weight ratios, 
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named Mix 1 (72:28 w/w) and Mix 2 (53:47 w/w), respectively. The surfactants were dissolved in 
the CPX and CS solutions, to obtain the suspensions T1–T3, whose final composition is reported in 
Table 4. Temperature: an aqueous solution of CS (0.5% w/v) was added dropwise, as previously 
described, to a solution of CPX (1% w/v) maintained under magnetic stirring, at a temperature of 40 
°C. The obtained suspension is named as B1 (final concentration 0.5%w/v). Stirring: CS solution 
(0.5% w/v) was dropwise added to CPX solution (1% w/v), sonicated and stirred by paddle. The 
obtained suspension was named C1 (final concentration 0.5% w/v). 
 
Table 2. Compositions (% w/v) of the solutions of CPX and CS used for the preparation of the 
suspensions A1–4. 
Components Solution A1 Solution A2 Solution A3 Solution A4 
CPX 0.250 0.50 1.00 1.50 
CS 0.125 0.25 0.50 0.75 
 
Table 3. Compositions (% w/v) of the CPX/CS suspensions A1–4. 
Components A1 A2 A3 A4 
CPX 0.125 0.250 0.50 0.750 
CS 0.075 0.125 0.25 0.375 
Final total concentrarion 0.200 0.370 0.75 1.130 
 
Table 4.Compositions (% w/v) of the suspensions T1–3 containing surfactants. 
Components T1 T2 T3 
CPX 0.500 0.500 0.500 
CS 0.250 0.250 0.250 
Tween 80 0.100   
Mix 1  0.100  
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Resuspension test 
To determine the resuspendability of the formulations, a test was carried out as follows: a sample of 
A3 suspension was centrifuged, the supernatant was then eliminated, and the coprecipitate 
resuspended in distilled water to obtain the original concentration (0.50% w/v CPX and 0.25 w/v 
CS) giving the suspension named C2. 
Particle-size analysis 
Particle size and particle-size distributions were determined and studied by the method of laser 
diffractometry, using the Colter Laser Diffraction apparatus (Colter LS 100Q Laser Sizer, Beckman 
Colter, Miami, FL). Particle size analyses were performed, at room temperature, on different 
samples of the prepared suspensions constituted by the drug/polymer coprecipitates. The samples of 
the suspensions were always manually stirred (for about 5 s) before analysis. The average particle 
sizes were expressed as volume-surface diameters (dvs, mm)45. The results were calculated as a 
mean of six determinations (SD50.30). Particle size distributions were expressed as percentage 
distribution by volume. The results of the particle size distributions were also expressed in terms of 
SPAN factor (mm), which was calculated as follows: 
SPAN = (d90 - d10) / d50                                                                                                                                                                                     1 
where d10, d50 and d90 are the diameter sizes and the given percentage value (by volume) is the 
percentage of particles smaller than that size. A high SPAN value indicates a wide particle size 
distribution [46,47]. 
Morphological analysis 
SEM microphotographs (Zeiss DSM 962, Zeiss, Germany) of the coprecipitate were taken as 
follows: after freeze-drying, the samples were placed on double-sided tape, which had been 
previously secured to aluminum stubs, and then analyzed at 20 kV acceleration voltage after gold 
spattering in an argon atmosphere. 
Evaluation of mucoadhesion by means of the ‘‘inclined plane’’ 
Mucoadhesion was measured using the method of the ‘‘inclined plane’’, as previously described 
[43,44]. Briefly, the ‘‘inclined plane’’ apparatus basically consisted of an inclined plane (angle of 
inclination = 60°, surface area = 28 cm2) thermostated at 37 °C and of an electronic microbalance 
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(Sartorius L420P, Germany) Q1 connected with a personal computer. Porcine gastric mucin 
(Sigma, Italy) was used as a biological substrate. Mucin films Q1 were prepared directly on the 
plane: 2.5 ml of an aqueous 8% w/w mucin dispersion were placed on the plane, which was kept 
horizontal at 45 °C for 45 min to dry, and 250 mg of formulation (suspension) was placed on the 
plane previously coated with the biological substrate and kept horizontal. The plane was then 
inclined and the amount of formulation dropped on the microbalance was recorded: the 
mucoadhesivity was expressed as percentage of formulation remained on the surface of the plane. 
As a comparison, measurements without mucin were also carried out using the inclined plane as 
such, at the same experimental conditions employed in presence of the biological substrates. The 
results are expression of three measurements (SD <4%). The ‘‘inclined plane’’ method aimed to 
evaluate the contribution of rheology of formulation to the mucoadhesive potential. 
Statistical analysis 
Statistical analysis of data was performed using analysis of variance (ANOVA) followed by a post-
hoc Tukey’s All Pairs Comparison (Graph-Pad Prism, version 2.01; GraphPad Software 
Incorporated). Significance was taken as p <0.05. 
Stability test 
The stability of the leader formulation (A3) was carried out as follows: the aqueous suspension of 
methylparaoxybenzoate (0.08% w/v) and propylparaoxybenzoate (0.02% w/v) was added and 
stored at 4–8 °C and 25 °C for 6 months. The morphology of the microparticles was checked by an 
optical microscope. 
 
RESULTS AND DISCUSSION 
The results of particle size analyses of COP 1–4 suspensions, expressed as percentage distribution 
by volume are reported in Table 5. Among all the suspensions, COP 1 (prepared using CS as 
polyelectrolyte) presents the best results in terms of particle size suitable for ocular administration. 
In fact 97% of the population of particles has a size <25 mm and 100% of particles have a size 
<<50 mm. The polyelectrolyte CR leads to particles of larger size: COP 2 presents in fact only 
13.6% of particles with a size <25 mm and about 44% with a size<50 mm. This result is probably 
due to the formation of aggregates among the microparticles, whose size becomes lower after 
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prolonged sonication (data not reported). SEM pictures confirmed that the process of 
coprecipitation creates almost spherical particles with rough surface, as previously reported [36]. 
The roughness of the microparticles depends on the technique of preparation, which involves the 
precipitation of self-assembled polymer chains, more hydrophobic owing to the interaction with the 
drug [36]. In order to keep the ocular formulation in the conjunctive area as long as possible, a 
mucoadhesive polymer was added. However, the addition of the mucoadhesive polymer CB 
determines different consequences on the particle size of the suspensions, depending on the 
polyelectrolyte used for the formation of the coprecipitates. The suspension based on CS (COP 3) is 
characterized by particles with a larger size with respect to the corresponding suspension without 
CB (COP 1) (about 49% <25 mm versus 97%, respectively). The suspension based on CR (COP 4) 
has particles with lower size with respect to the corresponding suspension without CB (COP 2) 
(47% <25 mm versus about 13%,respectively). As a consequence of this different effect of CB on 
the size of the suspensions based on the two polymers (CS and CR), COP 3 and COP 4 present a 
similar particle size distribution. The modification of the particle size of the suspensions that is 
found after the addition of the mucoadhesive polymer CB could be due to the adsorption of this 
polymer onto the surface of the microparticles made by the preformed coprecipitates. However, also 
a possible chemical interaction between the drug and the polyelectrolyte (CB) should be taken into 
account. Sahoo et al. [48] in fact recently prepared an oral controlled release gastro-retentive dosage 
form constituted by mucoadhesive suspensions of CPX with Carbopol 934, using a method of 
ultrasonication. Results from FTIR and Raman spectroscopic analyses carried out by the authors, 
suggested that in these formulations the carboxylic groups of CPX and hydroxyl groups of 
Carbopol undergo a chemical interaction, probably leading to esterification and hydrogen bonding, 
even if they do not report any influence of this chemical interaction on the particle size of the 
suspensions [48]. 
Table 5Percentage distribution by volume (dvs, µm). 
 % by volume 
Suspensions < 25 µm < 50 µm < 90 µm 
COP 1 97.0 100.0 100.0 
COP 2 13.6 43.8 81.0 
COP 3 49.0 81.1 99.1 
COP 4 47.3 80.2 99.6 
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Starting from the results of particle size analyses and from the consideration that the suspension 
containing CS has a good mucoadhesive behavior itself, even without the addition of Carbopol, it 
was decided to use CS as polyelectrolyte for the further preparation of the ocular suspensions, 
without any addition of CB to the formulations. The parameter evaluated was then the concentration 
of CPX and CS solutions used for the preparation of the microparticulate coprecipitates. Four 
different suspensions (A1–4) were prepared and characterized in terms of particle size, starting from 
four different combinations of CPX and CS concentrations (solutions A1–4, Table 2). The results 
were expressed as mean volume-surface diameter (dvs) [45] and SPAN values, calculated using 
Equation (1). The concentrations of the CPX and CS solutions used for the preparation of the 
suspensions have a remarkable influence in determining the particle size and particle size 
distributions. As shown in Figure 2 (where mean diameters dvs are reported), the solutions A2 and 
A3 lead to the suspensions A2 and A3, which are characterized by the lowest mean diameters (dvs 
about 3 µm). The solutions A4, characterized by higher CPX and CS concentrations with respect to 
A2 and A3, lead to the formation of A4 suspension, which has particles with a bigger size (dvs 4.25 
µm; p <0.0001). The use of more diluted concentrations (A1 solutions), leads to the highest mean 
diameter (dvs8.5 mm; p <0.0001). 
 
Figure 1.Mucoadhesive properties of COP 1–4 suspensions. 
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Figure 2.Mean diameters (dvs, µm) of A1–4suspensions. 
This latter result is probably due to the formation of aggregates among the microparticles, as 
suggested by the comparison between the particle size distributions of A3 (d90 = about 13 µm) and 
A1 (d90 = about 40 µm) suspensions, reported in Figure 3. A1 suspension in fact presents a typical 
bimodal profile, with a second peak located at higher dvs values, probably due to the presence of the 
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Figure 3.Particle size distributions of A1 and A3 suspensions. 
 
 
The comparison among SPAN values of A1–4 suspensions (Figure 4) shows that A3 suspension has 
the lowest SPAN value (1.94), thus corresponding to the narrowest particle size distribution, while 
A1 suspension (prepared from the more diluted CPX and CS solutions) has the highest SPAN 
value. A possible explanation of this behavior could be that drug and polymer concentrations 
influence the rate of the interaction process that leads to the formation of the microparticles, 
consequently the interaction rate is responsible of the final size of the microparticles formed. As a 
matter of fact, the more dilute solution determines the formation of microparticles with a larger 
particle size distribution.  
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Therefore, A3 suspension presents the lower dvs and the lower SPAN value at the same time with 
respect to the other suspensions and for these reasons, it can be considered the formulation with the 
best characteristics for a potential ocular administration of CPX. It has a final concentration of 
drug–polymer product of interaction of 0.75% w/v (corresponding to 0.50% w/v of drug and 0.25% 
w/v of polymer). 
Therefore, this suspension was chosen as reference formulation for the further study concerning the 
influence of the addition of surfactants on the size of the coprecipitates. Surfactants are in fact 
important additional excipients, which may be included in ophthalmic suspensions to disperse the 
microparticles during the product use and for this reason their addition can be an additional 
parameter to be evaluated in the preparation of an ocular formulation. Non-ionic surfactants are 
used in this study. Three different samples of A3 suspension were added of 0.100% w/v of Tween 
80 (obtaining T1 suspension), of 0.100% w/v or0.020% w/v of different weight ratios of Tween 80 




Figure 4. SPAN values of A1–4 suspensions 
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Figure 5 reports the mean diameters (dvs, µm) of T1–3 compared to the mean diameter of reference 
A3. As shown by this comparison, T1 (0.1% w/v concentration of Tween 80) has the lowest mean 
diameter (dvs 2.67 µm), even lower with respect to the reference formulation A3 (dvs 3.35 µm) (p < 
0.0001). T2 suspension (0.1% w/v of a mixture of Tween 80 and Span 80) has a dvs of 3.20 µm, 
while T3 suspension (0.02% w/v of surfactant mixture) presents the highest dvs value (5.13 mm) (p 
< 0.0001). The comparison among SPAN values (Figure 6) shows that this parameter is low for T1 
and T3 (1.75 and 1.78 µm, respectively) and very close to that of A3 (1.94 µm), meaning that a 
narrow particle size distribution is maintained. On thecontrary, T2 suspension has a SPAN value 
quite increased (6.96 µm), meaning that its particle size distribution is quite larger with respect to 
A3 and T1, despite mean diameters are similar (dvs of about 3 µm). 
These data show that Tween 80 alone (present in T1 formulation) gives the best results in terms of 
particle size suitable for ocular administration, preventing the formation of aggregates. The 
characteristics of A3 formulation are therefore even improved in T1 formulation, characterized by 
lower values of dvs and SPAN with respect to this reference formulation. The lower concentration of 
Tween 80, despite the presence of Span 80, always determines worse particle size characteristics, in 
terms of dvs and/or particle size distributions. Both surfactants are non-ionic; however, Tween 80 is 
characterized by a higher hydrophilicity with respect to Span 80 and for this reason it is more 
suitable for the prevention of formation of aggregates in an aqueous suspension. This probably 
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Figure 5. Mean diameters (dvs, µm) of T1–3 suspensions, compared to the suspension A3. 
 
Figure 6. SPAN values of T1–3 suspensions, compared to the suspension A3. 
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The fact that Tween 80 gives the best results in terms of particle size and stabilization of the 
suspension is particularly important for an ocular formulation because this non-ionic surfactant is 
widely utilized in ophthalmic formulations, due to its safety [49,50]. It is listed in the US 
Pharmacopeia-NationalFormulary, in the European Pharmacopeia and in the Japanese 
Pharmacopeia [49,50]. Furthermore, Tween 80 has been classified as practically non-irritant as 
shown by an interesting test of evaluation of ocular irritation, set up and described by Alany et al. 
[51]. 
Other suspensions were prepared using different conditions of preparation, in terms of temperature 
(B1) and stirring (C1). Moreover, the sedimentation of A3, followed by its resuspension led to the 
formation of the suspension named C2. Figure 7 showsthe corresponding mean diameters (dvs) 
compared to reference formulation A3. 
B1 and C1 present mean diameters (dvs 4.88 and 3.65 mm, respectively), which are higher than the 
mean diameter of A3 (dvs3.35 µm) (p < 0.0001 and <0.006, respectively), while C2 has a mean 
diameter lower (dvs 2.03 µm) (p < 0.0001). B1 and C2 are characterized by SPAN values higher 
with respect to A3, while C1 has a lower parameter (Figure 8). In the case of B1, an improvement 
of both mean particle size (dvs) and SPAN value with respect to A3 can be therefore found, meaning 
that in the preparation of the suspension the use of a higher temperature (40 °C), with respect to the 
room temperature, leads to worse characteristics of the suspensions. 
The sonication of the drug solution during the addition of polymer solution does not lead to any 
further improvement ofparticle size characteristics of the suspension (C1). The results obtained 
from the analyses carried out on C2 show that the sedimentation of the coprecipitates, followed by 
their resuspension with fresh medium leads to a new homogeneous suspension that maintains the 
good particle size characteristics, suitable for an ocular administration. 
Owing to its good characteristics, A3 formulations were chosen for preliminary stability tests. The 
morphology of the microparticles was not changed before and after the storage period: as shown by 
microscope pictures (not reported), no aggregation was found and no formation of drug crystals. 
This is particularly important because, as previously reported [36], CPX instability results in the 
precipitation of the drug in large acicular crystals (length of a few hundred microns) than can cause 
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Figure 7. Mean diameters (dvs, µm) of B1 and C1–2 suspensions, compared to the suspensionA3. 
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CONCLUSIONS 
Particle size in suspensions for ocular drug delivery is a critical parameter determining the quality 
of the preparation. For this reason, the study of the influence of the technological parameters on the 
size of the microparticles is very important.  
The results obtained from this study show that all the suspensions based on the drug/polyelectrolyte 
product of interaction are characterized by a positive mucoadhesivity, particularly those based on 
chondroitin sulfate. The addition of Carbopol obviously improves this property, but it determines a 
modification of particle size. 
Furthermore, chondroitin sulfate coprecipitates the best characteristics in terms of particle size 
suitable for ocular administration. 
As shown by comparison of dvs values, reduction in concentration of the solutions used to obtain 
the coprecipitates determines the formation of particles with smaller size but after a critical size 
reduction is achieved, agglomerates are formed, probably due to high surface energy. In the present 
case, the best formulation is characterized by 0.5% w/v concentration of drug and 0.25% w/v final 
concentration of polymer (A3). 
A further improvement of the particle size characteristics was found with the addition of Tween 80 
at the concentration of 0.1% w/v as surfactant, corresponding to T1 formulation. The presence of 
the surfactant also improves the resuspension properties of the formulation prepared and thus its 
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GENERAL CONCLUSIONS: 
In my PhD thesis the great potential of polysaccharides in wide areas of drug delivery was 
confirmed.  
Composite pellets prepared by embedding o/w emulsions in microcrystalline cellulose could be 
considered a potential oral carrier of hydrophobic drugs such as furosemide and propranolol. The 
results of these studies revealed that drug, surfactant and oil/surfactant ratio affected droplet size, 
viscosity and ζ of emulsions as well as size, shape, and friability of microcrystalline pellets. Drug 
migration was more evident for the less lipophilic drug (furosemide) and for the lower oil/surfactant 
ratio. 
Chitosan/glicerophosphate hydrogels could be considered a valid alternative to microspheres for 
transarterial embolization treatment of advanced stages of hepatocellular carcinoma. In addition, the 
strong electrostatic interaction between chitosan and indocyanine green can be exploited for 
intraoperative visualization of tumour nodules during hepatic resection.  
Chitosan chloride-based microparticles were suitable for the nose-to-brain delivery of UDCA-AZT 
improving the drug-uptake into the central nervous system. The prodrug was rapidly released and 
then adsorbed from nasal mucosa of rats. Furthermore, nasal administration of UDCA-AZT loaded 
chitosan microparticles produced detectable amount of this prodrug in the cerebrospinal fluid of rats 
that could be relevant to achieve an anti-HIV activity. 
Composite chitosan/alginate hydrogel with poly(lactic-co-glycolic acid) microspheres loaded with 
deferoxamine mesilate could be considered a novel strategy for the treatment of iron dysregulation 
diseases. This highly water soluble drug, can be encapsulated in biodegradable microspheres of 
poly(lactic-co-glycolic acid) but the co-formulation formulation with chitosan/alginate hydrogel is 
necessary in order to obtain sustained drug release: hydrogel is better capable to control the DFO 
release compared to PLGA microspheres. 
Ocular infections from Gram-positive and Gram-negative bacteria could be treated with 
ciprofloxacin loaded chondroitin sulphate or lambda carrageenan microparticulate controlled 
delivery systems. The result of ionic interactions between ciprofloxacin and these polysaccharides 
are coprecipitates that can act as vehicles for the sustained release of this drug after being displaced 
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